CUMULATIVE SUPPLEMENT 9

JAN'93-SEP'93

APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

SUBCRIBE NOW!

Available in March 1994

New 14th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION
1994

CONTENTS

- Prescription Drug Product List
- OTC Drug Product List
- Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List
- Discontinued Drug Product List
- USP Monograph Title Additions or Changes
- Orphan Drug Product Designations
- Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution
- Biopharmaceutic Guidance Availability
- ANDA Suitability Petitions
- Patent and Exclusivity Information

See Subscription Form Inside Back Cover

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

Cumulative Supplement 9

SEPTEMBER 1993

CONTENTS

APPROVED DRUG PRODUCTS
with
THERAPEUTIC EQUIVALENCE EVALUATIONS

13TH EDITION

CUMULATIVE SUPPLEMENT 9

SEPTEMBER 1993

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 13th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research and products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.]

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**ADD**> to the left of the line on which new information exists. The >**ADD**> symbol is then dropped in subsequent Cumulative Supplements for that item.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, and the Patent and Exclusivity Data are indicated by the symbol >**DLT**> (DELETE) to the left of the line containing overstruck print. The >**DLT**> symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print remains in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Patent and Exclusivity Data is dropped in subsequent Cumulative Supplements.

Products that have never been marketed, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the " ∂ " symbol to designate their non-marketed status. All products having a " ∂ " symbol in the 12th Cumulative Supplement of the 13th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 14th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (film, extended release; transdermal*)	JUL 15, 1993 (58 FR 38129)
Nitroglycerin (tablet, controlled release;oral)	SEP 07, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 05, 1985 (50 FR 27688)

*The Federal Register of July 15, 1993 (58 FR 38129) announced that the FDA was revoking the temporary exemption for nitroglycerin in a transdermal delivery system. Marketing of a drug product that is the subject of a conditionally approved ANDA may continue by meeting the requirements listed in the Federal Register. Firms wishing to submit a new ANDA before a drug product is approved (NDA or ANDA) and appears in the List should submit a 505(b)(2) application following the directions contained in the Federal Register. Nitro-Dur has been selected as the reference listed drug. The preamble to the final rule (57 FR 17958) states if there are multiple NDA's, the reference listed drug generally will be the market leader. This is the basis upon which Nitro-Dur was selected. In addition, the preamble states that, in multiple NDA situations, a product not designated as the reference listed drug and not shown to be bioequivalent to the reference listed drug may be shielded from generic competition. This is the case with Summit's Transderm-Nitro. The Office of Generic Drugs (OGD) has been requested to have a second listed drug as provided for in the Final Rule. OGD has granted this request. Therefore, at the time that Schering's and Summit's supplements are fully approved and their products are entered into the List, we will have two reference listed drugs for the nitroglycerin transdermal systems. Firms may, therefore, elect to conduct bioequivalence studies against either of these products. It is conceivable that a non-referenced listed drug may be fully approved and appear in the List; in this case, the Agency's referenced listed drug will not change and a 505(b)(2) application will be appropriate until the reference listed drugs are fully approved. Once they are fully approved, a 505(j) application will be the appropriate mechanism for an ANDA submission.

1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant; or when an applicant changes its name; or when an applicant name is changed to meet internal publication standards. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
AH ROBINS CO (ROBINS)	AH ROBINS CO (ROBINS AH)
ASTRA PHARMACEUTICAL PRODUCTS INC (ASTRA)	ASTRA USA INC (ASTRA)
BAKER CUMMINS PHARMACEUTICALS INC (BAKER CUMMINS)	BAKER NORTON PHARMACEUTICALS INC (BAKER NORTON)
BENEDICT NUCLEAR PHARMACEUTICALS INC (BENEDICT)	NORTH AMERICAN CHEMICAL CORPORATION (NORTH AM CHEM)
BOLAR PHARMACEUTICAL CO INC (BOLAR)	CIRCA PHARMACEUTICALS INC (CIRCA)
CIS US INC (CIS)	CIS US INC (CIS) **formerly** (CIS US)
CUTTER BIOLOGICAL DIV MILES LABORATORIES INC (CUTTER)	MILES LABORATORIES INC (MILES LABS)
DANBURY PHARMACAL INC (DANBURY)	DANBURY PHARMACAL INC (DANBURY PHARMA)
FUJISAWA PHARMACEUTICAL CO (FUJISAWA)	FUJISAWA USA INC (FUJISAWA)

APPLICANT NAME CHANGES

FORMER APPLICANT NAME (FORMER ABBREVIATED NAME)	NEW APPLICANT NAME (NEW ABBREVIATED NAME)
HERBERT LABORATORIES DIV SMITH KLINE AND FRENCH CO (HERBERT)	ALLERGAN HERBERT SKIN CARE DIV ALLERGAN INC (ALLERGAN HERBERT) **formerly** ALLERGAN HERBERT DIV ALLERGAN INC
ICI PHARMACEUTICALS GROUP DIV ICI AMERICAS (ICI)	ZENECA PHARMACEUTICALS GROUP DIV ZENECA INC (ZENECA) **formerly** ZENECA PHARMACEUTICALS GROUP
LEMMON CO (LEMMON)	LEMMON CO SUB TEVA PHARMACEUTICALS (LEMMON)
LYPHOMED DIV FUJISAWA USA INC (LYPHOMED)	FUJISAWA USA INC (FUJISAWA)
OWEN GALDERMA LABORATORIES INC (OWEN GALDERMA)	GALDERMA LABORATORIES INC (GALDERMA)
PIONEER PHARMACEUTICALS INC (PIONEER PHARMS)	PIONEER PHARMACEUTICALS CO INC (PIONEER PHARMS)
ROXANE LABORATORIES INC (ROXANE)	ROXANE LABORATORIES INC (ROXANE) **formerly** (ROXANE LABS)
RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV MCNEILAB (JOHNSON RW)	RW JOHNSON PHARMACEUTICAL RESEARCH INSTITUTE DIV ORTHO PHARMACEUTICAL CORP (JOHNSON RW)
SCHIAPPARELLI SEARLE (SCHIAPPARELLI SEARLE)	SCS PHARMACEUTICALS (SCS PHARMS)
SCHWARZ PHARMA KERMERS URBAN (SCHWARZ PHARMA)	SCHWARZ PHARMA DIV KREMERS URBAN CO (SCHWARZ PHARMA)
SOMERSET PHARMACEUTICALS INC (SOMERSET)	SOMERSET PHARMACEUTICALS INC (SOMERSET PHARMS)
STERLING DRUG INC (STERLING)	STERLING WINTHROP INC (STERLING WINTHROP)

1.4 USP MONOGRAPH TITLE ADDITIONS OR CHANGES

The U.S. Pharmacopeia (USP) periodically makes additions to or changes in monograph titles. Some of these additions or changes may affect dosage form terms listed in *Approved Drug Products with Therapeutic Equivalence Evaluations* (ADP). Instead of making the change in each affected product, the Cumulative Supplement (CS) will list applicable monograph title and dosage form additions or changes in this section. These will appear as soon as the modified USP monograph title is official. It is possible for these additions or changes to be listed in this section before all applicant holders have made labeling modifications.

The monograph title additions or changes shown below will remain in this section in each succeeding supplement of this edition. Once the next edition of the ADP is published, the products affected by the title additions or changes will be displayed with the new dosage form in the appropriate drug list. As notification to the reader, these monograph title additions or changes will also be listed in a special section of the ADP.

USP MONOGRAPH TITLE ADDITIONS OR CHANGES

FORMER USP MONOGRAPH TITLE (FORMER ADP DOSAGE FORM; ROUTE)	NEW USP MONOGRAPH TITLE (NEW ADP DOSAGE FORM; ROUTE)

THERE WERE NO USP MONOGRAPH TITLE ADDITIONS OR CHANGES DURING THE MONTH OF SEPTEMBER 1993.

1.5 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1992) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1992	MAR 1993	JUN 1993	SEP 1993
DRUG PRODUCTS LISTED	9488	9392	9194	
SINGLE SOURCE	2245 (23.7%)	2243 (23.9%)	2119 (23.0%)	
MULTISOURCE	7243 (76.3%)	7149 (76.1%)	7075 (77.0%)	
THERAPEUTICALLY EQUIVALENT	6516 (68.6%)	6432 (68.5%)	6357 (69.1%)	
NOT THERAPEUTICALLY EQUIVALENT	577 (6.1%)	562 (5.9%)	555 (6.1%)	
EXCEPTIONS[1]	150 (1.6%)	155 (1.7%)	163 (1.8%)	
NEW MOLECULAR ENTITIES APPROVED	--	3	2	
NUMBER OF APPLICANTS	477	484	508	

[1]Amino acid-containing products of varying composition (see Introduction, page xvii of the List).

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE; ORAL

ANOQUAN

/AB/	/MALLARD/	/325MG;50MG;40MG/	/N87628/001/ /OCT/01,/1986/
AB	ROBERTS HAUCK	325MG;50MG;40MG	N87628 001 OCT 01, 1986

TABLET; ORAL

/ESGIC/

/AB/	/FOREST/PHARMS/	/325MG;50MG;40MG/	/N89660/001/ /DEC/23,/1988/
@	FOREST PHARMS	325MG;50MG;40MG	N89660 001 DEC 23, 1988

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE; ORAL

COMPAL

AA	PURDUE FREDERICK	356.4MG;30MG;16MG	N88584 001 MAR 04, 1986
/AA/	/SOLVAY/	/356.4MG;30MG;16MG/	/N88584/001/ /MAR/04,/1986/

ACETAMINOPHEN; CODEINE PHOSPHATE

CAPSULE; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

@	LEMMON	300MG;30MG	N88324 001 DEC 29, 1983
	/ACETAMINOPHEN W/ CODEINE #3/ /LEMMON/	/300MG;30MG/	/N88324/001/ /DEC/29,/1983/

SOLUTION; ORAL

ACETAMINOPHEN AND CODEINE PHOSPHATE

AA	PENNEX PHARMS	120MG/5ML;12MG/5ML	N87006 001
/AA/	/PHARM/BASICS/	/120MG/5ML;12MG/5ML/	/N87006/001/

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

ALLAY

/AA/	/LUCHEM/	/500MG;5MG/	/N89907/001/ /JAN/13,/1989/
AA	NORTON HN	500MG;5MG	N89907 001 JAN 13, 1989

ACETAMINOPHEN; HYDROCODONE BITARTRATE

CAPSULE; ORAL

/BANCAP HC/

/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87961/001/ /MAR/17,/1983/
@	FOREST PHARMS	500MG;5MG	N87961 001 MAR 17, 1983

TABLET; ORAL

ANEXSIA

AA	BOEHRINGER MANNHEIM	500MG;5MG	N89160 001 APR 23, 1987
/AA/	/SKCP/	/500MG;5MG/	/N89160/001/ /APR/23,/1987/

ANEXSIA 7.5/650

AA	BOEHRINGER MANNHEIM	650MG;7.5MG	N89725 001 SEP 30, 1987
/AA/	/SKCP/	/650MG;7.5MG/	/N89725/001/ /SEP/30,/1987/

/DURADYNE DHC/

/AA/	/FOREST/PHARMS/	/500MG;5MG/	/N87809/001/ /MAR/17,/1983/
@	FOREST PHARMS	500MG;5MG	N87809 001 MAR 17, 1983

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

/AA/	/LUCHEM/	/500MG;5MG/	/N89696/001/ /APR/21,/1988/
AA	NORTON HN	500MG;5MG	N89696 001 APR 21, 1988

/NORCET/

/AA/	/ABANA/	/500MG;5MG/	/N88871/001/ /MAY/15,/1986/
@	ABANA	500MG;5MG	N88871 001 MAY 15, 1986

/TYCOLET/

/AA/	/JOHNSON/RW/	/500MG;5MG/	/N89385/001/ /AUG/27,/1986/
@	JOHNSON RW	500MG;5MG	N89385 001 AUG 27, 1986

ACETAMINOPHEN; PROPOXYPHENE NAPSYLATE

TABLET; ORAL

		PROPOXYPHENE NAPSYLATE AND ACETAMINOPHEN		
>_DLT_>/AB/	/HALSEY/	/325MG;50MG/	/N72105/001/	
>_DLT_>			/MAY/13,/1988/	
/AB/		/650MG;100MG/	/N72106/001/	
			/MAY/13,/1988/	
>_ADD_>	ə HALSEY	325MG;50MG	N72105 001	
>_ADD_>			MAY 13, 1988	
	ə	650MG;100MG	N72106 001	
			MAY 13, 1988	

ACETAZOLAMIDE SODIUM

INJECTABLE; INJECTION

		/ACETAZOLAMIDE SODIUM/	
/AP/	/QUAD/	/EQ 500MG/VIAL/	/N89619/001/
			/JAN/13,/1988/
	ə QUAD	EQ 500MG/VIAL	N89619 001
			JAN 13, 1988

DIAMOX

/AP/	/LEDERLE/	/EQ 500MG/VIAL/	/N09388/001/
			/DEC/05,/1990/
	LEDERLE	EQ 500MG/VIAL	N09388 001
			DEC 05, 1990

ACETYLCHOLINE CHLORIDE

POWDER FOR RECONSTITUTION; OPHTHALMIC

>_ADD_>	MIOCHOL-E		
>_ADD_>	+ IOLAB	20MG/VIAL	N20213 001
>_ADD_>			SEP 22, 1993

ACYCLOVIR SODIUM

INJECTABLE; INJECTION

ZOVIRAX		
+ BURROUGHS WELLCOME	EQ 1GM BASE/VIAL	N18603 002
		JUN 29, 1989
ə	EQ 250MG BASE/VIAL	N18603 003
		AUG 30, 1983

ALBUTEROL SULFATE

SOLUTION; INHALATION

	ALBUTEROL SULFATE		
AN	COPLEY	EQ 0.083% BASE	N73495 001
			MAY 28, 1993

SYRUP; ORAL

	ALBUTEROL SULFATE		
AA	WATSON LABS	EQ 2MG BASE/5ML	N73165 001
			APR 29, 1993

TABLET; ORAL

	ALBUTEROL SULFATE		
AB	NOVOPHARM	EQ 2MG BASE	N72779 001
			JUN 25, 1993
AB		EQ 4MG BASE	N72780 001
			JUN 25, 1993

TABLET, EXTENDED RELEASE; ORAL

	PROVENTIL		
/BC/+//SCHERING/		/EQ 4MG BASE/	/N19383/001/
			/JUL/13,/1987/
BC	SCHERING	EQ 4MG BASE	N19383 001
			JUL 13, 1987

	VOLMAX		
/BC/	/GLAXO/	/EQ 4MG BASE/	/N19604/002/
			/DEC/23,/1992/
/+/		/EQ 8MG BASE/	/N19604/001/
			/DEC/23,/1992/
BC +	MURO	EQ 4MG BASE	N19604 002
			DEC 23, 1992
+		EQ 8MG BASE	N19604 001
			DEC 23, 1992

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

	AMANTADINE HCL		
/AB/	/CIRCA/	/100MG/	/N71382/001/
			/JAN/21,/1987/
	ə CIRCA	100MG	N71382 001
			JAN 21, 1987

SYRUP; ORAL

	AMANTADINE HCL		
AA	MIKART	50MG/5ML	N74028 001
			JUN 28, 1993

SYRUP; ORAL
AMANTADINE HCL
AA MIKART 50MG/5ML N74028 001
JUN 28, 1993

AMANTADINE HYDROCHLORIDE

/TABLET;/ORAL/
/SYMMETREL/
/*//DUPONT/ /100MG/ /N18101/001/
@ DUPONT 100MG N18101 001

AMDINOCILLIN

/INJECTABLE;/INJECTION/
/COACTIN/
/ROCHE/ /250MG/VIAL/ /N50565/001/
/DEC/21,/1984/
/500MG/VIAL/ /N50565/002/
/DEC/21,/1984/
/1GM/VIAL/ /N50565/003/
/DEC/21,/1984/
@ ROCHE 250MG/VIAL N50565 001
DEC 21, 1984
@ 500MG/VIAL N50565 002
DEC 21, 1984
@ 1GM/VIAL N50565 003
DEC 21, 1984

AMIKACIN SULFATE

INJECTABLE; INJECTION
AMIKACIN
AP DUPONT MERCK EQ 50MG BASE/ML N63350 001
JUL 30, 1993
AP EQ 250MG BASE/ML N63350 002
JUL 30, 1993
> ADD > AP GENSIA EQ 50MG BASE/ML N64045 001
> ADD > SEP 28, 1993
> ADD > AP EQ 250MG BASE/ML N64045 002
> ADD > SEP 28, 1993
AMIKIN
> DLT >/AP/ /BRISTOL/ /EQ 250MG BASE/ML/ /N50495/002/
> ADD > AP + BRISTOL EQ 250MG BASE/ML N50495 002
/AMIKIN/IN/SODIUM/CHLORIDE/0.9%/IN/PLASTIC/CONTAINER/
/BRISTOL/ /EQ/5MG/BASE/ML/ /N50618/002/
/NOV/30,/1987/
/EQ/10MG/BASE/ML/ /N50618/001/
/NOV/30,/1987/
@ BRISTOL EQ 5MG BASE/ML N50618 002
NOV 30, 1987
@ EQ 10MG BASE/ML N50618 001
NOV 30, 1987

AMINO ACIDS

INJECTABLE; INJECTION
NOVAMINE 15% SULFITE FREE IN PLASTIC CONTAINER
BAXTER 15% N20107 001
FEB 05, 1993
/NOVAMINE/8.5%/
/KABIVITRUM/ /8.5%/ /N17957/002/
/AUG/09,/1982/
@ KABIVITRUM 8.5% N17957 002
AUG 09, 1982
TRAVASOL 10% IN PLASTIC CONTAINER
BAXTER 10% N18931 003
AUG 23, 1984
/10%/ /N18931/004/
/APR/27,/1988/
/TRAVASOL/10%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /10%/ /N18931/003/
/AUG/23,/1984/
TRAVASOL 5.5% IN PLASTIC CONTAINER
BAXTER 5.5% N18931 001
AUG 23, 1984
/TRAVASOL/5.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /5.5%/ /N18931/001/
/AUG/23,/1984/
TRAVASOL 8.5% IN PLASTIC CONTAINER
BAXTER 8.5% N18931 002
AUG 23, 1984
/TRAVASOL/8.5%/W/O/ELECTROLYTES/IN/PLASTIC/CONTAINER/
/BAXTER/ /8.5%/ /N18931/002/
/AUG/23,/1984/

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM CHLORIDE

INJECTABLE; INJECTION
/AMINOSYN/II/7%/W//ELECTROLYTES/
/ABBOTT/ /7%;102MG/100ML;45MG/100ML;/
/522MG/100ML;410MG/100ML//N19437/006/
/APR/03,/1986/
@ ABBOTT 7%;102MG/100ML;45MG/100ML;
522MG/100ML;410MG/100ML N19437 006
APR 03, 1986

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM PHOSPHATE, DIBASIC

INJECTABLE; INJECTION
/AMINOSYN/II/3.5%/M/
/ABBOTT/ /3.5%;30MG/100ML;97MG/100ML;/ /120MG/100ML;49MG/100ML/ /N19437/007/ /APR/03,/1986/

@ ABBOTT — 3.5%;30MG/100ML;97MG/100ML; 120MG/100ML;49MG/100ML — N19437 007 APR 03, 1986

AMINOCAPROIC ACID

INJECTABLE; INJECTION
AMINOCAPROIC ACID
/AP/ /LYPHOMED/ /250MG/ML/ /N70522/001/ /JUN/17,/1986/

@ LYPHOMED — 250MG/ML — N70522 001 JUN 17, 1986

AMINOPHYLLINE

/ENEMA;/RECTAL/
/SOMOPHYLLIN/
/FISONS/ /300MG/5ML/ /N18232/001/ /APR/02,/1982/

@ FISONS — 300MG/5ML — N18232 001 APR 02, 1982

INJECTABLE; INJECTION
AMINOPHYLLINE
/AP/ /BRISTOL/ /25MG/ML/ /N87431/001/
AP FUJISAWA 25MG/ML N88407 001 JAN 25, 1984

@ 25MG/ML N87431 001
/AP/ /LYPHOMED/ /25MG/ML/ /N88407/001/ /JAN/25,/1984/

SOLUTION; ORAL
AMINOPHYLLINE
@ PENNEX PHARMS 105MG/5ML N88156 001 DEC 05, 1983
/AA/ /PHARM/BASICS/ /105MG/5ML/ /N88156/001/ /DEC/05,/1983/

AMINOPHYLLINE

TABLET; ORAL
/AMINOPHYLLIN/
/AB//+/SEARLE/ /100MG/ /N02386/002/
/AB//+/ /200MG/ /N02386/003/

@ SEARLE 100MG N02386 002
@ 200MG N02386 003

AMINOPHYLLINE
/AB/ /ROXANE/ /100MG/ /N87500/001/ /FEB/09,/1982/

AB + ROXANE 100MG N87500 001 FEB 09, 1982

/AB/ /200MG/ /N87501/001/ /FEB/09,/1982/

AB + 200MG N87501 001 FEB 09, 1982

AMITRIPTYLINE HYDROCHLORIDE

INJECTABLE; INJECTION
ELAVIL
/AP/ /MSD/ /10MG/ML/
AP ZENECA 10MG/ML N12704 001

TABLET; ORAL
ELAVIL
/AB/ /MSD/ /10MG/ /N12703/001/
/AB//+/ /25MG/ /N12703/003/
/AB/ /50MG/ /N12703/004/
/AB/ /75MG/ /N12703/005/
/AB/ /100MG/ /N12703/006/
/AB/ /150MG/ /N12703/007/

AB ZENECA 10MG N12703 001
AB + 25MG N12703 003
AB 50MG N12703 004
AB 75MG N12703 005
AB 100MG N12703 006
AB 150MG N12703 007

AMOXICILLIN

CAPSULE; ORAL
/AMOXIN/
/AB/ /BRISTOL/ /250MG/ /N61885/001/
/AB/ /500MG/ /N61885/002/

AMOXICILLIN

CAPSULE; ORAL

/TRIMOX/

/AB/	/SQUIBB/	/250MG/	/N62098/001/
/AB/		/250MG/	/N62152/001/
/AB/		/500MG/	/N62098/002/
/AB/		/500MG/	/N62152/002/

TRIMOX

AB	APOTHECON	250MG	N61885 001
AB		500MG	N61885 002
	@ APOTHECON	250MG	N62098 001
	@	250MG	N62152 001
	@	500MG	N62098 002
	@	500MG	N62152 002

PONDER FOR RECONSTITUTION; ORAL

AMOXICILLIN

AB	CLONMEL	125MG/5ML	N62927 001 NOV 25, 1988
AB		250MG/5ML	N62927 002 NOV 25, 1988
/BX/		/125MG/5ML/	/N62927/001/ /NOV/25,/1988/
/BX/		/250MG/5ML/	/N62927/002/ /NOV/25,/1988/

/POLYMOX/

/AB/	/BRISTOL/	/125MG/5ML/	/N61886/002/
/AB/		/50MG/ML/	/N61886/001/
/AB/		/250MG/5ML/	/N61886/003/
/AB/	/BRISTOL/MYERS/	/125MG/5ML/	/N62885/001/ /MAR/08,/1988/
/AB/		/250MG/5ML/	/N62885/002/ /MAR/08,/1988/

/TRIMOX/

/AB/	/SQUIBB/	/125MG/5ML/	/N62099/001/
/AB/		/125MG/5ML/	/N62154/001/
/AB/		/250MG/5ML/	/N62099/002/
/AB/		/250MG/5ML/	/N62154/002/

TRIMOX

AB	APOTHECON	125MG/5ML	N61886 002
AB		125MG/5ML	N62885 001 MAR 08, 1988
AB		50MG/ML	N61886 001
AB		250MG/5ML	N61886 003
AB		250MG/5ML	N62885 002 MAR 08, 1988
	@ APOTHECON	125MG/5ML	N62099 001
	@	125MG/5ML	N62154 001
	@	250MG/5ML	N62099 002
	@	250MG/5ML	N62154 002

AMPHETAMINE ADIPATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE ADIPATE; DEXTROAMPHETAMINE SULFATE

/CAPSULE;/ORAL/

/DELCOBESE/

/LEMMON/

	/1.25MG;1.25MG;1.25MG;/ /1.25MG/	/N83564/001/
	/2.5MG;2.5MG;2.5MG;2.5MG/	/N83564/002/
	/3.75MG;3.75MG;3.75MG;/ /3.75MG/	/N83564/003/
	/5MG;5MG;5MG;5MG/	/N83564/004/
@ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83564 001
@	2.5MG;2.5MG;2.5MG;2.5MG	N83564 002
@	3.75MG;3.75MG;3.75MG; 3.75MG	N83564 003
@	5MG;5MG;5MG;5MG	N83564 004

/TABLET;/ORAL/

/DELCOBESE/

/LEMMON/

	/1.25MG;1.25MG;1.25MG;/ /1.25MG/	/N83563/004/
	/2.5MG;2.5MG;2.5MG;2.5MG/	/N83563/003/
	/3.75MG;3.75MG;3.75MG;/ /3.75MG/	/N83563/002/
	/5MG;5MG;5MG;5MG/	/N83563/001/
@ LEMMON	1.25MG;1.25MG;1.25MG; 1.25MG	N83563 004
@	2.5MG;2.5MG;2.5MG;2.5MG	N83563 003
@	3.75MG;3.75MG;3.75MG; 3.75MG	N83563 002
@	5MG;5MG;5MG;5MG	N83563 001

AMPHOTERICIN B

CREAM; TOPICAL

FUNGIZONE

+	APOTHECON	3%	N50314 001
	/SQUIBB/	/3%/	/N50314/001/

INJECTABLE; INJECTION

FUNGIZONE

AP	+ APOTHECON	50MG/VIAL	N60517 001
/AP/	/SQUIBB/	/50MG/VIAL/	/N60517/001/

LOTION; TOPICAL

FUNGIZONE

+	APOTHECON	3%	N60570 001
	/SQUIBB/	/3%/	/N60570/001/

AMPHOTERICIN B

OINTMENT; TOPICAL

	FUNGIZONE		
+	APOTHECON	3%	N50313 001
	/SQUIBB/	/3%/	/N50313/001/

AMPICILLIN SODIUM

INJECTABLE; INJECTION

AMPICILLIN SODIUM

AP	HANFORD	EQ 125MG BASE/VIAL	N63143 001 APR 15, 1993
AP		EQ 250MG BASE/VIAL	N63145 001 APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63146 001 APR 15, 1993
AP		EQ 500MG BASE/VIAL	N63147 001 APR 15, 1993
AP		EQ 1GM BASE/VIAL	N62772 001 APR 15, 1993
AP		EQ 1GM BASE/VIAL	N63139 001 APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63140 001 APR 15, 1993
AP		EQ 2GM BASE/VIAL	N63141 001 APR 15, 1993
AP		EQ 10GM BASE/VIAL	N63142 001 APR 15, 1993
AP	IBI	EQ 125MG BASE/VIAL	N62797 001 JUL 12, 1993
AP		EQ 2GM BASE/VIAL	N62797 002 JUL 12, 1993
/AP/	/LILLY/	/EQ 500MG BASE/VIAL/	/N62565/001/ /APR/04,/1985/
/AP/		/EQ 1GM BASE/VIAL/	/N62565/002/ /APR/04,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N62565/003/ /JUN/24,/1986/
	@ LILLY	EQ 500MG BASE/VIAL	N62565 001 APR 04, 1985
	@	EQ 1GM BASE/VIAL	N62565 002 APR 04, 1985
	@	EQ 2GM BASE/VIAL	N62565 003 JUN 24, 1986
	PENBRITIN-S /WYETH/AYERST/	/EQ 4GM BASE/VIAL/	/N50072/006/
	@ WYETH AYERST	EQ 4GM BASE/VIAL	N50072 006

AMPICILLIN SODIUM

INJECTABLE; INJECTION

/POLYCILLIN-N/

/AP/	/BRISTOL/	/EQ 125MG BASE/VIAL/	/N61395/001/
/AP/		/EQ 125MG BASE/VIAL/	/N62860/001/ /FEB/05,/1988/
/AP/		/EQ 250MG BASE/VIAL/	/N61395/002/
/AP/		/EQ 250MG BASE/VIAL/	/N62860/002/ /FEB/05,/1988/
/AP/		/EQ 500MG BASE/VIAL/	/N61395/003/
/AP/		/EQ 500MG BASE/VIAL/	/N62860/003/ /FEB/05,/1988/
/AP/		/EQ 1GM BASE/VIAL/	/N61395/004/
/AP/		/EQ 1GM BASE/VIAL/	/N62738/001/ /FEB/19,/1987/
/AP/		/EQ 1GM BASE/VIAL/	/N62860/004/ /FEB/05,/1988/
/AP/		/EQ 2GM BASE/VIAL/	/N61395/005/
/AP/		/EQ 2GM BASE/VIAL/	/N62738/002/ /FEB/19,/1987/
/AP/		/EQ 2GM BASE/VIAL/	/N62860/005/ /FEB/05,/1988/
/AP/		/EQ 10GM BASE/VIAL/	/N61395/006/

PRINCIPEN

AP	APOTHECON	EQ 125MG BASE/VIAL	N61395 001
AP		EQ 125MG BASE/VIAL	N62860 001 FEB 05, 1988
AP		EQ 250MG BASE/VIAL	N61395 002
AP		EQ 250MG BASE/VIAL	N62860 002 FEB 05, 1988
AP		EQ 500MG BASE/VIAL	N61395 003
AP		EQ 500MG BASE/VIAL	N62860 003 FEB 05, 1988
AP		EQ 1GM BASE/VIAL	N61395 004
AP		EQ 1GM BASE/VIAL	N62738 001 FEB 19, 1987
AP		EQ 1GM BASE/VIAL	N62860 004 FEB 05, 1988
AP		EQ 2GM BASE/VIAL	N61395 005
AP		EQ 2GM BASE/VIAL	N62738 002 FEB 19, 1987
AP		EQ 2GM BASE/VIAL	N62860 005 FEB 05, 1988
AP	+	EQ 10GM BASE/VIAL	N61395 006

AMPICILLIN SODIUM; SULBACTAM SODIUM

INJECTABLE; INJECTION

	UNASYN		
	PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N50608 003 DEC 31, 1986
	∂ PFIZER	EQ 500MG BASE/VIAL; EQ 250MG BASE/VIAL	N50608 003 DEC 31, 1986

AMPICILLIN/AMPICILLIN TRIHYDRATE

CAPSULE; ORAL

	POLYCILLIN		
AB	BRISTOL	EQ 250MG BASE	N61392 001
AB		EQ 500MG BASE	N61392 002
AB	BRISTOL/MYERS	EQ 250MG BASE	N62888 001 MAR 04, 1988
AB		EQ 500MG BASE	N62888 002 MAR 04, 1988
	PRINCIPEN		
AB	+ APOTHECON	EQ 250MG BASE	N61392 001
AB		EQ 250MG BASE	N62888 001 MAR 04, 1988
AB		EQ 500MG BASE	N61392 002
AB	+	EQ 500MG BASE	N62888 002 MAR 04, 1988
	PRINCIPEN '250'		
AB	SQUIBB	EQ 250MG BASE	N50056 001
AB		EQ 250MG BASE	N62157 002
	∂ APOTHECON	EQ 250MG BASE	N50056 001
	∂	EQ 250MG BASE	N62157 002
	PRINCIPEN '500'		
AB	SQUIBB	EQ 500MG BASE	N50056 002
AB		EQ 500MG BASE	N62157 001
	∂ APOTHECON	EQ 500MG BASE	N50056 002
	∂	EQ 500MG BASE	N62157 001
	TOTACILLIN		
AB	SMITHKLINE/BEECHAM	EQ 250MG BASE	N60060 001
AB		EQ 500MG BASE	N60060 002
	∂ SMITHKLINE BEECHAM	EQ 250MG BASE	N60060 001
	∂	EQ 500MG BASE	N60060 002

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN		
AB	BRISTOL	EQ 125MG BASE/5ML	N61394 002
AB		EQ 250MG BASE/5ML	N61394 003
AB		EQ 100MG BASE/ML	N61394 001

AMPICILLIN/AMPICILLIN TRIHYDRATE

POWDER FOR RECONSTITUTION; ORAL

	PRINCIPEN		
AB	APOTHECON	EQ 125MG BASE/5ML	N61394 002
AB		EQ 250MG BASE/5ML	N61394 003
AB		EQ 100MG BASE/ML	N61394 001
	PRINCIPEN '125'		
AB	SQUIBB	EQ 125MG BASE/5ML	N60127 002
AB		EQ 125MG BASE/5ML	N62151 001
	∂ APOTHECON	EQ 125MG BASE/5ML	N60127 002
	∂	EQ 125MG BASE/5ML	N62151 001
	PRINCIPEN '250'		
AB	SQUIBB	EQ 250MG BASE/5ML	N60127 001
AB		EQ 250MG BASE/5ML	N62151 002
	∂ APOTHECON	EQ 250MG BASE/5ML	N60127 001
	∂	EQ 250MG BASE/5ML	N62151 002

AMPICILLIN/AMPICILLIN TRIHYDRATE; PROBENECID

CAPSULE; ORAL

	PRINCIPEN W/ PROBENECID		
+	SQUIBB	EQ 389MG BASE;111MG	N50488 001
		EQ 389MG BASE;111MG	N62150 001
	∂ APOTHECON	EQ 389MG BASE;111MG	N50488 001
	∂	EQ 389MG BASE;111MG	N62150 001

POWDER FOR RECONSTITUTION; ORAL

	POLYCILLIN-PRB		
AB	+ APOTHECON	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001
AB	BRISTOL	EQ 3.5GM BASE/BOT; 1GM/BOT	N61898 001

ANISOTROPINE METHYLBROMIDE

TABLET; ORAL

	VALPIN 50		
	DUPONT	50MG	N13428 001
	∂ DUPONT	50MG	N13428 001

APRACLONIDINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	IOPIDINE		
+	ALCON	EQ 0.5% BASE	N20258 001 JUL 30, 1993

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

/INJECTABLE;/INJECTION/
/M.V.I.-12/LYOPHILIZED/
/ASTRA/ /100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL/
/15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;/
/40MG/VIAL;4MG/VIAL;3.6MG/VIAL;/
/3MG/VIAL;1MG/VIAL;/
/10MG/VIAL/ /N18933/002/
/AUG/08,/1985/

ə ASTRA 100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL
15MG/VIAL;5UGM/VIAL;0.4MG/VIAL;
40MG/VIAL;4MG/VIAL;3.6MG/VIAL;
3MG/VIAL;1MG/VIAL;
10MG/VIAL N18933 002
AUG 08, 1985

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE HYDROCHLORIDE; RIBOFLAVIN PHOSPHATE SODIUM; THIAMINE HYDROCHLORIDE; VITAMIN A; VITAMIN E

INJECTABLE; INJECTION
M.V.C. 903

AP FUJISAWA 10MG/ML;0.006MG/ML;0.5UGM/ML;
1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;
0.4MG/ML;0.36MG/ML;0.3MG/ML;
330 UNITS/ML;1 IU/ML N18440 002
AUG 08, 1985

/AP/ /LYPHOMED/ /10MG/ML;0.006MG/ML;0.5UGM/ML;/
/1.5MG/ML;20 IU/ML;0.04MG/ML;4MG/ML;/
/0.4MG/ML;0.36MG/ML;0.3MG/ML;/
/330 UNITS/ML;1 IU/ML/ /N18440/002/
/AUG/08,/1985/

ASPIRIN; BUTALBITAL

TABLET; ORAL
AXOTAL
/+///ADRIA/ /650MG;50MG/ /N88305/001/
/OCT/13,/1983/

\+ SAVAGE 650MG;50MG N88305 001
OCT 13, 1983

ATENOLOL

TABLET; ORAL
ATENOLOL

AB MUTUAL PHARM 50MG N73475 001
MAR 30, 1993

AB 100MG N73476 001
MAR 30, 1993

AB NOVOPHARM 50MG N73315 001
MAY 28, 1993

AB 100MG N73316 001
MAY 28, 1993

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL
ATENOLOL AND CHLORTHALIDONE

AB MUTUAL PHARM 50MG;25MG N73581 001
APR 29, 1993

AB 100MG;25MG N73582 001
APR 29, 1993

AZATHIOPRINE SODIUM

INJECTABLE; INJECTION
/AZATHIOPRINE/
/AP/ /QUAD/ /EQ 100MG BASE/VIAL/ /N71056/001/
/JUN/08,/1988/

ə QUAD EQ 100MG BASE/VIAL N71056 001
JUN 08, 1988

IMURAN
/AP/ /BURROUGHS/WELLCOME/ /EQ 100MG BASE/VIAL/ /N17391/001/
BURROUGHS WELLCOME EQ 100MG BASE/VIAL N17391 001

AZLOCILLIN SODIUM

INJECTABLE; INJECTION
AZLIN
/MILES/ /EQ/2GM/BASE/VIAL/ /N62388/001/ /SEP/08,/1982/
@ MILES EQ 2GM BASE/VIAL N62388 001 SEP 08, 1982
/EQ/2GM/BASE/VIAL/ /N62417/001/ /OCT/12,/1982/
@ EQ 2GM BASE/VIAL N62417 001 OCT 12, 1982
/EQ/4GM/BASE/VIAL/ /N62388/003/ /SEP/08,/1982/
@ EQ 4GM BASE/VIAL N62388 003 SEP 08, 1982
/EQ/4GM/BASE/VIAL/ /N62417/003/ /OCT/12,/1982/
@ EQ 4GM BASE/VIAL N62417 003 OCT 12, 1982

AZTREONAM

INJECTABLE; INJECTION
AZACTAM IN PLASTIC CONTAINER
/SQUIBB/ /10MG/ML/ /N50632/003/ /MAY/24,/1989/
@ SQUIBB 10MG/ML N50632 003 MAY 24, 1989

BACITRACIN ZINC; HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
CORTISPORIN
/AT/ /BURROUGHS/WELLCOME/ /400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/ /N50416/002/
+ BURROUGHS WELLCOME 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N50416 002
/ZINC BACITRACIN,NEOMYCIN SULFATE,POLYMYXIN B SULFATE &/ HYDROCORTISONE/
/AT/ /PHARMAFAIR/ /400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/ /N62389/001/ /JUL/02,/1982/
@ PHARMAFAIR 400 UNITS/GM;1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62389 001 JUL 02, 1982

BACITRACIN ZINC; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
/BACITRACIN ZINC-NEOMYCIN SULFATE-POLYMYXIN B SULFATE/
/AT/ /PHARMAFAIR/ /400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM/ /N62386/001/ /SEP/09,/1982/
@ PHARMAFAIR 400 UNITS/GM;EQ 3.5MG BASE/GM; 10,000 UNITS/GM N62386 001 SEP 09, 1982

BACITRACIN-NEOMYCIN-POLYMYXIN
/PHARMADERM/ /400/UNITS/GM;EQ/3.5MG/BASE/GM; 5,000/UNITS/GM/ /N62167/001/
@ PHARMADERM 400 UNITS/GM;EQ 3.5MG BASE/GM; 5,000 UNITS/GM N62167 001

BENTIROMIDE

SOLUTION; ORAL
CHYMEX
/ADRIA/ /500MG/7.5ML/ /N18366/001/ /DEC/29,/1983/
SAVAGE 500MG/7.5ML N18366 001 DEC 29, 1983

BENTONITE; SULFUR

/POWDER;/TOPICAL/
/BENSULFOID/
/POYTHRESS/ /66.64%;33.32%/ /N02918/001/
@ POYTHRESS 66.64%;33.32% N02918 001

BENZONATATE

CAPSULE; ORAL
BENZONATATE
AA PHARMACAPS 100MG N81297 001 JAN 29, 1993
TESSALON
AA FOREST LABS 100MG N11210 001

BENZTHIAZIDE

TABLET; ORAL
/AQUATAG/
/BP/ /SOLVAY/ /50MG/ /N16001/002/
@ SOLVAY 50MG N16001 002

BENZTHIAZIDE

TABLET; ORAL

EXNA

/BP/+//ROBINS/AH/ /50MG/ /N12489/001/

\+ ROBINS AH 50MG N12489 001

BEPRIDIL HYDROCHLORIDE

TABLET; ORAL

/DEPANIN/

/AB/ /WALLACE/ /200MG/ /N19001/001/ DEC/28,/1990/

/AB/ /300MG/ /N19001/002/ DEC/28,/1990/

/AB/ /400MG/ /N19001/003/ DEC/28,/1990/

@ WALLACE 200MG N19001 001 DEC 28, 1990

@ 300MG N19001 002 DEC 28, 1990

@ 400MG N19001 003 DEC 28, 1990

VASCOR

/AB/ /JOHNSON/RW/ /200MG/ /N19002/001/ DEC/28,/1990/

/AB/ /300MG/ /N19002/002/ DEC/28,/1990/

/AB//+/ /400MG/ /N19002/003/ DEC/28,/1990/

\+ JOHNSON RW 400MG N19002 003 DEC 28, 1990

200MG N19002 001 DEC 28, 1990

300MG N19002 002 DEC 28, 1990

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/ /PHARMADERM/ /EQ 0.05% BASE/ /N19136/001/ JUN/26,/1984/

@ PHARMADERM EQ 0.05% BASE N19136 001 JUN 26, 1984

BETAMETHASONE DIPROPIONATE

LOTION; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/ /PHARMADERM/ /EQ 0.05% BASE/ /N70274/001/ AUG/12,/1985/

@ PHARMADERM EQ 0.05% BASE N70274 001 AUG 12, 1985

OINTMENT; TOPICAL

BETAMETHASONE DIPROPIONATE

/AB/ /PHARMADERM/ /EQ 0.05% BASE/ /N19140/001/ SEP/04,/1984/

@ PHARMADERM EQ 0.05% BASE N19140 001 SEP 04, 1984

BETAMETHASONE VALERATE

CREAM; TOPICAL

BETAMETHASONE VALERATE

/AB/ /PHARMADERM/ /EQ 0.1% BASE/ /N18860/002/ AUG/31,/1983/

@ PHARMADERM EQ 0.1% BASE N18860 002 AUG 31, 1983

LOTION; TOPICAL

BETAMETHASONE VALERATE

/AB/ /PHARMADERM/ /EQ 0.1% BASE/ /N18870/001/ AUG/31,/1983/

@ PHARMADERM EQ 0.1% BASE N18870 001 AUG 31, 1983

OINTMENT; TOPICAL

BETAMETHASONE VALERATE

AB NMC EQ 0.1% BASE N70051 001 OCT 10, 1984

BETAMETHASONE VALERATE

/AB/ /PHARMADERM/ /EQ 0.1% BASE/ /N18864/001/ AUG/31,/1983/

@ PHARMADERM EQ 0.1% BASE N18864 001 AUG 31, 1983

/VALNAC/

/AB/ /NMC/ /EQ 0.1% BASE/ /N70051/001/ OCT/10,/1984/

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET; ORAL
ZIAC
+ LEDERLE — 10MG;6.25MG — N20186 002 MAR 26, 1993
2.5MG;6.25MG — N20186 003 MAR 26, 1993
5MG;6.25MG — N20186 001 MAR 26, 1993

BRETYLIUM TOSYLATE

INJECTABLE; INJECTION
BRETYLIUM TOSYLATE
> DLT > /AP/ /ASTRA/ /50MG/ML/ /N71152/001/ /AUG/10/1987/
> DLT >
> ADD > @ ASTRA — 50MG/ML — N71152 001 AUG 10, 1987
> ADD >

BROMODIPHENHYDRAMINE HYDROCHLORIDE; CODEINE PHOSPHATE

SYRUP; ORAL
MYDANYL
AA PENNEX PHARMS — 12.5MG/5ML;10MG/5ML — N88626 001 OCT 12, 1984
/AA/ /PHARM/BASICS/ /12.5MG/5ML;10MG/5ML/ /N88626/001/ /OCT/12/1984/

BROMPHENIRAMINE MALEATE

TABLET; ORAL
BROMPHENIRAMINE MALEATE
/AA/ /ANABOLIC/ /4MG/ /N86187/001/
@ ANABOLIC — 4MG — N86187 001
/AA/ /NEWTRON/ /4MG/ /N86987/001/
@ NEWTRON — 4MG — N86987 001
AA NYLOS TRADING — 4MG — N85592 001
/AA/ /TABLICAPS/ /4MG/ /N85592/001/
/AA/ /ZENITH/ /4MG/ /N84351/001/
@ ZENITH — 4MG — N84351 001

BROMPHENIRAMINE MALEATE; CODEINE PHOSPHATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DC
AA PENNEX PHARMS — 2MG/5ML;10MG/5ML; 12.5MG/5ML — N88904 001 FEB 21, 1985
/AA/ /PHARM/BASICS/ /2MG/5ML;10MG/5ML; 12.5MG/5ML/ /N88904/001/ /FEB/21/1985/

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP; ORAL
MYPHETANE DX
AA PENNEX PHARMS — 2MG/5ML;10MG/5ML; 30MG/5ML — N88811 001 JUN 07, 1985
/AA/ /PHARM/BASICS/ /2MG/5ML;10MG/5ML; 30MG/5ML/ /N88811/001/ /JUN/07/1985/

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL
BIPHETAP
@ PENNEX PHARMS — 4MG/5ML;25MG/5ML — N88687 001 SEP 26, 1984
/@/PHARM/BASICS/ /4MG/5ML;25MG/5ML/ /N88687/001/ /SEP/26/1984/

BUTABARBITAL SODIUM

ELIXIR; ORAL
BUTABARBITAL SODIUM
@ PENNEX PHARMS — 30MG/5ML — N85383 001
/AA/ /PHARM/BASICS/ /30MG/5ML/ /N85383/001/

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION
STADOL
+ APOTHECON — 1MG/ML — N17857 001
+ 2MG/ML — N17857 002
/BRISTOL/ /1MG/ML/ /N17857/001/
/2MG/ML/ /N17857/002/

CALCIFEDIOL, ANHYDROUS

CAPSULE; ORAL

CALDEROL			
+ ORGANON	0.05MG		N18312 002
	0.02MG		N18312 001
/+//UPJOHN/	/0.05MG/		/N18312/002/
	/0.02MG/		/N18312/001/

CALCITONIN, SALMON

INJECTABLE; INJECTION

CALCIMAR			
/AP/ /RHONE/POULENC/RORER/	/200 IU/ML/		/N17769/001/
AP + RHONE POULENC RORER	200 IU/ML		N17769 001
MIACALCIN			
/SANDOZ/	/100/IU/ML/		/N17808/001/
			/JUL/03,/1986/
@ SANDOZ	100 IU/ML		N17808 001
			JUL 03, 1986

CALCIUM CHLORIDE; DEXTROSE; GLUTATHIONE DISULFIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM PHOSPHATE

SOLUTION; IRRIGATION

ENDOSOL EXTRA			
AT ALLERGAN	0.154MG/ML;0.92MG/ML;0.184MG/ML; 0.2MG/ML;0.38MG/ML;2.1MG/ML; 7.14MG/ML;0.42MG/ML		N20079 001
			NOV 27, 1991
ENDOSOL PLUS			
/AT/ /ALLERGAN/	/0.154MG/ML;0.92MG/ML;0.184MG/ML;/ /0.2MG/ML;0.38MG/ML;2.1MG/ML;/ /7.14MG/ML;0.42MG/ML/		/N20079/001/
			/NOV/27,/1991/

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

ISOLYTE R IN DEXTROSE 5% IN PLASTIC CONTAINER			
MCGAW	37MG/100ML;5GM/100ML;31MG/100ML; 120MG/100ML;330MG/100ML; 88MG/100ML		N19864 001
			JUN 10, 1993

CALCIUM GLUCEPTATE

INJECTABLE; INJECTION

CALCIUM GLUCEPTATE			
/AP/ /ABBOTT/	/EQ 90MG CALCIUM/5ML/		/N80001/001/
+ ABBOTT	EQ 90MG CALCIUM/5ML		N80001 001
/AP/ /LILLY/	/EQ 90MG CALCIUM/5ML/		/N06470/001/
@ LILLY	EQ 90MG CALCIUM/5ML		N06470 001
/AP/ /LYPHOMED/	/EQ 90MG CALCIUM/5ML/		/N89373/001/
			/APR/30,/1987/
@ LYPHOMED	EQ 90MG CALCIUM/5ML		N89373 001
			APR 30, 1987

CARBENICILLIN DISODIUM

INJECTABLE; INJECTION

GEOPEN			
/AP/ /ROERIG/	/EQ 1GM BASE/VIAL/		/N50306/001/
/AP/	/EQ 2GM BASE/VIAL/		/N50306/004/
/AP/	/EQ 5GM BASE/VIAL/		/N50306/002/
/AP/	/EQ 10GM BASE/VIAL/		/N50306/006/
ROERIG	EQ 1GM BASE/VIAL		N50306 001
	EQ 2GM BASE/VIAL		N50306 004
	EQ 5GM BASE/VIAL		N50306 002
	EQ 10GM BASE/VIAL		N50306 006
PYOPEN			
/AP/ /SMITHKLINE/BEECHAM/	/EQ 1GM BASE/VIAL/		/N50298/001/
/AP/	/EQ 2GM BASE/VIAL/		/N50298/002/
/AP/	/EQ 5GM BASE/VIAL/		/N50298/003/
/AP/	/EQ 10GM BASE/VIAL/		/N50298/006/
@ SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL		N50298 001
@	EQ 2GM BASE/VIAL		N50298 002
@	EQ 5GM BASE/VIAL		N50298 003
@	EQ 10GM BASE/VIAL		N50298 006
	/EQ 20GM BASE/VIAL/		/N50298/007/
@	EQ 20GM BASE/VIAL		N50298 007

CARBIDOPA; LEVODOPA

TABLET; ORAL

CARBIDOPA AND LEVODOPA			
>ADD > AB PUREPAC	10MG;100MG		N74260 001
>ADD >			SEP 03, 1993
>ADD > AB	25MG;100MG		N74260 002
>ADD >			SEP 03, 1993
>ADD > AB	25MG;250MG		N74260 003
>ADD >			SEP 03, 1993

TABLET; ORAL

CARBIDOPA AND LEVODOPA

> ADD >	AB	WATSON LABS	10MG;100MG	N73381 001
> ADD >				SEP 28, 1993
> ADD >	AB		25MG;100MG	N73382 001
> ADD >				SEP 28, 1993
> ADD >	AB		25MG;250MG	N73383 001
> ADD >				SEP 28, 1993

CARBINOXAMINE MALEATE

/TABLET;/ORAL/

/CLISTIN/

/JOHNSON/RW/	/4MG/	/N08915/001/
@ JOHNSON RW	4MG	N08915 001

CARISOPRODOL

/CAPSULE;/ORAL/

/SOMA/

/WALLACE/	/250MG/	/N11792/003/
@ WALLACE	250MG	N11792 003

TABLET; ORAL

CARISOPRODOL

/AA/	/PIONEER/PHARMS/	/350MG/	/N89390/001/
			/OCT/13,/1988/
	@ PIONEER PHARMS	350MG	N89390 001
			OCT 13, 1988
	/RELA/		
/AA/	/SCHERING/	/350MG/	/N12155/001/
	@ SCHERING	350MG	N12155 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

OPTIPRESS

/BURROUGHS/WELLCOME/	/1%/	/N19972/001/
		/MAY/23,/1990/
OTSUKA	1%	N19972 001
		MAY 23, 1990

CAPSULE; ORAL

DURICEF

AB	+	BRISTOL MYERS SQUIBB	EQ 500MG BASE	N50512 001
/AB/	/+/	/MEAD/JOHNSON/	/EQ 500MG BASE/	/N50512/001/

POWDER FOR RECONSTITUTION; ORAL

DURICEF

AB	+	BRISTOL MYERS SQUIBB	EQ 125MG BASE/5ML	N50527 002
AB	+		EQ 250MG BASE/5ML	N50527 003
AB	+		EQ 500MG BASE/5ML	N50527 001
/AB/	/+/	/MEAD/JOHNSON/	/EQ 125MG BASE/5ML/	/N50527/002/
/AB/	/+/		/EQ 250MG BASE/5ML/	/N50527/003/
/AB/	/+/		/EQ 500MG BASE/5ML/	/N50527/001/

TABLET; ORAL

DURICEF

AB	+	BRISTOL MYERS SQUIBB	EQ 1GM BASE	N50528 001
/AB/	/+/	/MEAD/JOHNSON/	/EQ 1GM BASE/	/N50528/001/

CEFAMANDOLE NAFATE

INJECTABLE; INJECTION

MANDOL

+	LILLY	EQ 10GM BASE/VIAL	N50504 004

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

/AP/	/BEN/VENUE/	/EQ 250MG BASE/VIAL/	/N62894/001/ /JUL/21,/1988/
/AP/		/EQ 500MG BASE/VIAL/	/N62894/002/ /JUL/21,/1988/
/AP/		/EQ 1GM BASE/VIAL/	/N62894/003/ /JUL/21,/1988/
/AP/		/EQ 5GM BASE/VIAL/	/N62894/004/ /JUL/21,/1988/
/AP/		/EQ 10GM BASE/VIAL/	/N62894/005/ /JUL/21,/1988/
	@ BEN VENUE	EQ 250MG BASE/VIAL	N62894 001 JUL 21, 1988
	@	EQ 500MG BASE/VIAL	N62894 002 JUL 21, 1988
	@	EQ 1GM BASE/VIAL	N62894 003 JUL 21, 1988
	@	EQ 5GM BASE/VIAL	N62894 004 JUL 21, 1988
	@	EQ 10GM BASE/VIAL	N62894 005 JUL 21, 1988

CEFMENOXIME HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CEFMAX/
/TAP/

	/EQ/500MG/BASE/VIAL/	/N50571/001/ /DEC/30,/1987/
	/EQ/1GM/BASE/VIAL/	/N50571/002/ /DEC/30,/1987/
	/EQ/2GM/BASE/VIAL/	/N50571/003/ /DEC/30,/1987/
@ TAP	EQ 500MG BASE/VIAL	N50571 001 DEC 30, 1987
@	EQ 1GM BASE/VIAL	N50571 002 DEC 30, 1987
@	EQ 2GM BASE/VIAL	N50571 003 DEC 30, 1987

CEFONICID SODIUM

INJECTABLE; INJECTION
MONOCID

SMITHKLINE BEECHAM	EQ 1GM BASE/VIAL	N63295 001 JUL 26, 1993
	/EQ/2GM/BASE/VIAL/	/N50579/003/ /MAY/23,/1984/
@	EQ 2GM BASE/VIAL	N50579 003 MAY 23, 1984

CEFOTAXIME SODIUM

INJECTABLE; INJECTION
CLAFORAN

HOECHST ROUSSEL	EQ 500MG BASE/VIAL	N50547 001

CEFOTETAN DISODIUM

INJECTABLE; INJECTION
CEFOTAN

/AP/	/STUART/	/EQ 1GM BASE/VIAL/	/N50588/001/ /DEC/27,/1985/
/AP/		/EQ 2GM BASE/VIAL/	/N50588/002/ /DEC/27,/1985/
/AP/	/ZENECA/	/EQ 1GM BASE/VIAL/	/N63293/001/ /APR/29,/1993/
/AP/		/EQ 2GM BASE/VIAL/	/N63293/002/ /APR/29,/1993/
+	ZENECA	EQ 1GM BASE/VIAL	N50588 001 DEC 27, 1985
+		EQ 2GM BASE/VIAL	N50588 002 DEC 27, 1985
		EQ 1GM BASE/VIAL	N63293 001 APR 29, 1993
		EQ 2GM BASE/VIAL	N63293 002 APR 29, 1993

CEFOTAN IN PLASTIC CONTAINER

+ ZENECA	EQ 20MG BASE/ML	N50694 002 JUL 30, 1993
+	EQ 40MG BASE/ML	N50694 001 JUL 30, 1993

CEFOTIAM HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CERADON/
/TAKEDA/

	/EQ/1GM/BASE/VIAL/	/N50601/001/ /DEC/30,/1988/

CEFOTIAM HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/CERADON/
/TAKEDA/ /EQ/1GM/BASE/VIAL/ /N50601/001/
/DEC/30,/1988/

/INJECTABLE;/INJECTION/
/CERADON/
∂ TAKEDA EQ 1GM BASE/VIAL N50601 001
DEC 30, 1988

CEFOXITIN SODIUM

INJECTABLE; INJECTION
MEFOXIN IN PLASTIC CONTAINER
MERCK EQ 20MG BASE/ML N63182 001
JAN 25, 1993
EQ 40MG BASE/ML N63182 002
JAN 25, 1993

CEFPIRAMIDE SODIUM

/INJECTABLE;/INJECTION/
/CEFPIRAMIDE/SODIUM/
/WYETH/AYERST/ /EQ/1GM/BASE/VIAL/ /N50633/002/
/JAN/31,/1989/
/EQ/2GM/BASE/VIAL/ /N50633/003/
/JAN/31,/1989/
/EQ/10GM/BASE/VIAL/ /N50633/005/
/JAN/31,/1989/
∂ WYETH AYERST EQ 1GM BASE/VIAL N50633 002
JAN 31, 1989
∂ EQ 2GM BASE/VIAL N50633 003
JAN 31, 1989
∂ EQ 10GM BASE/VIAL N50633 005
JAN 31, 1989

CEFTAZIDIME SODIUM

INJECTABLE; INJECTION
CEFTAZIDIME SODIUM IN PLASTIC CONTAINER
AP BAXTER EQ 1GM BASE/ML N63221 001
APR 29, 1993
AP EQ 2GM BASE/ML N63221 002
APR 29, 1993
AP EQ 4GM BASE/ML N63221 003
APR 29, 1993

FORTAZ IN PLASTIC CONTAINER
AP GLAXO EQ 1GM BASE/ML N50634 001
APR 28, 1989
AP EQ 2GM BASE/ML N50634 002
APR 28, 1989
AP EQ 4GM BASE/ML N50634 003
APR 28, 1989

CEFTIZOXIME SODIUM

INJECTABLE; INJECTION
CEFIZOX
FUJISAWA EQ 500MG BASE/VIAL N50560 001
SEP 15, 1983
EQ 10GM BASE/VIAL N50560 005
MAR 19, 1993

CEFTRIAXONE SODIUM

INJECTABLE; INJECTION
ROCEPHIN
ROCHE EQ 250MG BASE/VIAL N63239 001
AUG 13, 1993
EQ 500MG BASE/VIAL N63239 002
AUG 13, 1993
EQ 1GM BASE/VIAL N63239 003
AUG 13, 1993

ROCEPHIN W/ DEXTROSE IN PLASTIC CONTAINER
/ROCHE/ /EQ/1GM/BASE/ML/ /N50624/001/
/FEB/11,/1987/
∂ ROCHE EQ 10MG BASE/ML N50624 001
FEB 11, 1987

CEFUROXIME SODIUM

INJECTABLE; INJECTION
CEFUROXIME
AP MARSAM EQ 750MG BASE/VIAL N64035 001
FEB 26, 1993
AP EQ 1.5GM BASE/VIAL N64035 002
FEB 26, 1993
AP EQ 7.5GM BASE/VIAL N64036 001
FEB 26, 1993

KEFUROX
AP LILLY EQ 7.5GM BASE/VIAL N62591 003
DEC 17, 1987

ZINACEF
AP GLAXO EQ 7.5GM BASE/VIAL N50558 004
OCT 23, 1986

CELLULOSE SODIUM PHOSPHATE

POWDER; ORAL
CALCIBIND
/+//MISSION/PHARMA/ /2.5GM/PACKET/ /N18757/002/
/DEC/28,/1982/
∂ MISSION PHARMA 2.5GM/PACKET N18757 002
DEC 28, 1982

CEPHALEXIN

CAPSULE; ORAL

CEFANEX

AB	APOTHECON	EQ 250MG BASE	N63063 001 SEP 29, 1989
AB		EQ 500MG BASE	N63063 002 SEP 29, 1989
/AB/	/BRISTOL/MYERS/	/EQ 250MG BASE/	/N63063/001/ /SEP/29,/1989/
/AB/		/EQ 500MG BASE/	/N63063/002/ /SEP/29,/1989/

CEPHALEXIN

AB	APOTHECON	EQ 250MG BASE	N62973 001 NOV 08, 1988
AB		EQ 500MG BASE	N62974 001 NOV 23, 1988
/AB/	/SQUIBB/MARK/	/EQ 250MG BASE/	/N62973/001/ /NOV/08,/1988/
/AB/		/EQ 500MG BASE/	/N62974/001/ /NOV/23,/1988/

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

@	APOTHECON	EQ 500MG BASE/VIAL	N50446 005
		EQ 500MG BASE/VIAL	N62961 001 SEP 20, 1988
@		EQ 1GM BASE/VIAL	N50446 001
		EQ 1GM BASE/VIAL	N61769 001
		EQ 1GM BASE/VIAL	N62724 001 DEC 23, 1986
		EQ 1GM BASE/VIAL	N62961 002 SEP 20, 1988
@		EQ 2GM BASE/VIAL	N50446 002
		EQ 2GM BASE/VIAL	N61769 002
		EQ 2GM BASE/VIAL	N62724 002 DEC 23, 1986
		EQ 2GM BASE/VIAL	N62961 003 SEP 20, 1988
@		EQ 4GM BASE/VIAL	N50446 003
		EQ 4GM BASE/VIAL	N61769 003
		EQ 4GM BASE/VIAL	N62961 004 SEP 20, 1988
@		EQ 20GM BASE/VIAL	N50446 004

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION

CEFADYL

/AP/	/BRISTOL/	/EQ 500MG BASE/VIAL/	/N50446/005/
/AP/		/EQ 1GM BASE/VIAL/	/N50446/001/
/AP/		/EQ 1GM BASE/VIAL/	/N61769/001/
/AP/		/EQ 1GM BASE/VIAL/	/N62724/001/ /DEC/23,/1986/
/AP/		/EQ 2GM BASE/VIAL/	/N50446/002/
/AP/		/EQ 2GM BASE/VIAL/	/N61769/002/
/AP/		/EQ 2GM BASE/VIAL/	/N62724/002/ /DEC/23,/1986/
/AP/		/EQ 4GM BASE/VIAL/	/N50446/003/
/AP/		/EQ 4GM BASE/VIAL/	/N61769/003/
		/EQ/20GM/BASE/VIAL/	/N50446/004/
/AP/	/BRISTOL/MYERS/	/EQ 500MG BASE/VIAL/	/N62961/001/ /SEP/20,/1988/
/AP/		/EQ 1GM BASE/VIAL/	/N62961/002/ /SEP/20,/1988/
/AP/		/EQ 2GM BASE/VIAL/	/N62961/003/ /SEP/20,/1988/
/AP/		/EQ 4GM BASE/VIAL/	/N62961/004/ /SEP/20,/1988/

/CEPHAPIRIN SODIUM

/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62723/001/ /NOV/17,/1986/
/AP/		/EQ 1GM BASE/VIAL/	/N62723/002/ /NOV/17,/1986/
/AP/		/EQ 2GM BASE/VIAL/	/N62723/003/ /NOV/17,/1986/
/AP/		/EQ 4GM BASE/VIAL/	/N62723/004/ /NOV/17,/1986/
	@ LYPHOMED	EQ 500MG BASE/VIAL	N62723 001 NOV 17, 1986
	@	EQ 1GM BASE/VIAL	N62723 002 NOV 17, 1986
	@	EQ 2GM BASE/VIAL	N62723 003 NOV 17, 1986
	@	EQ 4GM BASE/VIAL	N62723 004 NOV 17, 1986

CHLORAMPHENICOL SODIUM SUCCINATE

INJECTABLE; INJECTION

/MICHEL-S/

/AP/	/RACHELLE/	/EQ 1GM BASE/VIAL/	/N60132/001/
	@ RACHELLE	EQ 1GM BASE/VIAL	N60132 001

CHLORDIAZEPOXIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/LIBRELEASE/
/+//ROCHE/ /30MG/ /N17813/001/
/SEP/12,/1983/

@ ROCHE 30MG N17813 001
SEP 12, 1983

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE; ORAL
CHLORDIAZEPOXIDE HCL
/AB/ /PIONEER/PHARMS/ /25MG/ /N89558/001/
/JUL/15,/1988/

@ PIONEER PHARMS 25MG N89558 001
JUL 15, 1988

LIBRIUM
/AB/ /ROCHE/ /5MG/ /N12249/002/
/AB/ /10MG/ /N12249/001/
/AB//+/ /25MG/ /N12249/003/
/AB/ /25MG/ /N85475/001/
AB + ROCHE 25MG N85475 001
@ 5MG N12249 002
@ 10MG N12249 001
@ 25MG N12249 003

CHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL
ALDOCLOR-150
/AB/ /MSD/ /150MG;250MG/ /N16016/001/
MSD 150MG;250MG N16016 001
ALDOCLOR-250
/AB//+//MSD/ /250MG;250MG/ /N16016/002/
+ MSD 250MG;250MG N16016 002
/METHYLDOPA AND CHLOROTHIAZIDE/
/AB/ /PAR/ /150MG;250MG/ /N70783/001/
/NOV/06,/1987/
/AB/ /250MG;250MG/ /N70654/001/
/NOV/06,/1987/

@ PAR 150MG;250MG N70783 001
NOV 06, 1987

@ 250MG;250MG N70654 001
NOV 06, 1987

CHLOROTRIANISENE

CAPSULE; ORAL
TACE
/MERRELL/DOW/ /72MG/ /N16235/001/
@ MERRELL DOW 72MG N16235 001

CHLORPHENIRAMINE MALEATE

INJECTABLE; INJECTION
CHLORPHENIRAMINE MALEATE
/AP/ /BEL/MAR/ /10MG/ML/ /N80821/001/
@ BEL MAR 10MG/ML N80821 001
/AP/ /STERIS/ /100MG/ML/ /N86095/001/
STERIS 100MG/ML N86095 001
/PYRIDAMAL 100/
/AP/ /BEL/MAR/ /100MG/ML/ /N83733/001/
@ BEL MAR 100MG/ML N83733 001

TABLET; ORAL
CHLORPHENIRAMINE MALEATE
/AA/ /NEWTRON/ /4MG/ /N86519/001/
@ NEWTRON 4MG N86519 001

CHLORPROMAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
CHLORPROMAZINE HCL
@ PENNEX PHARMS 30MG/ML N87032 001
JUL 08, 1982
@ 100MG/ML N87053 001
/AA/ /PHARM/BASICS/ /30MG/ML/ /N87034/001/
/JUL/08,/1982/
/AA/ /100MG/ML/ /N87053/001/

INJECTABLE; INJECTION
CHLORPROMAZINE HCL
/AP/ /LYPHOMED/ /25MG/ML/ /N84911/001/
@ LYPHOMED 25MG/ML N84911 001

CHLORTHALIDONE

TABLET; ORAL
CHLORTHALIDONE
/AA/ /PHARM/BASICS/ /50MG/ /N89052/001/
/JUN/01,/1987/

@ PHARM BASICS 50MG N89052 001
JUN 01, 1987

CHLORTHALIDONE; METOPROLOL TARTRATE

/CAPSULE;ORAL/
/CHLORTHALIDONE/
/METOPROLOL TARTRATE/

/+//CIBA/	/25MG;200MG/	/N19451/002/ /DEC/31,/1987/
	/25MG;100MG/	/N19451/001/ /DEC/31,/1987/
ə CIBA	25MG;100MG	N19451 001 DEC 31, 1987
ə	25MG;200MG	N19451 002 DEC 31, 1987

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

/AA/	/PIONEER/PHARMS/	/250MG/	/N89592/001/ /JAN/06,/1989/
/AA/		/500MG/	/N89948/001/ /JAN/06,/1989/
ə PIONEER PHARMS		250MG	N89592 001 JAN 06, 1989
ə		500MG	N89948 001 JAN 06, 1989

CHYMOTRYPSIN

POWDER FOR RECONSTITUTION; OPHTHALMIC
CATARASE

+ IOLAB	300 UNITS/VIAL	N16938 001
	/150/UNITS/VIAL/	/N18121/001/
ə	150 UNITS/VIAL	N18121 001
	/300/UNITS/VIAL/	/N16938/001/

CISAPRIDE MONOHYDRATE

TABLET; ORAL
PROPULSID

+ JANSSEN	EQ 20MG BASE	N20210 002 JUL 29, 1993
	EQ 10MG BASE	N20210 001 JUL 29, 1993

CLADRIBINE

INJECTABLE; INJECTION
LEUSTATIN

+ JOHNSON RW	1MG/ML	N20229 001 FEB 26, 1993

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLEOCIN

AB	+ UPJOHN	EQ 75MG BASE	N50162 001
/AB//+/		/EQ 75MG BASE/	/N61809/001/
AB	+	EQ 150MG BASE	N50162 002
/AB//+/		/EQ 150MG BASE/	/N61809/002/
ə		EQ 75MG BASE	N61809 001
ə		EQ 150MG BASE	N61809 002

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLEOCIN PHOSPHATE

AP	+ UPJOHN	EQ 150MG BASE/ML	N50441 001
	CLINDAMYCIN PHOSPHATE IN DEXTROSE 5%		
/AP/	/LYPHOMED/	/EQ 12MG BASE/ML/	/N50636/001/ /DEC/22,/1989/
ə LYPHOMED		EQ 12MG BASE/ML	N50636 001 DEC 22, 1989

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

/AB/ /BIOCRAFT/	/0.1MG/	/N70747/001/ /MAR/20,/1986/
/AB/	/0.2MG/	/N70702/001/ /MAR/20,/1986/
/AB/	/0.3MG/	/N70659/001/ /MAR/20,/1986/
ə BIOCRAFT	0.1MG	N70747 001 JUL 08, 1986
ə	0.2MG	N70702 001 JUL 08, 1986
ə	0.3MG	N70659 001 JUL 08, 1986

TABLET; ORAL

CLONIDINE HCL

/AB/	/PAR/	/0.1MG/	/N70461/001/	/NOV/22,/1985/
/AB/		/0.2MG/	/N70460/001/	/NOV/22,/1985/
/AB/		/0.3MG/	/N70459/001/	/NOV/22,/1985/
	∂ PAR	0.1MG	N70461 001	JUL 08, 1986
	∂	0.2MG	N70460 001	JUL 08, 1986
	∂	0.3MG	N70459 001	JUL 08, 1986

CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE

AB	TARO	1%	N72640 001	AUG 31, 1993

LOTRIMIN

AB + /BT/+/	SCHERING	1% /1%/	N17619 001 /N17619/001/	

/CREAM;/VAGINAL/ /GYNE-LOTRIMIN/

/BT/	/SCHERING/	/1%/	/N18652/001/
/BT/	/MYCELEX-G/ /MILES/	/1%/	/N18236/001/

/TABLET;/VAGINAL/ /GYNE-LOTRIMIN/

/BT/	/SCHERING/	/100MG/	/N17717/001/
/BT/	/MYCELEX-G/ /MILES/	/100MG/	/N18182/001/

CLOXACILLIN SODIUM

CAPSULE; ORAL

TEGOPEN

AB + AB + /AB/+/	APOTHECON /BRISTOL/ /AD/+/	EQ 250MG BASE EQ 500MG BASE /EQ 250MG BASE/ /EQ 500MG BASE/	N61452 001 N61452 002 /N61452/001/ /N61452/002/	

CLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL

TEGOPEN

AA /AA/	APOTHECON /BRISTOL/	EQ 125MG BASE/5ML /EQ 125MG BASE/5ML/	N61453 001 /N61453/001/	

CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE VC W/ CODEINE

∂	PENNEX PHARMS	10MG/5ML;5MG/5ML; 6.25MG/5ML	N88896 001	JAN 04, 1985
/AA/	/PHARM/BASICS/	/10MG/5ML;5MG/5ML;/ /6.25MG/5ML/	/N88896/001/	/JAN/04,/1985/

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE W/ CODEINE

/AA/	/PENNEX/PHARMS/	/10MG/5ML;6.25MG/5ML/	/N88875/001/	/DEC/17,/1984/
∂	PENNEX PHARMS	10MG/5ML;6.25MG/5ML	N88875 001	DEC 17, 1984

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA	PENNEX PHARMS	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001	NOV 16, 1984
/AA/	/PHARM/BASICS/	/10MG/5ML;30MG/5ML;/ /1.25MG/5ML/	/N88833/001/	/NOV/16,/1984/

CORTICOTROPIN

INJECTABLE; INJECTION

ACTHAR

/AP/ /AP/	/ARMOUR/	/25 UNITS/VIAL/ /40 UNITS/VIAL/	/N07504/002/ /N07504/003/	
AP AP	RHONE POULENC RORER	25 UNITS/VIAL 40 UNITS/VIAL	N07504 002 N07504 003	

CORTICOTROPIN

INJECTABLE; INJECTION
H.P. ACTHAR GEL

/BC/	/ARMOUR/	/40/UNITS/ML/	/N08372/006/
/BC/+/		/80/UNITS/ML/	/N08372/008/
BC	RHONE POULENC RORER	40 UNITS/ML	N08372 006
BC +		80 UNITS/ML	N08372 008

/PURIFIED/CORTROPHIN/GEL/

/BC/	/ORGANON/	/40/UNITS/ML/	/N08975/001/
/BC/		/80/UNITS/ML/	/N08975/002/
	@ ORGANON	40 UNITS/ML	N08975 001
	@	80 UNITS/ML	N08975 002

CORTICOTROPIN-ZINC HYDROXIDE

/INJECTABLE;/INJECTION/
/CORTROPHIN-ZINC/

/+//ORGANON/		/40/UNITS/ML/	/N09854/001/
	@ ORGANON	40 UNITS/ML	N09854 001

CORTISONE ACETATE

TABLET; ORAL
CORTISONE ACETATE

/BP/	/HEATHER/	/25MG/	/N85736/001/
	@ HEATHER	25MG	N85736 001

CROMOLYN SODIUM

/SOLUTION;/NASAL/
/NASALCROM/

	/FISONS/	/4%/	/N18306/001/
			/MAR/18,/1983/

SPRAY, METERED; NASAL
NASALCROM

+	FISONS	5.2MG/INH	N18306 001 MAR 18, 1983

CYANOCOBALAMIN

INJECTABLE; INJECTION
CYANOCOBALAMIN

/AP/	/DELL/	/0.03MG/ML/	/N80689/001/
	DELL	0.03MG/ML	N80689 001
/AP/	/FUJISAWA/	/1MG/ML/	/N83075/001/
	@ FUJISAWA	1MG/ML	N83075 001

CYANOCOBALAMIN

INJECTABLE; INJECTION
/RUBIVITE/

/AP/	/BEL/MAR/	/0.03MG/ML/	/N10791/004/
/AP/		/0.1MG/ML/	/N10791/002/
/AP/		/1MG/ML/	/N10791/003/
		/0.05MG/ML/	/N10791/001/
		/0.12MG/ML/	/N10791/005/
	@ BEL MAR	0.03MG/ML	N10791 004
	@	0.05MG/ML	N10791 001
	@	0.1MG/ML	N10791 002
	@	0.12MG/ML	N10791 005
	@	1MG/ML	N10791 003

CYCLACILLIN

/POWDER/FOR/RECONSTITUTION;/ORAL/
/CYCLAPEN-W/

/+//WYETH/AYERST/		/500MG/5ML/	/N50508/003/
		/125MG/5ML/	/N50508/001/
		/250MG/5ML/	/N50508/002/
	@ WYETH AYERST	125MG/5ML	N50508 001
	@	250MG/5ML	N50508 002
	@	500MG/5ML	N50508 003

CYCLIZINE LACTATE

/INJECTABLE;/INJECTION/
/MAREZINE/

	/BURROUGHS/WELLCOME/	/50MG/ML/	/N09495/001/
	@ BURROUGHS WELLCOME	50MG/ML	N09495 001

CYCLOBENZAPRINE HYDROCHLORIDE

TABLET; ORAL
CYCLOBENZAPRINE HCL

AB	INVAMED	10MG	N73683 001 FEB 26, 1993

CYCLOPHOSPHAMIDE

INJECTABLE; INJECTION
HEOSAR

AP	ADRIA	100MG/VIAL	N40015 001 APR 29, 1993
AP		200MG/VIAL	N40015 002 APR 29, 1993
AP		500MG/VIAL	N40015 003 APR 29, 1993
AP		1GM/VIAL	N40015 004 APR 29, 1993
AP		2GM/VIAL	N40015 005 APR 29, 1993

CYPROHEPTADINE HYDROCHLORIDE

SYRUP; ORAL
CYPROHEPTADINE HCL

@ PENNEX PHARMS		2MG/5ML	N87001 001 NOV 04, 1982
/AA/	/PHARM/BASICS/	/2MG/5ML/	/N87001/001/ /NOV/04,/1982/

TABLET; ORAL
CYPROHEPTADINE HCL

/AA/	/MYLAN/	/4MG/	/N86678/001/
@ MYLAN		4MG	N86678 001

DESIPRAMINE HYDROCHLORIDE

/CAPSULE;/ORAL/
/PERTOFRANE/
/+//RHONE/POULENC/RORER//50MG/ /25MG/

@ RHONE POULENC RORER	25MG	/N13621/002/
@	50MG	/N13621/001/ N13621 001 N13621 002

DESLANOSIDE

/INJECTABLE;/INJECTION/
/CEDILANID-D/
/SANDOZ/

@ SANDOZ	/0.2MG/ML/ 0.2MG/ML	/N09282/002/ N09282 002

DESMOPRESSIN ACETATE

SPRAY, METERED; NASAL
DDAVP

RHONE POULENC RORER	0.01MG/INH	N17922 002 FEB 06, 1989

DESOXYCORTICOSTERONE PIVALATE

/INJECTABLE;/INJECTION/
/PERCORTEN/
/CIBA/

@ CIBA	/25MG/ML/ 25MG/ML	/N08822/001/ N08822 001

DEXAMETHASONE

ELIXIR; ORAL
DEXAMETHASONE

AA	BARRE	0.5MG/5ML	N88997 001 OCT 10, 1986
/AA/	/NASKA/	/0.5MG/5ML/	/N88997/001/ /OCT/10,/1986/

MYMETHASONE

AA	PENNEX PHARMS	0.5MG/5ML	N88254 001 JUL 27, 1983
/AA/	/PHARM/BASICS/	/0.5MG/5ML/	/N88254/001/ /JUL/27,/1983/

SOLUTION; ORAL
DEXAMETHASONE

/3/ROXANE/		/0.5MG/5ML/	/N88248/001/ /SEP/01,/1983/
ROXANE		0.5MG/5ML	N88248 001 SEP 01, 1983

TABLET; ORAL
DECADRON

AB	MSD	0.5MG	N11664 001
AB	+	0.75MG	N11664 002
AB		1.5MG	N11664 003
AB		4MG	N11664 005
/BP/		/0.5MG/	/N11664/001/
/BP/+/		/0.75MG/	/N11664/002/
/BP/		/1.5MG/	/N11664/003/
/BP/		/4MG/	/N11664/005/

DEXAMETHASONE

TABLET; ORAL
DEXAMETHASONE

AB	ROXANE	0.5MG	N84611 001
AB		0.75MG	N84613 001
AB		1.5MG	N84610 001
AB		4MG	N84612 001
/BP/		/0.5MG/	/N84611/001/
/BP/		/0.75MG/	/N84613/001/
/BP/		/1.5MG/	/N84610/001/
/BP/		/4MG/	/N84612/001/

DEXAMETHASONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

OINTMENT; OPHTHALMIC
/DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/GM;/ /10,000 UNITS/GM/	/N62411/001/ /MAY/16,/1983/

@ PHARMAFAIR — 0.1%;EQ 3.5MG BASE/GM; 10,000 UNITS/GM — N62411 001 MAY 16, 1983

SUSPENSION/DROPS; OPHTHALMIC
/DEXASPORIN/

/AT/	/PHARMAFAIR/	/0.1%;EQ 3.5MG BASE/ML;/ /10,000 UNITS/ML/	/N62428/001/ /MAY/18,/1983/

@ PHARMAFAIR — 0.1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML — N62428 001 MAY 18, 1983

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION
DEXAMETHASONE SODIUM PHOSPHATE

/AP/	/BEL MAR/	/EQ 4MG PHOSPHATE/ML/	/N84752/001/
	@ BEL MAR	EQ 4MG PHOSPHATE/ML	N84752 001
/AP/	/FUJISAWA/	/EQ 4MG PHOSPHATE/ML/	/N87065/001/
	@ FUJISAWA	EQ 4MG PHOSPHATE/ML	N87065 001
/AP/	/WYETH AYERST/	/EQ 4MG PHOSPHATE/ML/	/N85641/001/
	@ WYETH AYERST	EQ 4MG PHOSPHATE/ML	N85641 001
	HEXADROL		
	/ORGANON/	/EQ/20MG/PHOSPHATE/ML/	/N14694/004/
	@ ORGANON	EQ 20MG PHOSPHATE/ML	N14694 004

DEXCHLORPHENIRAMINE MALEATE

SYRUP; ORAL
MYLARAMINE

AA	PENNEX PHARMS	2MG/5ML	N88251 001
			MAR 23, 1984
/AA/	/PHARM/BASICS/	/2MG/5ML/	/N88251/001/ /MAR/23,/1984/

DEXTROAMPHETAMINE SULFATE

TABLET; ORAL
/DEXAMPEX/

/AA/	/LEMMON/	/5MG/	/N83735/001/
/AA/		/10MG/	/N83735/002/
	@ LEMMON	5MG	N83735 001
	@	10MG	N83735 002
	/FERNDEX/		
/AA/	/FERNDALE/	/5MG/	/N84001/001/
	@ FERNDALE	5MG	N84001 001

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
/PROMETHAZINE W/ DEXTROMETHORPHAN/

/AA/	/PHARM/BASICS/	/15MG/5ML;6.25MG/5ML/	/N88864/001/ /JAN/04,/1985/
	@ PENNEX PHARMS	15MG/5ML;6.25MG/5ML	N88864 001 JAN 04, 1985

DEXTROSE

INJECTABLE; INJECTION
DEXTROSE 50% IN PLASTIC CONTAINER

/AP/	/ABBOTT/	/500MG/ML/	/N19445/001/ /JUN/03,/1986/
	@ ABBOTT	500MG/ML	N19445 001 JUN 03, 1986

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE

INJECTABLE; INJECTION
ISOLYTE P IN DEXTROSE 5% IN PLASTIC CONTAINER

MCGAW	5GM/100ML;31MG/100ML;130MG/100ML; 26MG/100ML;320MG/100ML	N19873 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE H IN DEXTROSE 5% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;30MG/100ML;97MG/100ML; 220MG/100ML;140MG/100ML	N19844 001 JUN 10, 1993

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLUCONATE

INJECTABLE; INJECTION
ISOLYTE S IN DEXTROSE 5% IN PLASTIC CONTAINER

AP	MCGAW	5GM/100ML;30MG/100ML;37MG/100ML; 370MG/100ML;530MG/100ML; 500MG/100ML	N19843 001 AUG 09, 1993

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION
ISOLYTE M IN DEXTROSE 5% IN PLASTIC CONTAINER

	MCGAW	5GM/100ML;150MG/100ML;130MG/100ML; 280MG/100ML;91MG/100ML	N19870 001 JUN 10, 1993

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

/HYPAQUE-M;75%/			
/STERLING/	/50%;25%/		/N10220/003/
∂ STERLING	50%;25%		N10220 003
/HYPAQUE-M;90%/			
/STERLING/	/60%;30%/		/N10220/002/
∂ STERLING	60%;30%		N10220 002

DIATRIZOATE SODIUM

/SOLUTION;URETERAL/			
/HYPAQUE/SODIUM/20%/			
/STERLING/	/20%/		/N09561/002/
∂ STERLING	20%		N09561 002

DIAZEPAM

INJECTABLE; INJECTION
DIAZEPAM

AP	MARSAM	5MG/ML	N72370 001 JAN 29, 1993
AP		5MG/ML	N72371 001 JAN 29, 1993
AP		5MG/ML	N72397 001 JAN 29, 1993

VALIUM

/AP/	/ROCHE/	/5MG/ML/	/N16087/001/
AP	+ ROCHE	5MG/ML	N16087 001

INJECTABLE; INTRAVENOUS
DIZAC

	+ KABI	5MG/ML	N19287 001 JUN 18, 1993

TABLET; ORAL
DIAZEPAM

	∂ FERNDALE	2MG	N70903 001 APR 01, 1987
	∂	5MG	N70904 001 APR 01, 1987
	∂	10MG	N70905 001 APR 01, 1987
/AB/	/PHARM/BASICS/	/2MG/	/N70903/001/ /APR/01;/1987/
/AB/		/5MG/	/N70904/001/ /APR/01;/1987/
/AB/		/10MG/	/N70905/001/ /APR/01;/1987/
/AB/	/ZENITH/	/2MG/	/N70360/001/ /SEP/04;/1985/
/AB/		/5MG/	/N70361/001/ /SEP/04;/1985/
	∂ ZENITH	2MG	N70360 001 SEP 04, 1985
	∂	5MG	N70361 001 SEP 04, 1985

DIAZOXIDE

CAPSULE; ORAL
PROGLYCEM

	+ BAKER NORTON	50MG	N17425 001
/+//MEDCL/MKTG/		/50MG/	/N17425/001/

DIAZOXIDE

INJECTABLE; INJECTION

/AP/	/DIAZOXIDE/ QUAD/	/15MG/ML/	/N71908/001/ /JAN/26/1988/	
	∂ QUAD	15MG/ML	N71908 001 JAN 26, 1988	
/AP/	HYPERSTAT /SCHERING/ SCHERING	/15MG/ML/ 15MG/ML	/N16996/001/ N16996 001	

DICLOFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

	VOLTAREN /CIBA/	/0.1%/	/N20037/001/ /MAR/28/1991/
	CIBA VISION	0.1%	N20037 001 MAR 28, 1991

DICLOXACILLIN SODIUM

CAPSULE; ORAL

/AB/	DYCILL /SMITHKLINE/BEECHAM/	/EQ 250MG BASE/	/N60254/002/
/AB/		/EQ 500MG BASE/	/N60254/003/
	∂ SMITHKLINE BEECHAM	EQ 250MG BASE	N60254 002
	∂	EQ 500MG BASE	N60254 003
AB	DYNAPEN APOTHECON	EQ 125MG BASE	N61454 002
AB		EQ 250MG BASE	N61454 001
/AB/	/BRISTOL/	/EQ 125MG BASE/	/N61454/002/
/AB/		/EQ 250MG BASE/	/N61454/001/

POWDER FOR RECONSTITUTION; ORAL

AB	DYNAPEN APOTHECON	EQ 62.5MG BASE/5ML	N61455 001
/AB/	/BRISTOL/	/EQ 62.5MG BASE/5ML/	/N61455/001/

DICUMAROL

TABLET; ORAL

	DICUMAROL /*//ABBOTT/	/50MG/	/N05545/004/
	∂ ABBOTT	50MG	N05545 004

DICYCLOMINE HYDROCHLORIDE

CAPSULE; ORAL

/AB/	DICYCLOMINE HCL /PIONEER/PHARMS/	/10MG/	/N89361/001/ /JAN/10/1989/
	∂ PIONEER PHARMS	10MG	N89361 001 JAN 10, 1989

TABLET; ORAL

/AB/	DICYCLOMINE HCL /PIONEER/PHARMS/	/20MG/	/N88585/001/ /AUG/20/1986/
	∂ PIONEER PHARMS	20MG	N88585 001 AUG 20, 1986

DIETHYLSTILBESTROL

/INJECTABLE;/INJECTION/

	/STILBESTROL/ /SQUIBB/	/0.2MG/ML/	/N04056/003/
		/0.5MG/ML/	/N04056/004/
		/1MG/ML/	/N04056/005/
		/5MG/ML/	/N04056/006/
	∂ SQUIBB	0.2MG/ML	N04056 003
	∂	0.5MG/ML	N04056 004
	∂	1MG/ML	N04056 005
	∂	5MG/ML	N04056 006

/SUPPOSITORY;/VAGINAL/

	/STILBESTROL/ /*//SQUIBB/	/0.1MG/	/N04056/001/
	/*/	/0.5MG/	/N04056/002/
	∂ SQUIBB	0.1MG	N04056 001
	∂	0.5MG	N04056 002

TABLET, DELAYED RELEASE; ORAL

	STILBETIN		
/BE/	/SQUIBB/	/0.1MG/	/N04056/011/
	∂ SQUIBB	0.1MG	N04056 011

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
CARDIZEM CD

BC +	CARDERM	180MG	N20062 002 DEC 27, 1991
BC +		240MG	N20062 003 DEC 27, 1991
+		120MG	N20062 001 AUG 10, 1992
+		300MG	N20062 004 DEC 27, 1991
/BC/	/+//MARION/MERRELL/DOW/	/180MG/	/N20062/002/ /DEC/27,/1991/
/BC/	/+/	/240MG/	/N20062/003/ /DEC/27,/1991/
	/+/	/120MG/	/N20062/001/ /AUG/10,/1992/
	/+/	/300MG/	/N20062/004/ /DEC/27,/1991/

TABLET; ORAL
DILTIAZEM HCL

AB	APOTHECON	30MG	N74051 001 MAR 31, 1993
AB		60MG	N74051 002 MAR 31, 1993
AB		90MG	N74051 003 MAR 31, 1993
AB		120MG	N74051 004 MAR 31, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL
DIPHENHYDRAMINE HCL

/AA/	/LEMMON/	/25MG/	/N85874/001/
/AA/		/50MG/	/N85874/002/
	∂ LEMMON	25MG	N85874 001
	∂	50MG	N85874 002

INJECTABLE; INJECTION
DIPHENHYDRAMINE HCL

/AP/	/BEL/MAR/	/10MG/ML/	/N80822/001/
	∂ BEL MAR	10MG/ML	N80822 001
/AP/	/FRISTOL/	/10MG/ML/	/N87066/001/
	∂ FUJISAWA	10MG/ML	N87066 001

DIPHENYLPYRALINE HYDROCHLORIDE

/CAPSULE;/EXTENDED/RELEASE;/ORAL/
/HISPRIL/

/+//SMITHKLINE/BEECHAM/		/5MG/	/N11945/001/
∂ SMITHKLINE BEECHAM		5MG	N11945 001

DISOPYRAMIDE PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL
DISOPYRAMIDE PHOSPHATE

/AB/	/KV/	/EQ 100MG BASE/	/N71929/001/ /AUG/19,/1988/
B*	KV	EQ 100MG BASE	N71929 001 AUG 19, 1988

DIVALPROEX SODIUM

/TABLET;/DELAYED/RELEASE;/ORAL/
/DEPAKOTE/CP/

/ABBOTT/		/EQ/250MG/BASE/	/N19794/001/ /JUL/11,/1990/
		/EQ/500MG/BASE/	/N19794/002/ /JUL/11,/1990/
∂ ABBOTT		EQ 250MG BASE	N19794 001 JUL 11, 1990
∂		EQ 500MG BASE	N19794 002 JUL 11, 1990

DOPAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOPAMINE HCL

>_DLT_>/AP/	/ASTRA/	/40MG/ML/	/N70087/001/	
>_DLT_>			/OCT/23,/1985/	
>_DLT_>/AP/		/80MG/ML/	/N70089/001/	
>_DLT_>			/OCT/23,/1985/	
>_DLT_>/AP/		/80MG/ML/	/N70090/001/	
>_DLT_>			/OCT/23,/1985/	
>_DLT_>/AP/		/160MG/ML/	/N70093/001/	
>_DLT_>			/OCT/23,/1985/	
>_DLT_>/AP/		/160MG/ML/	/N70094/001/	
>_DLT_>			/OCT/23,/1985/	
>_ADD_>	@ ASTRA	40MG/ML	N70087 001 OCT 23, 1985	
>_ADD_>				
>_ADD_>	@	80MG/ML	N70089 001 OCT 23, 1985	
>_ADD_>				
>_ADD_>	@	80MG/ML	N70090 001 OCT 23, 1985	
>_ADD_>				
>_ADD_>	@	160MG/ML	N70093 001 OCT 23, 1985	
>_ADD_>				
>_ADD_>	@	160MG/ML	N70094 001 OCT 23, 1985	
>_ADD_>				
/AP/	/BRISTOL/	/40MG/ML/	/N18549/001/	
	@ FUJISAWA	40MG/ML	/MAR/11,/1983/ N18549 001 MAR 11, 1983	
/AP/	/LYPHOMED/	/40MG/ML/	/N70012/001/	
	@ LYPHOMED	40MG/ML	/JUN/12,/1985/ N70012 001 JUN 12, 1985	

DOXEPIN HYDROCHLORIDE

CONCENTRATE; ORAL

DOXEPIN HCL

AA	PENNEX PHARMS	EQ 10MG BASE/ML	N71918 001 JUL 20, 1988
/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N71918/001/ /JUL/20,/1988/

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE MONOHYDRATE

/+//MEDICOPHARMA/		/EQ/100MG/BASE/	/N50641/001/ /DEC/29,/1989/
+	VINTAGE	EQ 100MG BASE	N50641 001 DEC 29, 1989

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

DOXYCYCLINE HYCLATE

/AB/	/PAR/	/EQ 50MG BASE/	/N62434/001/ /OCT/19,/1984/
/AB/		/EQ 100MG BASE/	/N62442/001/ /DEC/22,/1983/
	@ PAR	EQ 50MG BASE	N62434 001 OCT 19, 1984
	@	EQ 100MG BASE	N62442 001 DEC 22, 1983

TABLET; ORAL

DOXY-TABS

	@ RACHELLE	EQ 50MG BASE	N62269 003
	DOXYCYCLINE HYCLATE		
/AB/	/HEATHER/	/EQ 100MG BASE/	/N62462/001/ /MAY/11,/1983/
	@ HEATHER	EQ 100MG BASE	N62462 001 MAY 11, 1983

DROPERIDOL

INJECTABLE; INJECTION

DROPERIDOL

/AP/	/QUAD/	/2.5MG/ML/	/N71941/001/ /AUG/17,/1988/
	@ QUAD	2.5MG/ML	N71941 001 AUG 17, 1988
/AP/	/SMITH/NEPHEW/SOLOPAK/	/2.5MG/ML/	/N71754/001/ /SEP/06,/1988/
/AP/		/2.5MG/ML/	/N71755/001/ /SEP/06,/1988/
AP	SOLOPAK	2.5MG/ML	N71754 001 SEP 06, 1988
AP		2.5MG/ML	N71755 001 SEP 06, 1988

DROPERIDOL; FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE AND DROPERIDOL

>_DLT_>/AP/	/ASTRA/	/2.5MG/ML;/ /EQ 0.05MG BASE/ML/	/N72028/001/ /APR/13,/1989/
>_DLT_>			
>_DLT_>			
>_ADD_>	@ ASTRA	2.5MG/ML; EQ 0.05MG BASE/ML	N72028 001 APR 13, 1989
>_ADD_>			
>_ADD_>			

EDETATE DISODIUM

INJECTABLE; INJECTION
/DISODIUM EDETATE/

/AP/	/STERIS/	/150MG/ML/	/N84356/001/
	@ STERIS	150MG/ML	N84356 001

EFLORNITHINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/ORNIDYL/

	/MERRELL/DOW/	/200MG/ML/	/N19879/002/ /NOV/28,/1990/
	@ MERRELL DOW	200MG/ML	N19879 002 NOV 28, 1990

ENCAINIDE HYDROCHLORIDE

/CAPSULE;/ORAL/
/ENCAID/

	/+//BRISTOL/	/50MG/	/N18981/004/ /DEC/24,/1986/
		/25MG/	/N18981/002/ /DEC/24,/1986/
		/35MG/	/N18981/003/ /DEC/24,/1986/
	@ BRISTOL	25MG	N18981 002 DEC 24, 1986
	@	35MG	N18981 003 DEC 24, 1986
	@	50MG	N18981 004 DEC 24, 1986

ENOXACIN

TABLE; ORAL
PENETREX

	/+//PARKE/DAVIS/	/400MG/	/N19616/005/ /DEC/31,/1991/
		/200MG/	/N19616/004/ /DEC/31,/1991/
	+ RHONE POULENC RORER	400MG	N19616 005 DEC 31, 1991
		200MG	N19616 004 DEC 31, 1991

ENOXAPARIN SODIUM

INJECTABLE; INJECTION
LOVENOX

	RHONE POULENC RORER	30MG/0.3ML	N20164 001 MAR 29, 1993

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION
LIDOCAINE HCL AND EPINEPHRINE

AP	STERLING WINTHROP	0.01MG/ML;2%	N40057 002 FEB 26, 1993
AP		0.02MG/ML;2%	N40057 001 FEB 26, 1993

LIDOCAINE HCL W/ EPINEPHRINE

/AP/	/BEL/MAR/	/0.01MG/ML;1%/	/N80820/001/
/AP/		/0.01MG/ML;2%/	/N80757/001/
	@ BEL MAR	0.01MG/ML;1%	N80820 001
	@	0.01MG/ML;2%	N80757 001

EPINEPHRINE; PROCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/
/PROCAINE/HCL/W//EPINEPHRINE/

	/BEL/MAR/	/0.02MG/ML;1%/	/N80758/001/
		/0.02MG/ML;2%/	/N80759/001/
	@ BEL MAR	0.02MG/ML;1%	N80758 001
	@	0.02MG/ML;2%	N80759 001

ERGOLOID MESYLATES

TABLET; ORAL
HYDERGINE

	/SANDOZ/	/0.5MG/	/N17993/003/
	@ SANDOZ	0.5MG	N17993 003

TABLET; SUBLINGUAL
HYDROGENATED ERGOT ALKALOIDS

/AA/	/ZENITH/	/0.5MG/	/N87186/001/
	@ ZENITH	0.5MG	N87186 001

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR

/AA/	/FISONS/	/2MG/	/N87693/001/ /FEB/24,/1993/

ERGOTAMINE TARTRATE

TABLET; SUBLINGUAL
ERGOMAR
AA LOTUS 2MG N87693 001 FEB 24, 1983

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL
/ERIC/SPRINGLES/
/*//FAULDING/ /125MG/ /N50593/001/ /JUL/22,/1985/
@ FAULDING 125MG N50593 001 JUL 22, 1985

GEL; TOPICAL
ERYGEL
/AT/ /HERBERT/ /2%/ /N50617/001/ /OCT/21,/1987/
AT + HERBERT 2% N50617 001 OCT 21, 1987

ERYTHROMYCIN
AT STIEFEL 2% N63211 001 JAN 29, 1993

OINTMENT; OPHTHALMIC
ERYTHROMYCIN
/AT/ /PHARMADERM/ /5MG/GM/ /N62446/001/ /SEP/26,/1983/
@ PHARMADERM 5MG/GM N62446 001 SEP 26, 1983
/AT/ /PHARMAFAIR/ /5MG/GM/ /N62481/001/ /APR/05,/1984/
@ PHARMAFAIR 5MG/GM N62481 001 APR 05, 1984

/POWDER;FOR RX/COMPOUNDING/
/ERYTHROMYCIN/
/PADDOCK/ /100%/ /N50610/001/ /NOV/07,/1986/
@ PADDOCK 100% N50610 001 NOV 07, 1986

SOLUTION; TOPICAL
ERYTHRA-DERM
AT PADDOCK 2% N62687 001 FEB 05, 1988

ERYTHROMYCIN

SOLUTION; TOPICAL
ERYTHROMYCIN
AT BARRE 2% N62957 001 JUL 21, 1988
/AT/ /NASKA/ /2%/ /N62957/001/ /JUL/21,/1988/
AT PENNEX PHARMS 2% N62825 001 OCT 23, 1987
/AT/ /PHARM/BASICS/ /2%/ /N62825/001/ /OCT/23,/1987/
/ETS-2%/
/AT/ /PADDOCK/ /2%/ /N62687/001/ /FEB/05,/1988/

SWAB; TOPICAL
C-SOLVE-2
AT SYOSSET 2% N62751 001 JUL 30, 1993

TABLET, COATED PARTICLES; ORAL
PCE
/*//ABBOTT/ /333MG/ /N50611/001/ /SEP/09,/1986/
+ ABBOTT 500MG N50611 002 AUG 22, 1990
333MG N50611 001 SEP 09, 1986
/500MG/ /N50611/002/ /AUG/22,/1990/

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL
ERYTHROMYCIN ESTOLATE
@ LIFE LABS EQ 250MG BASE/5ML N62362 001 DEC 17, 1982

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE
AP GENSIA EQ 500MG BASE/VIAL N63253 001 JUL 30, 1993
AP EQ 1GM BASE/VIAL N63253 002 JUL 30, 1993

ERYTHROMYCIN LACTOBIONATE

INJECTABLE; INJECTION
ERYTHROMYCIN LACTOBIONATE

/AP/	/LYPHOMED/	/EQ 500MG BASE/VIAL/	/N62604/001/	> ADD >	AB	WATSON LABS	0.75MG	N81213 001
			/NOV/24,/1986/	> ADD >				SEP 23, 1993
/AP/		/EQ 1GM BASE/VIAL/	/N62604/002/	> ADD >	AB		1.5MG	N81214 001
			/NOV/24,/1986/	> ADD >				SEP 23, 1993
	@ LYPHOMED	EQ 500MG BASE/VIAL	N62604 001	> ADD >	AB		3MG	N81215 001
			NOV 24, 1986	> ADD >				SEP 23, 1993
	@	EQ 1GM BASE/VIAL	N62604 002	> ADD >	AB		6MG	N81216 001
			NOV 24, 1986	> ADD >				SEP 23, 1993

ESMOLOL HYDROCHLORIDE

INJECTABLE; INJECTION
BREVIBLOC

+	ANAQUEST	10MG/ML	N19386 001	> ADD >	AB	OGEN 1,25 ABBOTT	1.5MG	N83220 002
			AUG 15, 1988	> DLT >		/-/	/1.5MG/	/N83220/002/
+		250MG/ML	N19386 002			OGEN 2,5		
			DEC 31, 1986	> ADD >	AB	+ ABBOTT	3MG	N83220 003
	/DUPONT/	/10MG/ML/	/N19386/001/	> DLT >		/-/	/3MG/	/N83220/003/
			/AUG/15,/1988/			OGEN 5		
		/250MG/ML/	/N19386/002/	> ADD >	AB	ABBOTT	6MG	N83220 004
			/DEC/31,/1986/					

ESTRADIOL

TABLET; ORAL
ESTRACE

	BRISTOL MYERS SQUIBB	0.5MG	N81295 001 JUN 30, 1993

ESTROGENS, CONJUGATED

CREAM; TOPICAL, VAGINAL
PREMARIN

+	AYERST	0.625MG/GM	N20216 001
/-/	/WYETH/AYERST/	/0.625MG/GM/	/N83273/001/

TABLET; ORAL
PREMARIN

+	NYETH AYERST	1.25MG	N04782 001
/-/		/2.5MG/	/N04782/002/
		/1.25MG/	/N04782/001/
		2.5MG	N04782 002

ESTROPIPATE

TABLET; ORAL
ESTROPIPATE

> ADD >	AB	WATSON LABS	0.75MG	N81213 001			
> ADD >				SEP 23, 1993			
> ADD >	AB		1.5MG	N81214 001			
> ADD >				SEP 23, 1993			
> ADD >	AB		3MG	N81215 001			
> ADD >				SEP 23, 1993			
> ADD >	AB		6MG	N81216 001			
> ADD >				SEP 23, 1993			
		OGEN 1,25					
/AB/	/-/	/ABBOTT/	/1.5MG/	/N83220/002/			
		OGEN 2,5					
> ADD >	AB	+ ABBOTT	3MG	N83220 003			
> DLT >		/-/	/3MG/	/N83220/003/			
		OGEN 5					
> ADD >	AB	ABBOTT	6MG	N83220 004			

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21
NORETHIN 1/35E-21

AB	ROBERTS	0.035MG;1MG	N71480 001	
			APR 12, 1988	
/AB/	/SCHIAPPARELLI/SEARLE/	0.035MG;1MG/	/N71480/001/	
			/APR/12,/1988/	

TABLET; ORAL-28
NORETHIN 1/35E-28

AB	ROBERTS	0.035MG;1MG	N71481 001	
			APR 12, 1988	
/AB/	/SCHIAPPARELLI/SEARLE/	0.035MG;1MG/	/N71481/001/	
			/APR/12,/1988/	

ETHOSUXIMIDE

SYRUP; ORAL
ETHOSUXIMIDE

AA	COPLEY	250MG/5ML	N81306 001 JUL 30, 1993

ZARONTIN

AA	PARKE DAVIS	250MG/5ML	N80258 001

ETHYNODIOL DIACETATE; MESTRANOL

/TABLET;ORAL-21/
/OVULEN-21/
/+//SEARLE/ /1MG;0.1MG/ /N16029/003/
@ SEARLE 1MG;0.1MG N16029 003

/TABLET;ORAL-28/
/OVULEN-28/
/SEARLE/ /1MG;0.1MG/ /N16705/001/
@ SEARLE 1MG;0.1MG N16705 001

ETIDRONATE DISODIUM

INJECTABLE; INJECTION
DIDRONEL
+ MGI 50MG/ML N19545 001
APR 20, 1987

/P/AND/S/ /50MG/ML/ /N19545/001/
/APR/20,/1987/

FELBAMATE

SUSPENSION; ORAL
FELBATOL
+ WALLACE 600MG/5ML N20189 003
JUL 29, 1993

TABLET; ORAL
FELBATOL
+ WALLACE 600MG N20189 002
JUL 29, 1993

400MG N20189 001
JUL 29, 1993

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ /0.01%/ /N88047/001/
/DEC/16,/1982/
/AT/ /0.025%/ /N88045/001/
/DEC/16,/1982/

@ PHARMADERM 0.01% N88047 001
DEC 16, 1982

@ 0.025% N88045 001
DEC 16, 1982

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL
FLUOCINOLONE ACETONIDE
>DLT >/AT/ /PHARMAFAIR/ /0.01%/ /N88499/001/
>DLT > /AUG/02,/1984/
>DLT >/AT/ /0.025%/ /N88506/001/
>DLT > /AUG/02,/1984/
>ADD > @ PHARMAFAIR 0.01% N88499 001
>ADD > AUG 02, 1984
>ADD > @ 0.025% N88506 001
>ADD > AUG 02, 1984

OINTMENT; TOPICAL
FLUOCINOLONE ACETONIDE
/AT/ /PHARMADERM/ /0.025%/ /N88046/001/
/DEC/16,/1982/
@ PHARMADERM 0.025% N88046 001
DEC 16, 1982
>DLT >/AT/ /PHARMAFAIR/ /0.025%/ /N88507/001/
>DLT > /FEB/27,/1984/
>ADD > @ PHARMAFAIR 0.025% N88507 001
>ADD > FEB 27, 1984

SOLUTION; TOPICAL
FLUOCINOLONE ACETONIDE
@ PENNEX PHARMS 0.01% N88312 001
JAN 27, 1984
/AT/ /PHARM/BASICS/ /0.01%/ /N88312/001/
/JAN/27,/1984/

FLUOROURACIL

INJECTABLE; INJECTION
FLUOROURACIL
/AP/ /MARCHAR/ /50MG/ML/ /N87791/001/
/JAN/18,/1983/
@ MARCHAR 50MG/ML N87791 001
JAN 18, 1983

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL
PROZAC
LILLY EQ 10MG BASE N18936 006
DEC 23, 1992

FLUPHENAZINE DECANOATE

INJECTABLE; INJECTION
PROLIXIN DECANOATE

AO	+ APOTHECON	25MG/ML	N16727 001	
/AO/	/SQUIBB/	/25MG/ML/	/N16727/001/	

FLUPHENAZINE ENANTHATE

INJECTABLE; INJECTION
PROLIXIN ENANTHATE

	+ APOTHECON	25MG/ML	N16110 001	
	/SQUIBB/	/25MG/ML/	/N16110/001/	

FLUPHENAZINE HYDROCHLORIDE

CONCENTRATE; ORAL
PROLIXIN

AA	APOTHECON	5MG/ML	N70533 001 NOV 07, 1985	
/AA/	/SQUIBB/	/5MG/ML/	/N70533/001/ /NOV/07,/1985/	

ELIXIR; ORAL
FLUPHENAZINE HCL

AA	COPLEY	2.5MG/5ML	N81310 001 APR 29, 1993	

PROLIXIN

AA	APOTHECON	2.5MG/5ML	N12145 003	
	/SQUIBB/	/2.5MG/5ML/	/N12145/003/	

INJECTABLE; INJECTION
PROLIXIN

AP	+ APOTHECON	2.5MG/ML	N11751 005	
/AP/	/SQUIBB/	/2.5MG/ML/	/N11751/005/	

TABLET; ORAL
PROLIXIN

AB	APOTHECON	1MG	N11751 004	
AB		2.5MG	N11751 001	
AB		5MG	N11751 003	
AB	+	10MG	N11751 002	
/AB/	/SQUIBB/	/1MG/	/N11751/004/	
/AB/		/2.5MG/	/N11751/001/	
/AB/		/5MG/	/N11751/003/	
/AB/		/10MG/	/N11751/002/	

FLUPHENAZINE HYDROCHLORIDE

/TABLET;/EXTENDED/RELEASE;/ORAL/
/PERMITIL/

/+/	/SCHERING/	/1MG/	/N12419/004/
	∂ SCHERING	1MG	N12419 004

FOLIC ACID

TABLET; ORAL
FOLIC ACID

/AA/	/PIONEER/PHARMS/	/1MG/	/N88949/001/ /SEP/13,/1985/	
	∂ PIONEER PHARMS	1MG	N88949 001 SEP 13, 1985	

FUROSEMIDE

INJECTABLE; INJECTION
FUROSEMIDE

>DLT>/AP/	/ASTRA/	/10MG/ML/	/N70014/001/ /SEP/09,/1985/	
>DLT> >ADD> >ADD>	∂ ASTRA	10MG/ML	N70014 001 SEP 09, 1985	

SOLUTION; ORAL
FUROSEMIDE

AA	PENNEX PHARMS	10MG/ML	N70655 001 OCT 02, 1987	
/AA/	/PHARM/BASICS/	/10MG/ML/	/N70655/001/ /OCT/02,/1987/	

TABLET; ORAL
FUROSEMIDE

/AB/	/PARKE/DAVIS/	/20MG/	/N18419/001/ /JAN/31,/1983/	
/AB/		/40MG/	/N18419/002/ /JAN/31,/1983/	
/AB/		/80MG/	/N18419/003/ /NOV/13,/1984/	
	∂ WARNER CHILCOTT	20MG	N18419 001 JAN 31, 1983	
	∂	40MG	N18419 002 JAN 31, 1983	
	∂	80MG	N18419 003 NOV 13, 1984	

GADODIAMIDE

INJECTABLE; INJECTION
OMNISCAN
STERLING WINTHROP 287MG/ML N20123 001
JAN 08, 1993

GEMFIBROZIL

CAPSULE; ORAL
GEMFIBROZIL
AB MYLAN 300MG N73466 001
JAN 25, 1993
AB PUREPAC 300MG N72929 001
JAN 29, 1993

LOPID
AB + PARKE DAVIS 300MG N18422 002

TABLET; ORAL
> ADD > GEMFIBROZIL
> ADD > AB LEDERLE 600MG N74270 001
> ADD > SEP 27, 1993

LOPID
> ADD > AB + PARKE DAVIS 600MG N18422 003
> ADD > NOV 20, 1986

GENTAMICIN SULFATE

CREAM; TOPICAL
GENTAMICIN SULFATE
/AT/ /PHARMADERM/ /EQ 1MG BASE/GM/ /N62553/001/
/JUL/05/1984/
∂ PHARMADERM EQ 1MG BASE/GM N62530 001
JUL 05, 1984

INJECTABLE; INJECTION
GENTAMICIN SULFATE
/AP/ /WYETH AYERST/ /EQ 10MG BASE/ML/ /N62264/001/
/AP/ /EQ 40MG BASE/ML/ /N62264/002/
∂ WYETH AYERST EQ 10MG BASE/ML N62264 001
∂ EQ 40MG BASE/ML N62264 002

OINTMENT; OPHTHALMIC
/GENTAFAIR/
/AT/ /PHARMAFAIR/ /EQ 3MG BASE/GM/ /N62443/001/
/MAY/26/1983/
∂ PHARMAFAIR EQ 3MG BASE/GM N62443 001
MAY 26, 1983

GLIPIZIDE

TABLET; ORAL
GLUCOTROL
+ PFIZER 10MG N17783 002
MAY 08, 1984
2.5MG N17783 003
MAY 11, 1993
5MG N17783 001
MAY 08, 1984
/+//PFIZER/ /10MG/ /N17783/002/
/MAY/08/1984/
/5MG/ /N17783/001/
/MAY/08/1984/

GLUCAGON HYDROCHLORIDE

INJECTABLE; INJECTION
GLUCAGON
/AP/ /LILLY/ /EQ 1MG BASE/VIAL/ /N12122/001/
LILLY EQ 1MG BASE/VIAL N12122 001
/AP/ /QUAD/ /EQ 1MG BASE/VIAL/ /N71022/001/
/MAR/04/1987/
∂ QUAD EQ 1MG BASE/VIAL N71022 001
MAR 04, 1987

GLUTETHIMIDE

CAPSULE; ORAL
DORIDEN
/∂/PHONE/POULENC/RORER//500MG/ /N009519/008/

GLYBURIDE

TABLET; ORAL
/GLYBATE/
/BX/ /HOECHST/ROUSSEL/ /1.5MG/ /N20055/001/
/APR/17/1992/
/BX/ /3MG/ /N20055/002/
/APR/17/1992/
∂ HOECHST ROUSSEL 1.5MG N20055 001
APR 17, 1992
∂ 3MG N20055 002
APR 17, 1992

GLYBURIDE

TABLET; ORAL
GLYNASE

/BX/	/UPJOHN/	/1.5MG/	/N20051/001/	
			/MAR/04,/1992/	
/+/		/3MG/	/N20051/002/	
			/MAR/04,/1992/	
	UPJOHN	3MG	N20051 002	
			MAR 04, 1992	
> ADD >	+	6MG	N20051 004	
> ADD >			SEP 24, 1993	
		1.5MG	N20051 001	
			MAR 04, 1992	
> ADD >		4.5MG	N20051 003	
> ADD >			SEP 24, 1993	

GONADORELIN ACETATE

INJECTABLE; INJECTION
LUTREPULSE KIT

+	FERRING	0.8MG/VIAL	N19687 001
			OCT 10, 1989
+		3.2MG/VIAL	N19687 002
			OCT 10, 1989
/LUTREPULSE/PUMP/KIT/			
/FERRING/		/0.8MG/VIAL/	/N19687/001/
			/OCT/10,/1989/
		/3.2MG/VIAL/	/N19687/002/
			/OCT/10,/1989/

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION
CHORIONIC GONADOTROPIN

/AP/	/BEL/MAR/	/5,000 UNITS/VIAL/	/N17054/001/
AP	@ BEL MAR	5,000 UNITS/VIAL	N17054 001
/AP/		/10,000 UNITS/VIAL/	/N17054/002/
AP	@	10,000 UNITS/VIAL	N17054 002

GOSERELIN ACETATE

IMPLANT; IMPLANTATION
ZOLADEX

/+//IMPERIAL/CHEM/		/EQ/3.6MG/BASE/	/N19726/001/
			/DEC/29,/1989/
+	ZENECA	EQ 3.6MG BASE	N19726 001
			DEC 29, 1989

GRAMICIDIN; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SOLUTION/DROPS; OPHTHALMIC
/NEO-POLYCIN/

/AT/	/DOW/	/0.025MG/ML;EQ 1.75MG BASE/ML;/	
		/10,000 UNITS/ML/	/N60427/001/
@ DOW		0.025MG/ML;EQ 1.75MG BASE/ML;	
		10,000 UNITS/ML	N60427 001

GRISEOFULVIN, MICROCRYSTALLINE

CAPSULE; ORAL
GRISACTIN

/WYETH/AYERST/		/125MG/	/N50051/002/
@ WYETH AYERST		125MG	N50051 002

HALOFANTRINE HYDROCHLORIDE

/TABLET;ORAL/
/HALFAN/

/+//SMITHKLINE/BEECHAM/		/250MG/	/N20250/001/
			/JUL/24,/1992/
@ SMITHKLINE BEECHAM		250MG	N20250 001
			JUL 24, 1992

HALOPERIDOL LACTATE

CONCENTRATE; ORAL
HALOPERIDOL

@ PENNEX PHARMS		EQ 2MG BASE/ML	N70710 001
			MAR 07, 1986
AA	PHARM ASSOC	EQ 2MG BASE/ML	N73037 001
			FEB 26, 1993
/AA/	/PHARM/BASICS/	/EQ 2MG BASE/ML/	/N70710/001/
			/MAR/07,/1986/
> ADD > AA	SILARX	EQ 2MG BASE/ML	N73364 001
> ADD >			SEP 28, 1993

INJECTABLE; INJECTION
HALOPERIDOL

AP	MARSAM	EQ 5MG BASE/ML	N72516 001
			FEB 25, 1993
AP		EQ 5MG BASE/ML	N72517 001
			FEB 25, 1993
/AP/	/SMITH/NEPHEW/SOLOPAK/	/EQ 5MG BASE/ML/	/N70661/001/
			/DEC/14,/1987/
/AP/		/EQ 5MG BASE/ML/	/N70664/001/
			/DEC/14,/1987/

HALOPERIDOL LACTATE

INJECTABLE; INJECTION
HALOPERIDOL

AP	SOLOPAK	EQ 5MG BASE/ML	N70801 001 DEC 14, 1987
AP		EQ 5MG BASE/ML	N70864 001 DEC 14, 1987

HEPARIN SODIUM

INJECTABLE; INJECTION
HEPARIN SODIUM

AP	ORGANON	20,000 UNITS/ML	N00552 001
AP	ORGANON	40,000 UNITS/ML	N00552 002

HEXACHLOROPHENE

AEROSOL; TOPICAL

	XTTRIUM	3%	N18375 001

EMULSION; TOPICAL

AT	HUNTINGTON	3%	N17411 001
AT	STERLING	3%	N08402 001
AT	XTTRIUM	3%	N19055 001 NOV 30, 1984

SOLUTION; TOPICAL

AT	DIAL	0.25%	N17421 002
	HUNTINGTON	1%	N17412 001
	HUNTINGTON	0.25%	N17412 002

HEXACHLOROPHENE

SPONGE; TOPICAL

AT	PROF DSPLS	3%	N18363 001
AT	STERLING	3%	N17446 001
	3M	330MG	N17413 001

HEXAFLUORENIUM BROMIDE

INJECTABLE; INJECTION
MYLAXEN

	WALLACE	20MG/ML	N09789 003

HISTAMINE PHOSPHATE

INJECTABLE; INJECTION
HISTAMINE PHOSPHATE

	LILLY	EQ 0.1MG BASE/ML	N00734 003
		EQ 0.2MG BASE/ML	N00734 002
		EQ 1MG BASE/ML	N00734 001

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

SYRUP; ORAL
MYCODONE

AA	PENNEX PHARMS	1.5MG/5ML;5MG/5ML	N88008 001 MAR 03, 1983
AA	PHARM BASICS	1.5MG/5ML;5MG/5ML	N88008 001 MAR 03, 1983

HYDRALAZINE HYDROCHLORIDE; RESERPINE

TABLET; ORAL
SERPASIL-APRESOLINE

	CIBA	25MG;0.2MG	N09296 002
	CIBA	25MG;0.1MG	N09296 004
		50MG;0.2MG	N09296 002

HYDROCHLOROTHIAZIDE

SOLUTION; ORAL

HYDROCHLOROTHIAZIDE

∂ PENNEX PHARMS	50MG/5ML	N89661 001 JUN 20, 1988	
/AA/ /PHARM/BASICS/	/50MG/5ML/	/N89661/001/ /JUN/20,/1988/	
/AA/ /ROXANE/	/50MG/5ML/	/N88587/001/ /JUL/02,/1984/	
ROXANE	50MG/5ML	N88587 001 JUL 02, 1984	

TABLET; ORAL

HYDROCHLOROTHIAZIDE

/AB/ /INWOOD/	/25MG/	/N84776/001/	
/AB/	/50MG/	/N84776/002/	
∂ INWOOD	25MG	N84776 001	
∂	50MG	N84776 002	
/AB/ /LEMMON/	/50MG/	/N88923/001/ /FEB/07,/1985/	
∂ LEMMON	50MG	N88923 001 FEB 07, 1985	

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

NORMOZIDE

/AB/ /SCHERING/	/25MG;100MG/	/N19046/001/ /APR/06,/1987/	
/AB/	/25MG;200MG/	/N19046/002/ /APR/06,/1987/	
/AB//+/	/25MG;300MG/	/N19046/003/ /APR/06,/1987/	
+ SCHERING	25MG;300MG	N19046 003 APR 06, 1987	
	25MG;100MG	N19046 001 APR 06, 1987	
	25MG;200MG	N19046 002 APR 06, 1987	

HYDROCHLOROTHIAZIDE; LABETALOL HYDROCHLORIDE

TABLET; ORAL

/TRIAMTERENE,HCT/

/AB/ /GLAXO/	/25MG;100MG/	/N19174/001/ /APR/10,/1987/	
/AB/	/25MG;200MG/	/N19174/002/ /APR/10,/1987/	
/AB/	/25MG;300MG/	/N19174/003/ /APR/10,/1987/	
∂ GLAXO	25MG;100MG	N19174 001 APR 10, 1987	
∂	25MG;200MG	N19174 002 APR 10, 1987	
∂	25MG;300MG	N19174 003 APR 10, 1987	

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC 20/12.5

/AB/ /IMPERIAL/CHEM/	/12.5MG;20MG/	/N19888/001/ /SEP/20,/1990/	
AB ZENECA	12.5MG;20MG	N19888 001 SEP 20, 1990	

ZESTORETIC 20/25

/AB/ /IMPERIAL/CHEM/	/25MG;20MG/	/N19888/002/ /JUL/20,/1989/	
AB ZENECA	25MG;20MG	N19888 002 JUL 20, 1989	

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE W/ HYDROCHLOROTHIAZIDE

/AB/ /UPSHER/SMITH/	/25MG;25MG/	/N87553/001/	
∂ UPSHER SMITH	25MG;25MG	N87553 001	

HYDROCHLOROTHIAZIDE; TRIAMTERENE

TABLET; ORAL

TRIAMTERENE AND HYDROCHLOROTHIAZIDE

> ADD >	AB	WATSON LABS	25MG;37.5MG	N73449 001 SEP 23, 1993
> ADD >				

HYDROCORTISONE

CREAM; TOPICAL

HYDROCORTISONE

AT	BARRE	2.5%	N89682 001 MAR 10, 1988
/AT/	/BIOCRAFT/	/0.5%/	/N80400/002/
/AT/		/1%/	/N80400/003/
/AT/		/2.5%/	/N80400/004/
	@ BIOCRAFT	0.5%	N80400 002
	@	1%	N80400 003
	@	2.5%	N80400 004
/AT/	/MASKA/	/2.5%/	/N89682/001/ /MAR/10,/1988/
/AT/	/PHARMADERM/	/1%/	/N88845/001/ /FEB/27,/1986/
	@ PHARMADERM	1%	N88845 001 FEB 27, 1986

LOTION; TOPICAL

ACTICORT

AT	BAKER NORTON	1%	N86535 001
/AT/	/KEY/PHARMS/	/1%/	/N86535/001/
/AT/	/BALNEOL-HC/ /SOLVAY/	/1%/	/N88041/001/ /DEC/03,/1982/
	@ SOLVAY	1%	N88041 001 DEC 03, 1982

OINTMENT; TOPICAL

HYDROCORTISONE

AT	FOUGERA	2.5%	N81203 001 MAY 28, 1993
/AT/	/PHARMADERM/	/1%/	/N88842/001/ /FEB/09,/1987/
	@ PHARMADERM	1%	N88842 001 FEB 09, 1987

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC

/NEOMYCIN SULFATE, POLYMYXIN B SULFATE & HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62617/001/ /SEP/18,/1985/
	@ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62617 001 SEP 18, 1985

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OPHTHALMIC

/NEOMYCIN SULFATE-POLYMYXIN B SULFATE-HYDROCORTISONE/

/AT/	/PHARMAFAIR/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/	/N62623/001/ /SEP/24,/1985/
	@ PHARMAFAIR	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML	N62623 001 SEP 24, 1985

HYDROCORTISONE ACETATE

INJECTABLE; INJECTION

HYDROCORTISONE ACETATE

/BP/	/BEL/MAR/	/25MG/ML/	/N83739/001/
/BP/		/50MG/ML/	/N83739/002/
	@ BEL MAR	25MG/ML	N83739 001
	@	50MG/ML	N83739 002

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

LOTION; TOPICAL

PRAMOSONE

	/FERNDALE/	/0.5%;1%/	/N83213/002/
	@ FERNDALE	0.5%;1%	N83213 002

HYDROFLUMETHIAZIDE

TABLET; ORAL

SALURON

>DLT>	/AB//*//ERISTOL/	/50MG/	/N11949/001/
>ADD>	AB * ROBERTS	50MG	N11949 001

HYDROFLUMETHIAZIDE; RESERPINE

TABLET; ORAL

SALUTENSIN

>DLT>	/BP/*//ERISTOL/	/50MG;0.125MG/	/N12359/003/
>ADD>	BP * ROBERTS	50MG;0.125MG	N12359 003

SALUTENSIN-DEMI

>DLT>	/ERISTOL/	/25MG;0.125MG/	/N12359/004/
>ADD>	ROBERTS	25MG;0.125MG	N12359 004

HYDROXOCOBALAMIN

INJECTABLE; INJECTION

	HYDROXOMIN		
/AP/	/BEL/MAR/	/1MG/ML/	/N84629/001/
	@ BEL MAR	1MG/ML	N84629 001

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL		
AP	FUJISAWA	25MG/ML	N88184 001 MAR 31, 1983
AP		50MG/ML	N88185 001 MAR 31, 1983
/AP/	/LYPHOMED/	/25MG/ML/	/N88184/001/ /MAR/31,/1983/
/AP/		/50MG/ML/	/N88185/001/ /MAR/31,/1983/
/AP/	/WYETH/AYERST/	/25MG/ML/	/N86258/001/
/AP/		/50MG/ML/	/N86258/002/
	@ WYETH AYERST	25MG/ML	N86258 001
	@	50MG/ML	N86258 002

SYRUP; ORAL

	HYDROXYZINE HCL		
AA	BARRE	10MG/5ML	N88785 001 FEB 03, 1988
/AA/	/NASKA/	/10MG/5ML/	/N88785/001/ /FEB/03,/1988/
AA	PENNEX PHARMS	10MG/5ML	N87294 001 APR 12, 1982
/AA/	/PHARM/BASICS/	/10MG/5ML/	/N87294/001/ /APR/12,/1982/

TABLET; ORAL

	HYDROXYZINE HCL		
/AB/	/CHELSEA/	/10MG/	/N86827/001/
/AB/		/25MG/	/N86829/001/
/AB/		/50MG/	/N86836/001/
	@ CHELSEA	10MG	N86827 001
	@	25MG	N86829 001
	@	50MG	N86836 001

IBUPROFEN

TABLET; ORAL

	IBUPROFEN		
AB	NORTON HN	400MG	N71145 001 SEP 23, 1986
AB		600MG	N71146 001 SEP 23, 1986
AB		800MG	N71769 001 MAY 08, 1987

	IBUPROFEN		
/AB/	/PAR/	/300MG/	/N70328/001/ /AUG/06,/1985/
	@ PAR	300MG	N70328 001 AUG 06, 1985
	/IFEN/		
/AB/	/LUCHEM/	/400MG/	/N71145/001/ /SEP/23,/1986/
/AB/		/600MG/	/N71146/001/ /SEP/23,/1986/
/AB/		/800MG/	/N71769/001/ /MAY/08,/1987/

IDOXURIDINE

/OINTMENT;/OPHTHALMIC/
/STOXIL/

/+//SMITHKLINE/BEECHAM/		/0.5%/	/N15868/001/
	@ SMITHKLINE BEECHAM	0.5%	N15868 001

SOLUTION/DROPS; OPHTHALMIC
/STOXIL/

/AT/	/SMITHKLINE/BEECHAM/	/0.1%/	/N13934/001/
	@ SMITHKLINE BEECHAM	0.1%	N13934 001

INDAPAMIDE

TABLET; ORAL

	LOZOL		
	RHONE POULENC RORER	1.25MG	N18538 002 APR 29, 1993

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

	IODOHIPPURATE SODIUM I 131		
/AP/	/CIS/	/0.2MCI/ML/	/N17313/001/
AP	SORIN	0.2MCI/ML	N17313 001

IOHEXOL

/INJECTABLE;/INJECTION/
/OMNIPAQUE/180/
/STERLING/ /38.8%/ /N18956/001/
/DEC/26,/1985/

/SOLUTION;/INJECTION,/ORAL/
/OMNIPAQUE/240/
/STERLING/ /51.8%/ /N18956/002/
/DEC/26,/1985/

/OMNIPAQUE/300/
/STERLING/ /64.7%/ /N18956/003/
/DEC/26,/1985/

SOLUTION; INJECTION, ORAL, RECTAL
OMNIPAQUE 180
+ STERLING 38.8% N18956 001
DEC 26, 1985

OMNIPAQUE 240
+ STERLING 51.8% N18956 002
DEC 26, 1985

OMNIPAQUE 300
+ STERLING 64.7% N18956 003
DEC 26, 1985

IOTROLAN

/INJECTABLE;/INTRAVENOUS/
/SCHWARZ/
/BERLEX/ /EQ/190MG/IODINE/ML/ /N19580/001/
/DEC/07,/1989/
/EQ/240MG/IODINE/ML/ /N19580/002/
/DEC/07,/1989/

∂ BERLEX EQ 190MG IODINE/ML N19580 001
DEC 07, 1989

∂ EQ 240MG IODINE/ML N19580 002
DEC 07, 1989

IPRATROPIUM BROMIDE

>ADD> SOLUTION; INHALATION
>ADD> ATROVENT
>ADD> + BOEHRINGER INGELHEIM 0.02% N20228 001
>ADD> SEP 29, 1993

IRON DEXTRAN

INJECTABLE; INJECTION
INFED
BP + SCHEIN PHARM EQ 50MG IRON/ML N17441 001
/IRON/DEXTRAN/
/BP/ /STERIS/ /EQ/50MG/IRON/ML/ /N17441/001/

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION
ISOETHARINE HCL
/AN/ /ASTRA/ /0.125%/ /N87938/001/
/NOV/15,/1982/
/0.062%/ /N87937/001/
/NOV/15,/1982/

∂ ASTRA 0.062% N87937 001
NOV 15, 1982

∂ 0.125% N87938 001
NOV 15, 1982

/AN/ /PARKE/DAVIS/ /1%/ /N85889/001/
/0.5%/ /N85997/001/

∂ PARKE DAVIS 0.5% N85997 001
∂ 1% N85889 001

ISOFLURANE

LIQUID; INHALATION
FORANE
AN + ANAQUEST 99.9% N17624 001
ISOFLURANE
AN ABBOTT 99.9% N74097 001
JAN 25, 1993

ISONIAZID

INJECTABLE; INJECTION
NYDRAZID
+ APOTHECON 100MG/ML N08662 001
/SQUIBB/ /100MG/ML/ /N08662/001/

TABLET; ORAL
ISONIAZID
/AA/ /EON/LABS/ /100MG/ /N08678/002/
AA + EON LABS 100MG N08678 002
/AA/ /300MG/ /N08678/003/
AA + 300MG N08678 003

ISONIAZID

TABLET; ORAL

/AA/	/STANDARD/ /EVERYLIFE/ @ EVERYLIFE	/300MG/ 300MG	/N060126/002/ N80126 002

ISOPROPAMIDE IODIDE

/TABLET;ORAL/
/DARBID/

/SMITHKLINE/BEECHAM/ @ SMITHKLINE BEECHAM	/EQ/5MG/BASE/ EQ 5MG BASE	/N010744/001/ N10744 001

ISOPROTERENOL HYDROCHLORIDE

SOLUTION; INHALATION

	AEROLONE		
/AN/	/LILLY/	/0.25%/	/N017245/001/
	+ LILLY	0.25%	N07245 001
	/ISOPROTERENOL HCL/		
/AN/	/PARKE/DAVIS/	/0.25%/	/N085994/001/
/AN/		/0.5%/	/N085540/001/
	@ PARKE DAVIS	0.25%	N85994 001
	@	0.5%	N85540 001
	ISUPREL		
/AN/	/STERLING/	/0.5%/	/N063217/002/
	+ STERLING WINTHROP	0.5%	N06327 002
	/VARO-TSO/		
/AN/	/FISONS/	/0.5%/	/N016813/001/
	@ FISONS	0.5%	N16813 001

TABLET; RECTAL, SUBLINGUAL

ISUPREL		
/STERLING/	/15MG/	/N063228/002/
@ STERLING	15MG	N06328 002

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE		
/AB/	/ICI/	/20MG/	/N066405/002/ /AUG/21/1990/
/AB/		/30MG/	/N068124/001/ /AUG/21/1990/
/AB/		/40MG/	/N068125/001/ /AUG/21/1990/

ISOSORBIDE DINITRATE

TABLET; ORAL

	SORBITRATE		
AB	ZENECA	20MG	N86405 002 AUG 21, 1990
AB		30MG	N88124 001 AUG 21, 1990
AB		40MG	N88125 001 AUG 21, 1990

ISOSORBIDE MONONITRATE

TABLET; ORAL

	ISMO		
/AB/	/WYETH/	/20MG/	/N019091/001/ /DEC/30/1991/
BX +	WYETH	20MG	N19091 001 DEC 30, 1991
	MONOKET		
BX	SCHWARZ PHARMA	20MG	N20215 001 JUN 30, 1993
		10MG	N20215 002 JUN 30, 1993

TABLET, EXTENDED RELEASE; ORAL

IMDUR		
@ SCHERING PLOUGH	30MG	N20225 001 AUG 12, 1993
	60MG	N20225 002 AUG 12, 1993

KANAMYCIN SULFATE

CAPSULE; ORAL

	KANTREX		
	APOTHECON	EQ 500MG BASE	N62726 001 MAR 06, 1987
	/BRISTOL/	/EQ/500MG/BASE/	/N062726/001/ /MAR/06/1987/

INJECTABLE; INJECTION

	KANTREX		
AP	APOTHECON	EQ 75MG BASE/2ML	N61901 003
AP		EQ 500MG BASE/2ML	N61901 001
AP		EQ 1GM BASE/3ML	N61901 002
/AP/	/BRISTOL/	/EQ 75MG BASE/2ML/	/N061901/003/
/AP/		/EQ 500MG BASE/2ML/	/N061901/001/
/AP/		/EQ 1GM BASE/3ML/	/N061901/002/

KANAMYCIN SULFATE

INJECTABLE; INJECTION

/AP/	/KLEOCIL/ /SMITHKLINE/BEECHAM/	/EQ 75MG BASE/2ML/	/N62170/001/	
/AP/		/EQ 500MG BASE/2ML/	/N62170/002/	
/AP/		/EQ 1GM BASE/3ML/	/N62170/003/	
	∂ SMITHKLINE BEECHAM	EQ 75MG BASE/2ML	N62170 001	
	∂	EQ 500MG BASE/2ML	N62170 002	
	∂	EQ 1GM BASE/3ML	N62170 003	

KETOPROFEN

CAPSULE; ORAL

KETOPROFEN

AB	LEDERLE	25MG	N74014 001 JAN 29, 1993
AB		50MG	N74014 002 JAN 29, 1993
AB		75MG	N74014 003 JAN 29, 1993

CAPSULE, EXTENDED RELEASE; ORAL

ORUVAIL

>ADD>	+ WYETH AYERST	200MG	N19816 001 SEP 24, 1993

LACTULOSE

SOLUTION; ORAL

/AA/	/CEPHULAC/ /MERRELL/DOW/	/10GM/15ML/	/N17651/001/	
/AA/	/ENULOSE/ /BARRE/	/10GM/15ML/	/N71548/001/ /AUG/15,/1988/	
AA	EVALOSE COPLEY	10GM/15ML	N73497 001 MAY 28, 1993	
	LACTULOSE ∂ PENNEX PHARMS	10GM/15ML	N71841 001 SEP 22, 1988	
/AA/	/PHARM/BASICS/	/10GM/15ML/	/N71841/001/ /SEP/22,/1988/	
	/LACTULOSE/ /SOLVAY/	/10GM/15ML/	/N71986/001/	

LACTULOSE

/SOLUTION;/ORAL/

AA	LAXILOSE TECHNILAB	10GM/15ML	N73686 001 MAY 28, 1993

SOLUTION; ORAL, RECTAL

AA	ACILAC TECHNILAB	10GM/15ML	N73685 001 MAY 28, 1993
AA	CEPHULAC MERRELL DOW	10GM/15ML	N17657 001
AA	ENULOSE BARRE	10GM/15ML	N71548 001 AUG 15, 1988
/AA/	GENERLAC /PHARM/BASICS/	/10GM/15ML/	/N71842/001/ /SEP/27,/1988/
	∂ PENNEX PHARMS	10GM/15ML	N71842 001 SEP 27, 1988
AA	HEPTALAC COPLEY	10GM/15ML	N73504 001 MAY 28, 1993
	LACTULOSE ∂ SOLVAY	10GM/15ML	N17906 001
/AA/	/CHRYSALAC/ /SOLVAY/	/10GM/15ML/	/N72374/001/ /MAR/22,/1989/
	∂ SOLVAY	10GM/15ML	N72374 001 MAR 22, 1989

LEUCOVORIN CALCIUM

INJECTABLE; INJECTION

LEUCOVORIN CALCIUM

>ADD>	AP	GENSIA	EQ 50MG BASE/VIAL	N81278 001 SEP 28, 1993
>ADD>	AP		EQ 100MG BASE/VIAL	N81277 001 SEP 28, 1993

TABLET; ORAL

LEUCOVORIN CALCIUM

AB	LEDERLE	EQ 10MG BASE	N71962 001 NOV 19, 1987
AB	+	EQ 15MG BASE	N71104 001 MAR 04, 1987

LEUCOVORIN CALCIUM

TABLET; ORAL

	LEUCOVORIN CALCIUM		
AB	ROXANE	EQ 5MG BASE	N72733 001 FEB 22, 1993
AB		EQ 10MG BASE	N72734 001 FEB 22, 1993
AB		EQ 15MG BASE	N72735 001 FEB 22, 1993
AB		EQ 25MG BASE	N72736 001 FEB 22, 1993

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	LUPRON		
/+/	/TAP/	/1MG/0.2ML/	/N19816/001/ /APR/09,/1985/
+	TAP	5MG/ML	N19010 001 APR 09, 1985
		5MG/ML	N20263 001 APR 16, 1993
	LUPRON DEPOT		
+	TAP	3.75MG/VIAL	N20011 001 OCT 22, 1990
+		7.5MG/VIAL	N19732 001 JAN 26, 1989
		/3.75MG/VIAL/	/N20011/001/ /OCT/22,/1990/
		/7.5MG/VIAL/	/N19732/001/ /JAN/26,/1989/
	LUPRON DEPOT-PED		
+	TAP	3.75MG/VIAL&7.5MG/VIAL	N20263 003 APR 16, 1993
+		7.5MG/VIAL&7.5MG/VIAL	N20263 004 APR 16, 1993
+		7.5MG/VIAL	N20263 002 APR 16, 1993

LEVOMETHADYL ACETATE HYDROCHLORIDE

CONCENTRATE; ORAL

	ORLAAM		
>ADD<	BIODEVELOPMENT	10MG/ML	N20315 001 JUL 09, 1993
>ADD<			
>DLT<	/BIOMETRICS/RES/	/10MG/ML/	/N20315/001/ /JUL/09,/1993/
>DLT<			

LEVONORDEFRIN; PROCAINE HYDROCHLORIDE; PROPOXYCAINE HYDROCHLORIDE

	/INJECTABLE;/INJECTION/		
	/PROCAINE/AND/NOVOCAIN/W/NEO-COBEFRIN/		
	/COOK/WAITE/	/0.05MG/ML;2%;0.4%/	/N088592/001/
ə	STERLING WINTHROP	0.05MG/ML;2%;0.4%	N08592 007

LIDOCAINE

	/SUPPOSITORY;/RECTAL/		
	/XYLOCAINE/		
	/ASTRA/	/100MG/	/N13077/001/
ə	ASTRA	100MG	N13077 001

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL		
/AP/	/BEL/MAR/	/1%/	/N80710/001/
/AP/		/2%/	/N80760/001/
ə	BEL MAR	1%	N80710 001
ə		2%	N80760 001
/AP/	/BRISTOL/	/1%/	/N80390/001/
/AP/		/2%/	/N80390/002/
AP	FUJISAWA	1%	N80404 002
AP		2%	N80404 003
ə		1%	N80390 001
ə		2%	N80390 002
/AP/	/LYPHOMED/	/1%/	/N86464/002/
/AP/		/1%/	/N86761/001/
/AP/		/2%/	/N86464/003/
/AP/		/2%/	/N86761/002/
ə	LYPHOMED	1%	N86761 001
ə		2%	N86761 002

JELLY; TOPICAL

	LIDOCAINE HCL		
AT	COPLEY	2%	N81318 001 APR 29, 1993

SOLUTION; ORAL

	MYLOCAINE		
AT	PENNEX PHARMS	2%	N87872 001 NOV 18, 1982
/AT/	/PHARM/BASICS/	/2%/	/N87872/001/ /NOV/18,/1982/

LIDOCAINE HYDROCHLORIDE

SOLUTION; TOPICAL

/AT/	/PHARM/BASICS/	/4%/	/N87881/001/	/NOV/18,/1982/
	@ PENNEX PHARMS	4%	N87881 001	NOV 18, 1982

LINDANE

LOTION; TOPICAL

LINDANE

AT	PENNEX PHARMS	1%	N88190 001	AUG 16, 1984
/AT/	/PHARM/BASICS/	/1%/	/N88190/001/	/AUG/16,/1984/

SHAMPOO; TOPICAL

LINDANE

AT	PENNEX PHARMS	1%	N88191 001	SEP 18, 1984
/AT/	/PHARM/BASICS/	/1%/	/N88191/001/	/SEP/18,/1984/

LIOTRIX (T4;T3)

TABLET; ORAL

	THYROLAR-0.25			
	FOREST LABS	0.0125MG;0.0031MG	N16807 001	
	/PHONE/POULENC/RORER//0.0125MG;0.0031MG/		/N16807/001/	
	THYROLAR-0.5			
	FOREST LABS	0.025MG;0.00625MG	N16807 005	
	/PHONE/POULENC/RORER//0.025MG;0.00625MG/		/N16807/005/	
	THYROLAR-1			
	FOREST LABS	0.05MG;0.0125MG	N16807 004	
	/PHONE/POULENC/RORER//0.05MG;0.0125MG/		/N16807/004/	
	THYROLAR-2			
	FOREST LABS	0.1MG;0.025MG	N16807 002	
	/PHONE/POULENC/RORER//0.1MG;0.025MG/		/N16807/002/	
	THYROLAR-3			
+	FOREST LABS	0.15MG;0.0375MG	N16807 003	
/+/	/PHONE/POULENC/RORER//0.15MG;0.0375MG/		/N16807/003/	
	THYROLAR-5			
	@ FOREST LABS	0.25MG;0.0625MG	N16807 006	
/+/	/PHONE/POULENC/RORER//0.25MG;0.0625MG/		/N16807/006/	

LISINOPRIL

TABLET; ORAL

ZESTRIL

/AB/	/IMPERIAL/CHEM/	/5MG/	/N19777/001/	/MAY/19,/1988/
/AB/		/10MG/	/N19777/002/	/MAY/19,/1988/
/AB/		/20MG/	/N19777/003/	/MAY/19,/1988/
/AB//+/		/40MG/	/N19777/004/	/MAY/19,/1988/
AB	ZENECA	5MG	N19777 001	MAY 19, 1988
AB		10MG	N19777 002	MAY 19, 1988
AB		20MG	N19777 003	MAY 19, 1988
AB	+	40MG	N19777 004	MAY 19, 1988
		2.5MG	N19777 005	APR 29, 1993

LITHIUM CARBONATE

TABLET; ORAL

ESKALITH

/AB//+/	/SMITHKLINE/BEECHAM	/300MG/	/N17971/001/
	@ SMITHKLINE BEECHAM	300MG	N17971 001

LITHIUM CITRATE

SYRUP; ORAL

LITHIUM CITRATE

AA	PENNEX PHARMS	EQ 300MG CARBONATE/5ML	N70755 001	MAY 21, 1986
/AA/	/PHARM/BASICS/	/EQ 300MG CARBONATE/5ML/	/N70755/001/	/MAY/21,/1986/

> ADD > LODOXAMIDE TROMETHAMINE

> ADD > SOLUTION/DROPS; OPHTHALMIC

> ADD > ALOMIDE

> ADD > + ALCON EQ 0.1% BASE N20191 001

> ADD > SEP 23, 1993

LORATADINE

TABLET; ORAL
CLARITIN
+ SCHERING — 10MG — N19658 001 — APR 12, 1993 — > ADD >

MAFENIDE ACETATE

CREAM; TOPICAL
SULFAMYLON
+ HICKAM — EQ 85MG BASE/GM — N16763 001
/STERLING/ — /EQ/85MG/BASE/GM/ — /N16763/001/

MANGANESE SULFATE

INJECTABLE; INJECTION
MANGANESE SULFATE
FUJISAWA — EQ 0.1MG MANGANESE/ML — N19228 001 — MAY 05, 1987 — > ADD >
/LYPHOMED/ — /EQ/0.1MG/MANGANESE/ML/ — /N19228/001/ — /MAY/05,/1987/ — > ADD >

MANNITOL

INJECTABLE; INJECTION
MANNITOL 10% IN PLASTIC CONTAINER
AP MCGAW — 10GM/100ML — N20006 002 — JUL 26, 1993

MANNITOL 15% IN PLASTIC CONTAINER
AP MCGAW — 15GM/100ML — N20006 003 — JUL 26, 1993

MANNITOL 20% IN PLASTIC CONTAINER
AP MCGAW — 20GM/100ML — N20006 004 — JUL 26, 1993

MANNITOL 5% IN PLASTIC CONTAINER
AP MCGAW — 5GM/100ML — N20006 001 — JUL 26, 1993

MASOPROCOL

CREAM; TOPICAL
ACTINEX
+ BLOCK DRUG — 10% — N19940 001 — SEP 04, 1992
/#//CHEMEX/ — /10%/ — /N19940/001/ — /SEP/04,/1992/

MEGESTROL ACETATE

SUSPENSION; ORAL
MEGACE
+ BRISTOL MYERS SQUIBB — 40MG/ML — N20264 001 — SEP 10, 1993

MENADIOL SODIUM DIPHOSPHATE

/INJECTABLE;/INJECTION/
/SYNKAYVITE/
/ROCHE/ — /5MG/ML/ — /N03718/004/
/10MG/ML/ — /N03718/006/
/37.5MG/ML/ — /N03718/008/
ə ROCHE — 5MG/ML — N03718 004
ə — 10MG/ML — N03718 006
ə — 37.5MG/ML — N03718 008

/TABLET;/ORAL/
/SYNKAYVITE/
/ROCHE/ — /5MG/ — /N03718/010/
ə ROCHE — 5MG — N03718 010

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
MEPERIDINE HCL

AP	ASTRA	10MG/ML	N81002 001	
>DLT>	/AP/	/25MG/ML/	JUL 30, 1993 /N89781/001/	
>DLT>			/MAR/31,/1989/	
>DLT>	/AP/	/50MG/ML/	/N89782/001/	
>DLT>			/MAR/31,/1989/	
>DLT>	/AP/	/50MG/ML/	/N89783/001/	
>DLT>			/MAR/31,/1989/	
>DLT>	/AP/	/75MG/ML/	/N89785/001/	
>DLT>			/MAR/31,/1989/	
>DLT>	/AP/	/100MG/ML/	/N89786/001/	
>DLT>			/MAR/31,/1989/	
>DLT>	/AP/	/100MG/ML/	/N89787/001/	
>DLT>			/MAR/31,/1989/	
>ADD>	@	25MG/ML	N89781 001 MAR 31, 1989	
>ADD>				
>ADD>	@	50MG/ML	N89782 001 MAR 31, 1989	
>ADD>				
>ADD>	@	50MG/ML	N89783 001 MAR 31, 1989	
>ADD>				
>ADD>	@	75MG/ML	N89785 001 MAR 31, 1989	
>ADD>				
>ADD>	@	100MG/ML	N89786 001 MAR 31, 1989	
>ADD>				
>ADD>	@	100MG/ML	N89787 001 MAR 31, 1989	
AP	INTL MEDICATION	10MG/ML	N81309 001 AUG 30, 1993	

MEPROBAMATE

TABLET; ORAL
MEPROBAMATE

/AA/	/LEE/LABS/	/400MG/	/N89538/001/ /NOV/25,/1987/
@ LEE LABS		400MG	N89538 001 NOV 25, 1987

MESALAMINE

CAPSULE, EXTENDED RELEASE; ORAL
PENTASA

+	MARION MERRELL DOW	250MG	N20049 001 MAY 10, 1993

MESTRANOL; NORETHINDRONE

/TABLET;/ORAL-20/
/NORINYL/

/SYNTEX/	/0.1MG;2MG/	/N13625/004/
@ SYNTEX	0.1MG;2MG	N13625 004

TABLET; ORAL-21
NORETHIN 1/50M-21

AB	ROBERTS	0.05MG;1MG	N71539 001 APR 12, 1988 /N71539/001/ /APR/12,/1988/
/AB/	/SCHIAPPARELLI/SEARLE/	0.05MG;1MG/	

TABLET; ORAL-28
NORETHIN 1/50M-28

AB	ROBERTS	0.05MG;1MG	N71540 001 APR 12, 1988 /N71540/001/ /APR/12,/1988/
/AB/	/SCHIAPPARELLI/SEARLE/	0.05MG;1MG/	

MESTRANOL; NORETHYNODREL

/TABLET;/ORAL/
/ENOVID/

/E//SEARLE/	/0.15MG;0.85MG/	/N10976/005/
	/0.075MG;5MG/	/N10976/008/
@ SEARLE	0.075MG;5MG	N10976 008
@	0.15MG;9.85MG	N10976 005

METAPROTERENOL SULFATE

SOLUTION; INHALATION
METAPROTERENOL SULFATE

@ PENNEX PHARMS	5%	N72190 001 JUN 07, 1988 /N72190/001/ /JUN/07,/1988/
/AN/ /PHARM/BASICS/	/5%/	

SYRUP; ORAL
METAPROTERENOL SULFATE

AA	PENNEX PHARMS	10MG/5ML	N71656 001 OCT 13, 1987 /N71656/001/ /OCT/13,/1987/
/AA/	/PHARM/BASICS/	/10MG/5ML/	

INJECTABLE; INJECTION

METARAMINOL BITARTRATE

AP	FUJISAWA	EQ 10MG BASE/ML	N80431 001
AP		EQ 10MG BASE/ML	N80722 001
/AP/	/LYPHOMED/	/EQ 10MG BASE/ML/	/N80431/001/
/AP/		/EQ 10MG BASE/ML/	/N80722/001/

METHADONE HYDROCHLORIDE

TABLET; ORAL

METHADOSE

AA	MALLINCKRODT	5MG	N40050 001 APR 15, 1993
AA		10MG	N40050 002 APR 15, 1993

TABLET, DISPERSIBLE; ORAL

METHADONE HCL

AA	LILLY	40MG	N17058 001

METHADOSE

AA	MALLINCKRODT	40MG	N74184 001 APR 29, 1993

METHAMPHETAMINE HYDROCHLORIDE

TABLET; ORAL

/METHAMPEX/

/AA/	/LEMMON/	/10MG/	/N83889/001/
	@ LEMMON	10MG	N83889 001

METHAMPHETAMINE HCL

/AA/	/LEMMON/	/5MG/	/N86359/001/
	@ LEMMON	5MG	N86359 001
/AA/	/REXAR/	/10MG/	/N84931/002/
	REXAR	10MG	N84931 002

METHANTHELINE BROMIDE

TABLET; ORAL

BANTHINE

	ROBERTS	50MG	N07390 001
	/SCHIAPPARELLI/SEARLE/50MG/		/N07390/001/

TABLET; ORAL

METHAZOLAMIDE

AB	COPLEY	25MG	N40001 001 JUN 30, 1993
AB		50MG	N40001 002 JUN 30, 1993
AB	GENEVA	25MG	N40036 001 JUN 30, 1993
AB		50MG	N40036 002 JUN 30, 1993

NEPTAZANE

AB	LEDERLE	25MG	N11721 002 NOV 25, 1991
AB +		50MG	N11721 001

METHICILLIN SODIUM

INJECTABLE; INJECTION

STAPHCILLIN

+	APOTHECON	EQ 900MG BASE/VIAL	N61449 001
+		EQ 3.6GM BASE/VIAL	N61449 002
+		EQ 5.4GM BASE/VIAL	N61449 003
	/BRISTOL/	/EQ/900MG/BASE/VIAL/	/N61449/001/
		/EQ/3.6GM/BASE/VIAL/	/N61449/002/
		/EQ/5.4GM/BASE/VIAL/	/N61449/003/

METHOCARBAMOL

TABLET; ORAL

/DELAXIN/

/AA/	/FERNDALE/	/500MG/	/N85454/001/
	@ FERNDALE	500MG	N85454 001

METHOCARBAMOL

AA	NYLOS TRADING	750MG	N85033 001
/AA/	/PIONEER/PHARMS/	/500MG/	/N88731/001/ /DEC/13,/1985/
/AA/		/750MG/	/N89082/001/ /DEC/13,/1985/
	@ PIONEER PHARMS	500MG	N88731 001 DEC 13, 1985
	@	750MG	N89082 001 DEC 13, 1985
/AA/	/TABLICAPS/	/750MG/	/N85033/001/
/AA/	/UPSHER/SMITH/	/500MG/	/N87453/001/
/AA/		/750MG/	/N87454/001/
	@ UPSHER SMITH	500MG	N87453 001
	@	750MG	N87454 001

METHOTREXATE SODIUM

INJECTABLE; INJECTION
METHOTREXATE SODIUM

/AP/	/AKORN/	/EQ 25MG BASE/ML/	/N88648/001/	
/AP/	/LYPHOMED/	/EQ 25MG BASE/ML/	/N89263/001/	
	@ LYPHOMED	EQ 25MG BASE/ML	N89263 001	JUN 13, 1986
AP	NORBROOK	EQ 25MG BASE/ML	N88648 001	MAY 09, 1986

METHOXYFLURANE

/SOLUTION;INHALATION/			
/PENTHRANE/			
/ABBOTT/	/99.9%/	/N13656/003/	

METHYLDOPATE HYDROCHLORIDE

INJECTABLE; INJECTION
METHYLDOPATE HCL

/AP/	/LYPHOMED/	/50MG/ML/	/N70652/001/	
	@ LYPHOMED	50MG/ML	N70652 001	JUN 03, 1986

METHYLPREDNISOLONE

TABLET; ORAL
METHYLPREDNISOLONE

/AB/	/CHELSEA/	/4MG/	/N86161/001/	
B*	CHELSEA	4MG	N86161 001	FEB 09, 1982

METHYLPREDNISOLONE ACETATE

INJECTABLE; INJECTION
/M-PREDROL/

/BP/	/BEL/MAR/	/40MG/ML/	/N86666/001/	
/BP/		/80MG/ML/	/N87135/001/	
	@ BEL MAR	40MG/ML	N86666 001	
	@	80MG/ML	N87135 001	

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE

/AP/	/LYPHOMED/	/EQ 40MG BASE/VIAL/	/N89143/001/	
/AP/		/EQ 125MG BASE/VIAL/	/N89144/001/	
/AP/		/EQ 500MG BASE/VIAL/	/N89187/001/	
/AP/		/EQ 1GM BASE/VIAL/	/N89189/001/	
	@ LYPHOMED	EQ 40MG BASE/VIAL	N89143 001	MAR 28, 1986
	@	EQ 125MG BASE/VIAL	N89144 001	MAR 28, 1986
	@	EQ 500MG BASE/VIAL	N89187 001	MAR 28, 1986
	@	EQ 1GM BASE/VIAL	N89189 001	MAR 28, 1986

METHYLTESTOSTERONE

CAPSULE; ORAL
/METHYLTESTOSTERONE/

/BP/	/HEATHER/	/10MG/	/N84967/001/
	@ HEATHER	10MG	N84967 001

TESTRED

/BP/	/ICN/	/10MG/	/N83976/001/
BP +	ICN	10MG	N83976 001

METHYPRYLON

/CAPSULE;ORAL/			
/NOLUDAR/			
/ROCHE/		/300MG/	/N09660/008/
@ ROCHE		300MG	N09660 008
/TABLET;ORAL/			
/NOLUDAR/			
/ROCHE/		/200MG/	/N09660/004/
@ ROCHE		200MG	N09660 004

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION

METOCLOPRAMIDE HCL

/AP/	/AKORN/	/EQ 10MG BASE/2ML/	/N70892/001/ /AUG/26,/1988/
/AP/	/FUJISAWA/	/EQ 10MG BASE/2ML/	/N70293/001/ /JAN/24,/1986/
	@ FUJISAWA	EQ 10MG BASE/2ML	N70293 001 JAN 24, 1986
	@ NORBROOK	EQ 10MG BASE/2ML	N70892 001 AUG 26, 1988

SOLUTION; ORAL

METOCLOPRAMIDE HCL

AA	LEMMON	EQ 5MG BASE/5ML	N71315 001 JUN 30, 1993
AA	LIQUIPHARM	EQ 5MG BASE/5ML	N71402 001 JUN 25, 1993
AA	PENNEX PHARMS	EQ 5MG BASE/5ML	N70949 001 MAR 06, 1987
/AA/	/PHARM/BASICS/	/EQ 5MG BASE/5ML/	/N70949/001/ /MAR/06,/1987/

TABLET; ORAL

METOCLOPRAMIDE HCL

AB	BIOCRAFT	EQ 5MG BASE	N72801 001 JUN 15, 1993
AB	MUTUAL PHARM	EQ 10MG BASE	N71536 001 APR 28, 1993
/AB/	/PAR/	/EQ 10MG BASE/	/N70342/001/ /MAR/25,/1986/
	@ PAR	EQ 10MG BASE	N70342 001 MAR 25, 1986

METRONIDAZOLE

TABLET; ORAL

/GASTRIC/

/AB/	/SAVAGE/	/250MG/	/N70029/001/ /MAR/19,/1985/
/AB/		/500MG/	/N70731/001/ /JUN/08,/1987/
	@ SAVAGE	250MG	N70029 001 MAR 19, 1985
	@	500MG	N70731 001 JUN 08, 1987

MEZLOCILLIN SODIUM MONOHYDRATE

INJECTABLE; INJECTION

MEZLIN

MILES	EQ 1GM BASE/VIAL	N62372 005 JAN 13, 1983

MICONAZOLE NITRATE

/CREAM;/VAGINAL/

/MONISTAT/7/

/JOHNSON/RW/	/2%/	/N17456/001/

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT DUAL-PAK

+ JOHNSON RW	2%;200MG	N18888 002 OCT 17, 1988

/LOTION;/TOPICAL/

/MONISTAT-DERM/

/+//JOHNSON/RW/	/2%/	/N17739/001/
@ JOHNSON RW	2%	N17739 001

/SUPPOSITORY;/VAGINAL/

/MONISTAT/7/

/JOHNSON/RW/	/100MG/	/N18526/001/ /MAR/15,/1982/

MILRINONE LACTATE

INJECTABLE; INJECTION

MILRINONE LACTATE

+ STERLING	EQ 1MG BASE/ML	N19436 001 DEC 31, 1987
/@/	/EQ 1MG BASE/ML/	/N19436/001/ /DEC/31,/1987/

MITOXANTRONE HYDROCHLORIDE

INJECTABLE; INJECTION

NOVANTRONE

+ IMMUNEX	EQ 2MG BASE/ML	N19297 001 DEC 23, 1987
/LEDERLE/	/EQ 2MG BASE/ML/	/N19297/001/ /DEC/23,/1987/

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
/DUPONT/

	/200MG/	/N19753/001/ /JUN/19,/1990/	/AP/
	/250MG/	/N19753/002/ /JUN/19,/1990/	/AP/
	/300MG/	/N19753/003/ /JUN/19,/1990/	/AP/
ROBERTS	200MG	N19753 001 JUN 19, 1990	/AP/
	250MG	N19753 002 JUN 19, 1990	/AP/
	300MG	N19753 003 JUN 19, 1990	/AP/

NABILONE

/CAPSULE;ORAL/
/CESAMET/
/+//LILLY/

/1MG/	/N18677/001/ /DEC/26,/1985/	
∂ LILLY	1MG	N18677 001 DEC 26, 1985

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

AP	APOTHECON	EQ 500MG BASE/VIAL	N62527 001 AUG 02, 1984	>DLT >/AP/ >DLT >
AP		EQ 1GM BASE/VIAL	N62527 002 AUG 02, 1984	>DLT >/AP/ >DLT >
AP		EQ 1GM BASE/VIAL	N62732 001 DEC 23, 1986	>ADD >
AP		EQ 2GM BASE/VIAL	N62527 003 AUG 02, 1984	>ADD >
AP		EQ 2GM BASE/VIAL	N62732 002 DEC 23, 1986	>ADD >
AP		EQ 10GM BASE/VIAL	N62527 004 AUG 02, 1984	>ADD >

NAFCILLIN SODIUM

INJECTABLE; INJECTION
NAFCIL

/BRISTOL/	/EQ 500MG BASE/VIAL/	/N62527/001/ /AUG/02,/1984/	/AP/
	/EQ 1GM BASE/VIAL/	/N62527/002/ /AUG/02,/1984/	/AP/
	/EQ 1GM BASE/VIAL/	/N62732/001/ /DEC/23,/1986/	/AP/
	/EQ 2GM BASE/VIAL/	/N62527/003/ /AUG/02,/1984/	/AP/
	/EQ 2GM BASE/VIAL/	/N62732/002/ /DEC/23,/1986/	/AP/
	/EQ 10GM BASE/VIAL/	/N62527/004/ /AUG/02,/1984/	/AP/

/POWDER/FOR/RECONSTITUTION;ORAL/
/UNIPEN/
/+//WYETH/AYERST/

/EQ/250MG/BASE/5ML/	/N50199/001/	
∂ WYETH AYERST	EQ 250MG BASE/5ML	N50199 001

NALBUPHINE HYDROCHLORIDE

INJECTABLE; INJECTION
NALBUPHINE HCL

/ASTRA/	/10MG/ML/	/N72071/001/ /APR/10,/1989/	>DLT >/AP/ >DLT >	
	/10MG/ML/	/N72072/001/ /APR/10,/1989/	>DLT >/AP/ >DLT >	
	/20MG/ML/	/N72074/001/ /APR/10,/1989/	>DLT >/AP/ >DLT >	
	/20MG/ML/	/N72075/001/ /APR/10,/1989/	>DLT >/AP/ >DLT >	
∂ ASTRA	10MG/ML	N72071 001 APR 10, 1989	>ADD >	
∂	10MG/ML	N72072 001 APR 10, 1989	>ADD >	
∂	20MG/ML	N72074 001 APR 10, 1989	>ADD >	
∂	20MG/ML	N72075 001 APR 10, 1989	>ADD >	

NALBUPHINE HYDROCHLORIDE

ABBOTT	1.5MG/ML	N20200 001 MAR 12, 1993	

INJECTABLE; INJECTION

NALOXONE HCL

>DLT>	/AP/	/ASTRA/	/0.02MG/ML/	/N72082/001/APR/11,/1989/
>DLT>	/AP/		/0.02MG/ML/	/N72083/001/APR/11,/1989/
>DLT>	/AP/		/0.02MG/ML/	/N72084/001/APR/11,/1989/
>DLT>	/AP/		/0.02MG/ML/	/N72085/001/APR/11,/1989/
>DLT>	/AP/		/0.4MG/ML/	/N72087/001/APR/11,/1989/
>DLT>	/AP/		/0.4MG/ML/	/N72088/001/APR/11,/1989/
>DLT>	/AP/		/0.4MG/ML/	/N72089/001/APR/11,/1989/
>DLT>	/AP/		/1MG/ML/	/N72090/001/APR/11,/1989/
>DLT>	/AP/		/1MG/ML/	/N72092/001/APR/11,/1989/
>ADD>		@ ASTRA	0.02MG/ML	N72082 001 APR 11, 1989
>ADD>		@	0.02MG/ML	N72083 001 APR 11, 1989
>ADD>		@	0.02MG/ML	N72084 001 APR 11, 1989
>ADD>		@	0.02MG/ML	N72085 001 APR 11, 1989
>ADD>		@	0.4MG/ML	N72087 001 APR 11, 1989
>ADD>		@	0.4MG/ML	N72088 001 APR 11, 1989
>ADD>		@	0.4MG/ML	N72089 001 APR 11, 1989
>ADD>		@	0.4MG/ML	N72090 001 APR 11, 1989
>ADD>		@	1MG/ML	N72092 001 APR 11, 1989
>ADD>		@	1MG/ML	N72093 001 APR 11, 1989
	/AP/	/LYPHOMED/	/0.02MG/ML/	/N70661/001/NOV/17,/1986/
		@ LYPHOMED	0.02MG/ML	N70661 001 NOV 17, 1986

INJECTABLE; INJECTION

NARCAN

/AP/	/DUPONT/	/0.4MG/ML/	/N71083/001/JUL/28,/1988/
/AP/		/1MG/ML/	/N71084/001/JUL/28,/1988/
/AP/		/1MG/ML/	/N71311/001/JUL/28,/1988/
	@ DUPONT	0.4MG/ML	N71083 001 JUL 28, 1988
	@	1MG/ML	N71084 001 JUL 28, 1988
	@	1MG/ML	N71311 001 JUL 28, 1988

NANDROLONE DECANOATE

INJECTABLE; INJECTION

NANDROLONE DECANOATE

/AO/	/LYPHOMED/	/100MG/ML/	/N88290/001/OCT/03,/1983/
/AO/		/200MG/ML/	/N88317/001/OCT/14,/1983/
	@ LYPHOMED	100MG/ML	N88290 001 OCT 03, 1983
	@	200MG/ML	N88317 001 OCT 14, 1983

NAPROXEN SODIUM

TABLET; ORAL

ANAPROX

AB	SYNTEX	275MG	N18164 001

ANAPROX DS

AB	+ SYNTEX	550MG	N18164 003 SEP 30, 1987

NAPROXEN SODIUM

AB	HAMILTON	275MG	N74106 001 AUG 31, 1993
AB		550MG	N74106 002 AUG 31, 1993

NEOMYCIN SULFATE

TABLET; ORAL

NEOMYCIN SULFATE

/AA/	/EON/LABS/	/EQ 350MG BASE/	/N61586/001/
	@ EON LABS	EQ 350MG BASE	N61586 001

NIACIN

/CAPSULE;/ORAL/
/MANPOCAP/
/WALLACE/ /500MG/ /N11073/003/
@ WALLACE 500MG N11073 003

TABLET; ORAL
NIACIN
/AA/ /ZENITH/ /500MG/ /N83180/001/
@ ZENITH 500MG N83180 001

NIFEDIPINE

CAPSULE; ORAL
NIFEDIPINE
AB FLEMINGTON 10MG N72781 001
JUL 30, 1993

TABLET, EXTENDED RELEASE; ORAL
ADALAT CC
BC MILES 30MG N20198 001
APR 21, 1993
BC 60MG N20198 002
APR 21, 1993
BC 90MG N20198 003
APR 21, 1993

PROCARDIA XL
BC + PFIZER 30MG N19684 001
SEP 06, 1989
BC + 60MG N19684 002
SEP 06, 1989
BC + 90MG N19684 003
SEP 06, 1989
/+/ /30MG/ /N19684/001/
/SEP/06,/1989/
/+/ /60MG/ /N19684/002/
/SEP/06,/1989/
/+/ /90MG/ /N19684/003/
/SEP/06,/1989/

NITROFURANTOIN

TABLET; ORAL
NITROFURANTOIN
/AB/ /ZENITH/ /50MG/ /N80078/002/
/AB/ /100MG/ /N80078/001/
@ ZENITH 50MG N80078 002
@ 100MG N80078 001

NITROFURANTOIN, MACROCRYSTALLINE

CAPSULE; ORAL
NITROFURANTOIN
AB ZENITH 50MG N73671 001
JAN 28, 1993
AB 100MG N73652 001
JAN 28, 1993

NITROGLYCERIN

INJECTABLE; INJECTION
NITRO-BID
/MARION/MERRELL/DOW/ /10MG/ML/ /N71159/001/
/FEB/28,/1990/
@ MARION MERRELL DOW 10MG/ML N71159 001
FEB 28, 1990

NORTRIPTYLINE HYDROCHLORIDE

CAPSULE; ORAL
NORTRIPTYLINE HCL
AB MYLAN EQ 10MG BASE N74234 001
JUL 26, 1993
AB EQ 25MG BASE N74234 002
JUL 26, 1993
AB EQ 50MG BASE N74234 003
JUL 26, 1993
AB EQ 75MG BASE N74234 004
JUL 26, 1993

NYSTATIN

CREAM; TOPICAL
NYSTATIN
AT BARRE 100,000 UNITS/GM N62949 001
JUN 13, 1988
/AT/ /NASKA/ /100,000 UNITS/GM/ /N62949/001/
/JUN/13,/1988/
AT TARO 100,000 UNITS/GM N64022 001
JAN 29, 1993

OINTMENT; TOPICAL
NYSTATIN
AT BARRE 100,000 UNITS/GM N62840 001
NOV 13, 1987
/AT/ /NASKA/ /100,000 UNITS/GM/ /N62840/001/
/NOV/13,/1987/

POWDER; ORAL

	NYSTATIN 100		
AA	BARLAN	100%	N62489 001 APR 27, 1988
	@ BARLAN	100%	N62489 001 APR 27, 1988

SUSPENSION; ORAL

	MYCOSTATIN		
AA	APOTHECON	100,000 UNITS/ML	N61533 001
AA	BRISTOL/MYERS/SQUIBB	100,000 UNITS/ML	N61533 001
	NYSTATIN		
AA	BARRE	100,000 UNITS/ML	N62571 001 OCT 29, 1985
AA	NASKA	100,000 UNITS/ML	N62571 001 OCT 29, 1985
AA	PENNEX PHARMS	100,000 UNITS/ML	N62512 001 OCT 29, 1984
	@	100,000 UNITS/ML	N62835 001 NOV 19, 1987
AA	PHARM BASICS	100,000 UNITS/ML	N62512 001 OCT 29, 1984
AA		100,000 UNITS/ML	N62835 001 NOV 19, 1987
AA	PHARMADERM	100,000 UNITS/ML	N62518 001 JUL 06, 1984
	@ PHARMADERM	100,000 UNITS/ML	N62518 001 JUL 06, 1984

NYSTATIN; TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE		
AT	BARRE	100,000 UNITS/GM;0.1%	N63010 001 DEC 20, 1988
AT	NASKA	100,000 UNITS/GM;0.1%	N63010 001 DEC 20, 1988
	NYSTATIN-TRIAMCINOLONE ACETONIDE		
AT	PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001 OCT 08, 1985
	@ PHARMADERM	100,000 UNITS/GM;0.1%	N62596 001 OCT 08, 1985

OINTMENT; TOPICAL

	NYSTATIN AND TRIAMCINOLONE ACETONIDE		
AT	TARO	100,000 UNITS/GM;0.1%	N63305 001 MAR 29, 1993

INJECTABLE; INJECTION

	SANDOSTATIN		
	SANDOZ	EQ 0.05MG BASE/ML	N19667 001 OCT 21, 1988
	SANDOZ	EQ 0.1MG BASE/ML	N19667 002 OCT 21, 1988
	SANDOZ	EQ 0.2MG BASE/ML	N19667 004 JUN 12, 1991
	SANDOZ	EQ 0.5MG BASE/ML	N19667 003 OCT 21, 1988
	SANDOZ	EQ 1MG BASE/ML	N19667 005 JUN 12, 1991

OFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

	OCUFLOX		
+	ALLERGAN	0.3%	N19921 001 JUL 30, 1993

OXACILLIN SODIUM

CAPSULE; ORAL

	PROSTAPHLIN		
AB	APOTHECON	EQ 250MG BASE	N61450 002
AB		EQ 500MG BASE	N61450 001
AB	BRISTOL	EQ 250MG BASE	N61450 002
AB		EQ 500MG BASE	N61450 001

POWDER FOR RECONSTITUTION; ORAL

	PROSTAPHLIN		
AA	APOTHECON	EQ 250MG BASE/5ML	N61457 001
AA	BRISTOL	EQ 250MG BASE/5ML	N61457 001

OXPRENOLOL HYDROCHLORIDE

/CAPSULE;ORAL/
/TRASICOR/
/+//CIBA/

	/160MG/	/N18166/004/ /DEC/28,/1983/
	/20MG/	/N18166/001/ /DEC/28,/1983/
	/40MG/	/N18166/002/ /DEC/28,/1983/
	/80MG/	/N18166/003/ /DEC/28,/1983/
∂ CIBA	20MG	N18166 001 DEC 28, 1983
∂	40MG	N18166 002 DEC 28, 1983
∂	80MG	N18166 003 DEC 28, 1983
∂	160MG	N18166 004 DEC 28, 1983

OXTRIPHYLLINE

SOLUTION; ORAL
CHOLEDYL
/AA/ /PARKE/DAVIS/ /100MG/5ML/ /N09268/012/ /NOV/27,/1984/

PARKE DAVIS 100MG/5ML N09268 012 NOV 27, 1984

/OXTRIPHYLLINE/
/AA/ /PHARM/BASICS/ /100MG/5ML/ /N88243/001/ /DEC/05,/1983/

∂ PENNEX PHARMS 100MG/5ML N88243 001 DEC 05, 1983

SYRUP; ORAL
CHOLEDYL
/AA/ /PARKE/DAVIS/ /50MG/5ML/ /N09268/011/

PARKE DAVIS 50MG/5ML N09268 011

/OXTRIPHYLLINE/PEDIATRICS/
/AA/ /PHARM/BASICS/ /50MG/5ML/ /N88242/001/ /DEC/05,/1983/

∂ PENNEX PHARMS 50MG/5ML N88242 001 DEC 05, 1983

PAMIDRONATE DISODIUM

INJECTABLE; INJECTION
AREDIA

+ CIBA GEIGY	60MG/VIAL	N20036 003 MAY 06, 1993
+	90MG/VIAL	N20036 004 MAY 06, 1993

PANCURONIUM BROMIDE

INJECTABLE; INJECTION
PANCURONIUM BROMIDE
>_DLT_>/AP/ /ASTRA/ /2MG/ML/ /N72212/001/ /MAR/31,/1988/

>_DLT_>
>_ADD_> ∂ ASTRA 2MG/ML N72212 001 MAR 31, 1988
>_ADD_>

PARAMETHASONE ACETATE

TABLET; ORAL
HALDRONE
/+//LILLY/

	/2MG/	/N12772/006/
	/1MG/	/N12772/005/
∂ LILLY	1MG	N12772 005
∂	2MG	N12772 006

PAROXETINE HYDROCHLORIDE

TABLET; ORAL
PAXIL
/+//SMITHKLINE/BEECHAM/ /EQ/10MG/BASE/ /N20031/001/ /DEC/29,/1992/

/+/ /EQ/20MG/BASE/ /N20031/004/ /DEC/29,/1992/

∂ SMITHKLINE BEECHAM EQ 10MG BASE N20031 001 DEC 29, 1992

/EQ/40MG/BASE/ /N20031/005/ /DEC/29,/1992/

∂ EQ 40MG BASE N20031 005 DEC 29, 1992

∂ EQ 50MG BASE N20031 004 DEC 29, 1992

PENICILLIN G BENZATHINE

INJECTABLE; INJECTION

BICILLIN L-A

+ WYETH AYERST	300,000 UNITS/ML	N50131 001
∂	300,000 UNITS/ML	N50131 001
	600,000 UNITS/ML	N50141 003

TABLET; ORAL

BICILLIN

+ WYETH AYERST	200,000 UNITS	N50128 001
∂ WYETH AYERST	200,000 UNITS	N50128 001

PENICILLIN G POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

PENTCILLIN

AA BIOCRAFT	200,000 UNITS/5ML	N60307 002
PENTIDS 200		
AA SQUIBB	200,000 UNITS/5ML	N62149 001
∂ APOTHECON	200,000 UNITS/5ML	N62149 001
PENTIDS 400		
AA SQUIBB	400,000 UNITS/5ML	N62149 002
∂ APOTHECON	400,000 UNITS/5ML	N62149 002

TABLET; ORAL

PENICILLIN G POTASSIUM

∂ APOTHECON	250,000 UNITS	N60392 003
AB SQUIBB	250,000 UNITS	N60392 003
PENTIDS 200		
AB SQUIBB	200,000 UNITS	N62155 001
∂ APOTHECON	200,000 UNITS	N62155 001
PENTIDS 250		
AB SQUIBB	250,000 UNITS	N62155 002
∂ APOTHECON	250,000 UNITS	N62155 002
PENTIDS 400		
AB SQUIBB	400,000 UNITS	N60392 004
AB	400,000 UNITS	N62155 003
∂ APOTHECON	400,000 UNITS	N60392 004
∂	400,000 UNITS	N62155 003
PENTIDS 800		
AB SQUIBB	800,000 UNITS	N60392 005
AB	800,000 UNITS	N62155 004
∂ APOTHECON	800,000 UNITS	N60392 005
∂	800,000 UNITS	N62155 004

PENICILLIN G PROCAINE

INJECTABLE; INJECTION

DURACILLIN A.S.

AP LILLY	300,000 UNITS/ML	N60093 001
∂ LILLY	300,000 UNITS/ML	N60093 001

PENICILLIN V

POWDER FOR RECONSTITUTION; ORAL

V-CILLIN

+ LILLY	125MG/0.6ML	N60002 001
∂ LILLY	125MG/0.6ML	N60002 001

PENICILLIN V POTASSIUM

POWDER FOR RECONSTITUTION; ORAL

VEETIDS 125

AA SQUIBB	EQ 125MG BASE/5ML	N61206 001
AA	EQ 125MG BASE/5ML	N62153 001
∂ APOTHECON	EQ 125MG BASE/5ML	N61206 001
∂	EQ 125MG BASE/5ML	N62153 001

VEETIDS 250

AA SQUIBB	EQ 250MG BASE/5ML	N61206 002
AA	EQ 250MG BASE/5ML	N62153 002
∂ APOTHECON	EQ 250MG BASE/5ML	N61206 002
∂	EQ 250MG BASE/5ML	N62153 002

TABLET; ORAL

BETAPEN-VK

AB APOTHECON	EQ 250MG BASE	N61411 001
AB	EQ 500MG BASE	N61411 002
AA BRISTOL	EQ 250MG BASE	N61411 001
AB BRISTOL	EQ 500MG BASE	N61411 002

VEETIDS 250

AA SQUIBB	EQ 250MG BASE	N61164 001
AB SQUIBB	EQ 250MG BASE	N62156 002
∂ APOTHECON	EQ 250MG BASE	N61164 001
∂	EQ 250MG BASE	N62156 002

VEETIDS 500

AB SQUIBB	EQ 500MG BASE	N61164 002
AB	EQ 500MG BASE	N62156 001
∂ APOTHECON	EQ 500MG BASE	N61164 002
∂	EQ 500MG BASE	N62156 001

PENTOBARBITAL SODIUM

INJECTABLE; INJECTION
PENTOBARBITAL SODIUM
/BP/ /ELKINS/SINN/ /50MG/ML/ /N83270/001/
@ ELKINS SINN 50MG/ML N83270 001

PERFLUBRON

LIQUID; ORAL
IMAGENT
+ ALLIANCE PHARM 100% N20091 001 AUG 13, 1993

PERMETHRIN

/LOTION;TOPICAL/
/NIX/
/AT//+//BURROUGHS/WELLCOME/ /1%/ /N19435/001/ /MAR/31,/1986/
@ BURROUGHS WELLCOME 1% N19435 001 MAR 31, 1986

PERPHENAZINE

/TABLET;/EXTENDED/RELEASE;/ORAL/
/TRILAFON/
/+//SCHERING/ /8MG/ /N11361/002/
@ SCHERING 8MG N11361 002

PHENDIMETRAZINE TARTRATE

CAPSULE; ORAL
/STATOBEX/
/AA/ /LEMMON/ /35MG/ /N85507/001/
@ LEMMON 35MG N85507 001

TABLET; ORAL
/ANOREX/
/AA/ /FERNDALE/ /35MG/ /N83655/001/
@ FERNDALE 35MG N83655 001
/METRA/
/AA/ /FOREST/PHARMS/ /35MG/ /N83754/001/
@ FOREST PHARMS 35MG N83754 001

PHENDIMETRAZINE TARTRATE
/AA/ /ANABOLIC/ /35MG/ /N86020/001/
@ ANABOLIC 35MG N86020 001

PHENDIMETRAZINE TARTRATE

TABLET; ORAL
PHENDIMETRAZINE TARTRATE
/AA/ /FERNDALE/ /35MG/ /N86834/001/ /SEP/15,/1983/
@ FERNDALE 35MG N86834 001 SEP 15, 1983

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL
ADIPEX-P
/AA/ /LEMMON/ /30MG/ /N86911/001/
/OBESITY-30/
/AA/ /FERNDALE/ /30MG/ /N87144/001/
@ FERNDALE 30MG N87144 001

PHENTERMINE HCL
@ LEMMON 30MG N86911 001
/AA/ /ZENITH/ /30MG/ /N86329/001/
@ ZENITH 30MG N86329 001

PHENYLBUTAZONE

CAPSULE; ORAL
PHENYLBUTAZONE
>ADD> AB CHELSEA 100MG N87756 001 DEC 17, 1982
>ADD>
>DLT> /B*/ /100MG/ /N87756/001/ /DEC/17,/1982/
>DLT>

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL
PROMETHAZINE VC PLAIN
@ PENNEX PHARMS 5MG/5ML;6.25MG/5ML N88897 001 JAN 04, 1985
/AA/ /PHARM/BASICS/ /5MG/5ML;6.25MG/5ML/ /N88897/001/ /JAN/04,/1985/

PHYTONADIONE

INJECTABLE; INJECTION
AQUAMEPHYTON
/BP/ /MSD/ /10MG/ML/ /N12223/001/
BP + MSD 10MG/ML N12223 001

INJECTABLE; INJECTION

KONAKION

/BP/	/+//ROCHE/	/10MG/ML/	/N11745/003/
BP	ROCHE	10MG/ML	N11745 003

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	GENEVA	5MG	N73608 001 MAR 29, 1993
AB		10MG	N73609 001 MAR 29, 1993
AB	PUREPAC	5MG	N74125 001 APR 28, 1993
AB		10MG	N74125 002 APR 28, 1993
AB	ZENITH	5MG	N73687 001 FEB 26, 1993
AB		10MG	N73687 002 FEB 26, 1993

PIROXICAM

CAPSULE; ORAL

PIROXICAM

AB	MEPHA AG	10MG	N74116 001 JUN 15, 1993
AB		20MG	N74118 001 JUN 15, 1993
AB	MUTUAL PHARM	10MG	N73535 001 MAR 12, 1993
AB		20MG	N73536 001 MAR 12, 1993
AB	ROXANE	10MG	N73651 001 FEB 26, 1993
AB		20MG	N73651 002 FEB 26, 1993

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

PEG-LYTE

AA	INVAMED	236GM/BOT;2.97GM/BOT;6.74GM/BOT; 5.86GM/BOT;22.74GM/BOT	N73098 001 AUG 31, 1993

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

/AB/	/ADRIA/	/8MEQ/	/N73398/001/ /JAN/28,/1992/
/AB/		/10 MEQ/	/N72427/001/ /MAR/28,/1990/
AB	SAVAGE	8MEQ	N73398 001 JAN 28, 1992
AB		10 MEQ	N72427 001 MAR 28, 1990

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

AP	FUJISAWA	2MEQ/ML	N84290 001
AP		2MEQ/ML	N87787 001 APR 20, 1982
/AP/	/LUITPOLD/	/2MEQ/ML/	/N80221/001/
/AP/		/2MEQ/ML/	/N80736/001/
	∂ LUITPOLD	2MEQ/ML	N80221 001
	∂	2MEQ/ML	N80736 001
/AP/	/LYPHOMED/	/2MEQ/ML/	/N84290/001/
/AP/		/2MEQ/ML/	/N87787/001/ /APR/20,/1982/

TABLET, EXTENDED RELEASE; ORAL

K+8

AB	ALRA	8MEQ	N70998 001 JAN 25, 1993
	KAON CL /ADRIA/ SAVAGE	/6.7MEQ/ 6.7MEQ	/N17046/001/ N17046 001
	KAON CL-10		
/BC/	/ADRIA/	/10MEQ/	/N17046/002/
BC	SAVAGE	10MEQ	N17046 002

POTASSIUM CITRATE

/POWDER/FOR/RECONSTITUTION;/ORAL/

	/POTASSIUM/CITRATE/ /+//UNIV/TX/	/20MEQ/PACKET/	/N19647/001/ /OCT/13,/1988/
		/10MEQ/PACKET/	/N19647/002/ /OCT/13,/1988/
	∂ UNIV TX	10MEQ/PACKET	N19647 002 OCT 13, 1988
	∂	20MEQ/PACKET	N19647 001 OCT 13, 1988

POTASSIUM CITRATE

TABLET, EXTENDED RELEASE; ORAL
POTASSIUM CITRATE

/+//UNIV/TX/	/5MEQ/	/N19071/001/	
		/AUG/30,/1985/	
+ UNIV TX	10MEQ	N19071 002	
		AUG 31, 1992	
	5MEQ	N19071 001	
		AUG 30, 1985	

PRAVASTATIN SODIUM

TABLET; ORAL
PRAVACHOL

/+//BRISTOL/MYERS/SQUIBB/	/40MG/	/N19898/003/	
		/OCT/31,/1991/	
+ BRISTOL MYERS SQUIBB	40MG	N19898 004	
		MAR 22, 1993	
	20MG	N19898 003	
		OCT 31, 1991	

PRAZEPAM

/TABLET;/ORAL/
/CENTRAX/

/+//PARKE/DAVIS/	/10MG/	/N17415/001/	
@ PARKE DAVIS	10MG	N17415 001	

PREDNICARBATE

OINTMENT; TOPICAL
/DERMATOP/

/HOECHST/ROUSSEL/	/0.1%/	/N19568/001/	
		/SEP/23,/1991/	
@ HOECHST ROUSSEL	0.1%	N19568 001	
		SEP 23, 1991	

PREDNISOLONE

TABLET; ORAL
PREDNISOLONE

/BX/	/WEST/WARD/	/5MG/	/N80324/001/	
	@ WEST WARD	5MG	N80324 001	

PREDNISOLONE ACETATE; SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC
CETAPRED

	ALCON	0.25%;10%		N87771 001
				AUG 06, 1993

SUSPENSION/DROPS; OPHTHALMIC
/PREDSULFATE/

>DLT>				
>DLT>/AT/	/PHARMAFAIR/	/0.5%;10%/		/N88007/001/
>DLT>				/APR/19,/1983/
>ADD>	@ PHARMAFAIR	0.5%;10%		N88007 001
>ADD>				APR 19, 1983

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS; OPHTHALMIC
SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	STERIS	EQ 0.23% PHOSPHATE;10%	N73630 001
			MAY 27, 1993

VASOCIDIN

AT	IOLAB	EQ 0.23% PHOSPHATE;10%	N18988 001
			AUG 26, 1988

PREDNISONE

SOLUTION; ORAL
PREDNISONE

	@ PENNEX PHARMS	5MG/5ML	N89726 001
			AUG 02, 1988
/AA/	/PHARM/BASICS/	/5MG/5ML/	/N89726/001/
			/AUG/02,/1988/
/AA/	/ROXANE/	/5MG/5ML/	/N88703/001/
			/NOV/08,/1984/
	ROXANE	5MG/5ML	N88703 001
			NOV 08, 1984

TABLET; ORAL
DELTASONE

AB	UPJOHN	2.5MG	N09986 005
/BX/		/2.5MG/	/N09986/005/

PREDNISONE

/AA/	/HEATHER/	/10MG/	/N84341/001/
/AA/		/20MG/	/N84417/001/
/AA/		/20MG/	/N85543/001/
/AA/		/50MG/	/N86946/001/
	@ HEATHER	10MG	N84341 001
	@	20MG	N84417 001
	@	20MG	N85543 001
	@	50MG	N86946 001

TABLET; ORAL

PREDNISONE

/BX/	/KV/	/5MG/	/N84236/001/
	@ KV	5MG	N84236 001
BX	NYLOS TRADING	5MG	N85115 001
/BX/	/TABLICAPS/	/5MG/	/N85115/001/
/BX/	/UPSHER/SMITH/	/5MG/	/N87471/001/
/BX/		/20MG/	/N87470/001/
	@ UPSHER SMITH	5MG	N87471 001
	@	20MG	N87470 001

PROCAINAMIDE HYDROCHLORIDE

CAPSULE; ORAL

PRONESTYL

AB	APOTHECON	250MG	N07335 001
AB		375MG	N07335 004
AB	+	500MG	N07335 003
/AB/	/SQUIBB/	/250MG/	/N07335/001/
/AB/		/375MG/	/N07335/004/
/AB/	/+/	/500MG/	/N07335/003/

INJECTABLE; INJECTION

PROCAINAMIDE HCL

/AP/	/LYPHOMED/	/100MG/ML/	/N89415/001/ /NOV 17, 1986/
/AP/		/500MG/ML/	/N89416/001/ /NOV 17, 1986/
	@ LYPHOMED	100MG/ML	N89415 001 NOV 17, 1986
	@	500MG/ML	N89416 001 NOV 17, 1986

PRONESTYL

AP	+ APOTHECON	100MG/ML	N07335 002
AP	+	500MG/ML	N07335 005
/AP/	/SQUIBB/	/100MG/ML/	/N07335/002/
/AP/		/500MG/ML/	/N07335/005/

PROCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

PROCAINE HCL

/AP/	/BEL/MAR/	/1%/	/N80711/001/
/AP/		/2%/	/N80756/001/
	@ BEL MAR	1%	N80711 001
	@	2%	N80756 001

CONCENTRATE; ORAL

PROCHLORPERAZINE EDISYLATE

@ PENNEX PHARMS	EQ 10MG BASE/ML	N88598 001 OCT 25, 1984
/@/PHARM/BASICS/	/EQ/10MG/BASE/ML/	/N88598/001/ /OCT/25/1984/

SYRUP; ORAL

PROCHLORPERAZINE EDISYLATE

@ PENNEX PHARMS	EQ 5MG BASE/5ML	N88597 001 OCT 25, 1984
/@/PHARM/BASICS/	/EQ/5MG/BASE/5ML/	/N88597/001/ /OCT/25/1984/

PROCYCLIDINE HYDROCHLORIDE

TABLET; ORAL

KEMADRIN

/BURROUGHS/WELLCOME/	/2MG/	/N09818/005/
@ BURROUGHS WELLCOME	2MG	N09818 005

PROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION

SPARINE

>DLT>	/AP/	/WYETH/AYERST/	/25MG/ML/	/N10349/009/

PROMETHAZINE HYDROCHLORIDE

SUPPOSITORY; RECTAL

PROMETHACON

/BR/	/ALCON/	/25MG/	/N84901/001/
/BR/		/50MG/	/N84902/001/
BR	POLYMEDICA	25MG	N84901 001
BR		50MG	N84902 001

SYRUP; ORAL

PROMETHAZINE PLAIN

@ PENNEX PHARMS		6.25MG/5ML	N87953 001 NOV 15, 1982
/AA/	/PHARM/BASICS/	/6.25MG/5ML/	/N87953/001/ /NOV/15/1982/

PROMETHAZINE HYDROCHLORIDE

TABLET; ORAL
PROMETHAZINE HCL

/BP/	/CIRCA/	/25MG/	/N83204/001/
	∂ CIRCA	25MG	N83204 001
/BP/	/ZENITH/	/50MG/	/N83613/001/
	∂ ZENITH	50MG	N83613 001

PROPOFOL

INJECTABLE; INJECTION
DIPRIVAN

/ICI/	/10MG/ML/	/N19627/001/ /OCT/02/1989/
+ ZENECA	10MG/ML	N19627 001 OCT 02, 1989

PROPRANOLOL HYDROCHLORIDE

SOLUTION; ORAL
PROPRANOLOL HCL

∂ PENNEX PHARMS	20MG/5ML	N71984 001 MAR 03, 1989
∂	40MG/5ML	N71985 001 MAR 03, 1989
/∂/PHARM/BASICS/	/20MG/5ML/	/N71984/001/ /MAR/03/1989/
/∂/	/40MG/5ML/	/N71985/001/ /MAR/03/1989/

/SUSPENSION;/ORAL/
/INDERAL/

/WYETH/AYERST/	/10MG/ML/	/N19536/001/ /DEC/12/1986/
∂ WYETH AYERST	10MG/ML	N19536 001 DEC 12, 1986

TABLET; ORAL
PROPRANOLOL HCL

/AB/	/MYLAN/	/60MG/	/N72275/001/ /JUN/09/1989/
	∂ MYLAN	60MG	N72275 001 JUN 09, 1989

PROPYLIODONE

/SUSPENSION;/INTRATRACHEAL/
/DIONOSIL/OILY/

/GLAXO/	/60%/	/N09309/002/
∂ GLAXO	60%	N09309 002

PROTAMINE SULFATE

INJECTABLE; INJECTION
PROTAMINE SULFATE

/AP/	/QUAD/	/10MG/ML/	/N89306/001/ /MAY/30/1986/
	∂ QUAD	10MG/ML	N89306 001 MAY 30, 1986

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
/NISTAFED/

/AA/	/LIFE/LABS/	/30MG/5ML;1.25MG/5ML/	/N88283/001/ /APR/20/1984/
	∂ CENCI	30MG/5ML;1.25MG/5ML	N88283 001 APR 20, 1984

PYRANTEL PAMOATE

/SUSPENSION;/ORAL/
/ANTIMINTH/

/*/ROERIG/	/EQ/250MG/BASE/5ML/	/N16883/001/

PYRIDOSTIGMINE BROMIDE

INJECTABLE; INJECTION
MESTINON

/AP/	/ICN/	/5MG/ML/	/N09830/001/
AP	ROCHE	5MG/ML	N09830 001

SYRUP; ORAL
MESTINON

/ICN/	/60MG/5ML/	/N15193/001/
ROCHE	60MG/5ML	N15193 001

TABLET; ORAL
MESTINON

/*/ICN/	/60MG/	/N09829/002/
+ ROCHE	60MG	N09829 002

PYRIDOSTIGMINE BROMIDE

TABLET, EXTENDED RELEASE; ORAL

MESTINON			
/+//ICN/	/180MG/	/N11665/001/	
+ ROCHE	180MG	N11665 001	

PYRIDOXINE HYDROCHLORIDE

INJECTABLE; INJECTION

/HEMA-DETALIN/				
/AP/ /LILLY/	/100MG/ML/	/N80854/001/		
@ LILLY	100MG/ML	N80854 001		
PYRIDOXINE HCL				
/AP/ /BEL/MAR/	/100MG/ML/	/N80761/001/		
@ BEL MAR	100MG/ML	N80761 001		
AP FUJISANA	100MG/ML	N80618 001		
/AP/ /LYPHOMED/	/100MG/ML/	/N80618/001/		

QUAZEPAM

TABLET; ORAL

DORAL			
/+//BAKER/NORTON/	/15MG/	/N18708/001/	
		/DEC/27/1985/	
	/7.5MG/	/N18708/003/	
		/FEB/26/1987/	
+ WALLACE	15MG	N18708 001	
		DEC 27, 1985	
	7.5MG	N18708 003	
		FEB 26, 1987	

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

/DURAQUIN/			
/PARKE/DAVIS/	/330MG/	/N17917/001/	
@ WARNER CHILCOTT	330MG	N17917 001	

QUINIDINE SULFATE

TABLET; ORAL

QUINIDINE SULFATE			
/AB/ /PARKE/DAVIS/	/200MG/	/N83879/001/	
@ WARNER CHILCOTT	200MG	N83879 001	

RAUWOLFIA SERPENTINA

TABLET; ORAL

RAUDIXIN			
BP APOTHECON	50MG	N08842 001	
BP +	100MG	N08842 002	
/BP/ /SQUIBB/	/50MG/	/N08842/001/	
/BP/+/	/100MG/	/N08842/002/	

RESERPINE

TABLET; ORAL

RESERPINE			
/BP/ /LEMMON/	/0.1MG/	/N89020/001/	
		/MAR/07/1985/	
/BP/	/0.25MG/	/N89019/001/	
		/MAR/07/1985/	
@ LEMMON	0.1MG	N89020 001	
		MAR 07, 1985	
@	0.25MG	N89019 001	
		MAR 07, 1985	

RESERPINE; TRICHLORMETHIAZIDE

TABLET; ORAL

/NAQUIVAL/			
/BP/+//SCHERING/	/0.1MG;4MG/	/N12265/003/	
@ SCHERING	0.1MG;4MG	N12265 003	

>ADD> RIMANTADINE HYDROCHLORIDE

>ADD> SYRUP; ORAL

>ADD> FLUMADINE

>ADD> + FOREST LABS 50MG/5ML N19650 001

>ADD> SEP 17, 1993

>ADD>

>ADD> TABLET; ORAL

>ADD> FLUMADINE

>ADD> + FOREST LABS 100MG N19649 001

>ADD> SEP 17, 1993

RITODRINE HYDROCHLORIDE

INJECTABLE; INJECTION
RITODRINE HCL

/AP/	/QUAD/	/10MG/ML/	/N70700/001/ /OCT/06,/1986/
	ə QUAD	10MG/ML	N70700 001 OCT 06, 1986

SELENIUM SULFIDE

LOTION/SHAMPOO; TOPICAL
SELENIUM SULFIDE

	ə PENNEX PHARMS	2.5%	N88228 001 SEP 01, 1983
/AT/	/PHARM/BASICS/	/2.5%/	/N88228/001/ /SEP/01,/1983/

SERACTIDE ACETATE

/INJECTABLE;/INJECTION/
/ACTHAR/GEL-SYNTHETIC/

/ARMOUR/	/40/UNITS/ML/	/N17861/001/
	/80/UNITS/ML/	/N17861/002/
ə ARMOUR	40 UNITS/ML	N17861 001
ə	80 UNITS/ML	N17861 002

SILVER SULFADIAZINE

/DRESSING/TOPICAL/
/SILDIMAC/

ə BIOPLASTY	1%	N19608 001 NOV 30, 1989
/SILDIMAC/ /ENDO/	/1%/	/N19608/001/ /NOV/30,/1989/

SODIUM BICARBONATE

/INJECTABLE;/INJECTION/
/SODIUM/BICARBONATE/IN/PLASTIC/CONTAINER/

/ABBOTT/	/0.9MEQ/ML/	/N19443/001/ /JUN/03,/1986/
	/1MEQ/ML/	/N19443/002/ /JUN/03,/1986/

SODIUM BICARBONATE

/INJECTABLE;/INJECTION/
/SODIUM/BICARBONATE/IN/PLASTIC/CONTAINER/

ə ABBOTT	0.9MEQ/ML	N19443 001 JUN 03, 1986
ə	1MEQ/ML	N19443 002 JUN 03, 1986

SODIUM CHLORIDE

INJECTABLE; INJECTION
BACTERIOSTATIC SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

AP	FUJISAWA	9MG/ML	N88911 001 FEB 07, 1985
/AP/	/LYPHOMED/	/9MG/ML/	/N88911/001/ /FEB/07,/1985/

SODIUM CHLORIDE 23.4% IN PLASTIC CONTAINER

ə FUJISAWA	234MG/ML	N19329 001 APR 22, 1987
/ə/LYPHOMED/	/234MG/ML/	/N19329/001/ /APR/22,/1987/

SODIUM CHROMATE, CR-51

INJECTABLE; INJECTION
CHROMITOPE SODIUM

/SQUIBB/	/2MCI/VIAL/	/N13993/002/
ə SQUIBB	2MCI/VIAL	N13993 002

SODIUM IODIDE, I-131

CAPSULE; ORAL
SODIUM IODIDE I 131

/ə/CIS/	/50/UCI/	/N17316/001/
ə CIS	50 UCI	N17316 001
	/100/UCI/	/N17316/002/
	100 UCI	N17316 002

SOLUTION; ORAL
SODIUM IODIDE I 131

/CIS/	/50MCI/ML/	/N17315/001/
CIS	50MCI/ML	N17315 001

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

	@ PENNEX PHARMS	453.6GM/BOT	N88786 001 SEP 11, 1984
/AA/	/PHARM/BASICS/	/453.6GM/BOT/	/N88786/001/ /SEP/11,/1984/

SUSPENSION; ORAL, RECTAL
SODIUM POLYSTYRENE SULFONATE

	@ PENNEX PHARMS	15GM/60ML	N88717 001 SEP 11, 1984
/AA/	/PHARM/BASICS/	/15GM/60ML/	/N88717/001/ /SEP/11,/1984/

SOYBEAN OIL

INJECTABLE; INJECTION
NUTRILIPID 10%

AP	MCGAW	10%	N19531 001 MAY 28, 1993

NUTRILIPID 20%

AP	MCGAW	20%	N19531 002 MAY 28, 1993

SPIRONOLACTONE

TABLET; ORAL
SPIRONOLACTONE

/AB/	/CHELSEA/	/25MG/	/N87078/001/
B*	CHELSEA	25MG	N87078 001
/AB/	/UPSHER/SMITH/	/25MG/	/N87554/001/
	@ UPSHER SMITH	25MG	N87554 001

STRONTIUM CHLORIDE, SR-89

INJECTABLE; INJECTION
METASTRON

	MEDI PHYSICS	1MCI/ML	N20134 001 JUN 18, 1993

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

>DLT>	/SULFAIR 10/		
>DLT>/AT/	/PHARMAFAIR/	/10%/	/N88000/001/ /DEC/22,/1982/
>DLT>			

SULFACETAMIDE SODIUM

OINTMENT; OPHTHALMIC

>DLT>	/SULFAIR 10/		
>ADD>	@ PHARMAFAIR	10%	N88000 001 DEC 22, 1982
>ADD>			

SULFADIAZINE

TABLET; ORAL
SULFADIAZINE

	/ABBOTT/	/300MG/	/N04125/005/
	@ ABBOTT	300MG	N04125 005

SULFAMETHIZOLE

TABLET; ORAL
THIOSULFIL

	/WYETH/AYERST/	/250MG/	/N08565/001/
	@ WYETH AYERST	250MG	N08565 001

SULFAMETHOXAZOLE

TABLET; ORAL

	/GANTANOL-DS/		
	/ROCHE/	/1GM/	/N12715/003/
	@ ROCHE	1GM	N12715 003

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
TRIMETH/SULFA

AB	BARRE	200MG/5ML;40MG/5ML	N72289 001 MAY 23, 1988
AB		200MG/5ML;40MG/5ML	N72398 001 MAY 23, 1988
/AB/	/NASKA/	/200MG/5ML;40MG/5ML/	/N72289/001/ /MAY/23,/1988/
/AB/		/200MG/5ML;40MG/5ML/	/N72398/001/ /MAY/23,/1988/

SULFISOXAZOLE

TABLET; ORAL
SULFISOXAZOLE

/AB/	/HEATHER/	/500MG/	/N80189/001/
	@ HEATHER	500MG	N80189 001

SULFISOXAZOLE ACETYL

/EMULSION;/ORAL/
/LIPO/GANTRISIN/
/ROCHE/ /EQ/1GM/BASE/5ML/ /N09182/009/
@ ROCHE EQ 1GM BASE/5ML N09182 009

SULFISOXAZOLE DIOLAMINE

/OINTMENT;/OPHTHALMIC/
/GANTRISIN/
/ROCHE/ /EQ/4%/BASE/ /N08414/002/
@ ROCHE EQ 4% BASE N08414 002

SULINDAC

TABLET; ORAL
SULINDAC
AB MYLAN 150MG N73038 001
JUN 22, 1993
AB 200MG N73039 001
JUN 22, 1993

> ADD > TACRINE HYDROCHLORIDE

> ADD > CAPSULE; ORAL
> ADD > COGNEX
> ADD > + PARKE DAVIS EQ 40MG BASE N20070 004
> ADD > SEP 09, 1993
> ADD > EQ 10MG BASE N20070 001
> ADD > SEP 09, 1993
> ADD > EQ 20MG BASE N20070 002
> ADD > SEP 09, 1993
> ADD > EQ 30MG BASE N20070 003
> ADD > SEP 09, 1993

TAMOXIFEN CITRATE

TABLET; ORAL
NOLVADEX
/+//STUART/ /EQ/10MG/BASE/ /N17970/001/
+ ZENECA EQ 10MG BASE N17970 001

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
/A-N/STANNOUS/AGGREGATED/ALBUMIN/
/BS/ /NORTH/AM/CHEM/ /N/A/ /N17916/001/
@ NORTH AM CHEM N/A N17916 001

AN-MAA
BS SORIN N/A N17792 001
/N/A/ /N17792/001/
/TECHNETIUM/TC/99M/MAA/
/BS/ /MEDI/PHYSICS/ /N/A/ /N17773/001/
@ MEDI PHYSICS N/A N17773 001

TECHNETIUM TC-99M MEDRONATE KIT

INJECTABLE; INJECTION
/AMERSCAN MDP KIT/
/AP/ /AMERSHAM/ /N/A/ /N18335/001/
/AUS/05/1982/
@ AMERSHAM N/A N18335 001
AUG 05, 1982

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

SOLUTION; INJECTION, ORAL
/MINITEC/
/SQUIBB/ /0.22-2.22CI/GENERATOR/ /N17339/001/
@ SQUIBB 0.22-2.22CI/GENERATOR N17339 001

TEMAZEPAM

CAPSULE; ORAL
TEMAZEPAM
AB DANBURY PHARMA 15MG N71446 001
MAY 21, 1993
AB 30MG N71447 001
MAY 21, 1993

TERAZOSIN HYDROCHLORIDE

TABLET; ORAL

	HYTRIN			
>DLT>	/+///ABBOTT/	/2MG/		/N19057/002/ /AUG/07,/1987/
>DLT>				
>ADD>	+ ABBOTT		EQ 2MG BASE	N19057 002 AUG 07, 1987
>ADD>				
>ADD>	+		EQ 2MG/BASE	N20223 002 SEP 29, 1993
>ADD>		/1MG/		/N19057/001/ /AUG/07,/1987/
>DLT>				
>DLT>			EQ 1MG BASE	N19057 001 AUG 07, 1987
>ADD>				
>ADD>			EQ 1MG BASE	N20223 001 SEP 29, 1993
>ADD>		/5MG/		/N19057/003/ /AUG/07,/1987/
>DLT>				
>DLT>			EQ 5MG BASE	N19057 003 AUG 07, 1987
>ADD>				
>ADD>			EQ 5MG BASE	N20223 003 SEP 29, 1993
>ADD>		/10MG/		/N19057/004/ /AUG/07,/1987/
>DLT>				
>DLT>			EQ 10MG BASE	N19057 004 AUG 07, 1987
>ADD>				
>ADD>			EQ 10MG BASE	N20223 004 SEP 29, 1993
>ADD>				

TESTOSTERONE PROPIONATE

INJECTABLE; INJECTION

	TESTOSTERONE PROPIONATE			
/AO/	/BEL/MAR/	/25MG/ML/		/N80741/001/
/AO/		/50MG/ML/		/N80742/001/
/AO/		/100MG/ML/		/N80743/001/
	@ BEL MAR		25MG/ML	N80741 001
	@		50MG/ML	N80742 001
	@		100MG/ML	N80743 001
/AO/	/STERIS/	/25MG/ML/		/N80188/001/
/AO/		/25MG/ML/		/N85490/001/
/AO/		/100MG/ML/		/N80188/003/
/AO/		/100MG/ML/		/N83595/003/
	+ STERIS		25MG/ML	N80188 001
	+		100MG/ML	N80188 003
			25MG/ML	N85490 001
			100MG/ML	N83595 003

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL

	TETRACYCLINE HCL			
/AB/	/ICN/	/250MG/		/N60471/001/
	@ ICN	250MG		N60471 001

TABLET; ORAL

	SUMYCIN			
AB	APOTHECON	50MG		N61147 003
AB		100MG		N61147 002
AB		250MG		N61147 001
AB	+	500MG		N61147 004
/AB/	/SQUIBB/	/50MG/		/N61147/003/
/AB/		/100MG/		/N61147/002/
/AB/		/250MG/		/N61147/001/
/AB//+/		/500MG/		/N61147/004/

THALLOUS CHLORIDE, TL-201

INJECTABLE; INJECTION

	THALLOUS CHLORIDE TL 201			
/AP/	/SQUIBB/	/1MCI/ML/		/N18548/001/ /DEC/30,/1982/
	@ SQUIBB	1MCI/ML		N18548 001 DEC 30, 1982

THEOPHYLLINE

ELIXIR; ORAL

	/THEOPHYL-225/			
	/JOHNSON/RW/	/112.5MG/15ML/		/N86485/001/
	@ JOHNSON RW	112.5MG/15ML		N86485 001
	THEOPHYLLINE			
AA	BARRE	80MG/15ML		N89223 001 MAY 27, 1988
/AA/	/NASKA/	/80MG/15ML/		/N89223/001/ /MAY/27,/1988/
AA	PENNEX PHARMS	80MG/15ML		N86748 001
/AA/	/PHARM/BASICS/	/80MG/15ML/		/N86748/001/

TABLET; ORAL

	QUIBRON-T			
	/+///BRISTOL/MYERS/	/300MG/		/N88656/001/ /AUG/22,/1985/
	+ ROBERTS	300MG		N88656 001 AUG 22, 1985

THEOPHYLLINE

TABLET; ORAL

/THEOPHYL-225/ /JOHNSON/RW/	/225MG/	/N84726/001/
@ JOHNSON RW	225MG	N84726 001

/TABLET;/CHEWABLE;/ORAL/

/THEOPHYL/ /JOHNSON/RW/	/100MG/	/N86506/001/ /SEP/12;/1985/
@ JOHNSON RW	100MG	N86506 001 SEP 12, 1985

TABLET, EXTENDED RELEASE; ORAL

	QUIBRON-T/SR		
/BC/	/BRISTOL/MYERS/	/300MG/	/N87563/001/ /JUN/21;/1983/
BC	ROBERTS	300MG	N87563 001 JUN 21, 1983

THEOPHYLLINE SODIUM GLYCINATE

/ELIXIR;/ORAL/ /SYRAMYLATE/ /CENTRAL/PHARMS/	/EQ/165MG/BASE/15ML/	/N06333/008/
@ CENTRAL PHARMS	EQ 165MG BASE/15ML	N06333 008

THIAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

THIAMINE HCL

/AP/	/BEL/MAR/	/100MG/ML/	/N80718/001/
/AP/		/200MG/ML/	/N80712/001/
	@ BEL MAR	100MG/ML	N80718 001
	@	200MG/ML	N80712 001
AP	FUJISAWA	100MG/ML	N80556 001
/AP/	/LYPHOMED/	/100MG/ML/	/N80556/001/
/AP/	/STERIS/	/200MG/ML/	/N80571/002/
/AP/		/200MG/ML/	/N83534/002/
	+ STERIS	200MG/ML	N80571 002
		200MG/ML	N83534 002

THIORIDAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

THIORIDAZINE HCL

	@ PENNEX PHARMS	30MG/ML	N88258 001 JUL 25, 1983
	@	100MG/ML	N88227 001 JUL 05, 1983
/AA/	/PHARM/BASICS/	/30MG/ML/	/N88258/001/ /JUL/25;/1983/
/AA/		/100MG/ML/	/N88227/001/ /JUL/05;/1983/

TABLET; ORAL

THIORIDAZINE HCL

/AB/	/PAR/	/10MG/	/N88351/001/ /DEC/05;/1983/
/AB/		/15MG/	/N88352/001/ /DEC/05;/1983/
/AB/		/25MG/	/N88336/001/ /DEC/05;/1983/
/AB/		/50MG/	/N88322/001/ /DEC/05;/1983/
/AB/		/100MG/	/N88480/001/ /DEC/29;/1983/
	@ PAR	10MG	N88351 001 DEC 05, 1983
	@	15MG	N88352 001 DEC 05, 1983
	@	25MG	N88336 001 DEC 05, 1983
	@	50MG	N88322 001 DEC 05, 1983
	@	100MG	N88480 001 DEC 29, 1983
/AB/	/ZENITH/	/100MG/	/N88273/001/ /OCT/03;/1983/
	@ ZENITH	100MG	N88273 001 OCT 03, 1983

THIOTEPA

INJECTABLE; INJECTION

/THIO-TEPA/ /LEDERLE/	/15MG/VIAL/	/N11683/001/
THIOTEPA		
+ LEDERLE	15MG/VIAL	N11683 001

TICARCILLIN DISODIUM

INJECTABLE; INJECTION

	TICAR		
+	SMITHKLINE BEECHAM	EQ 20GM BASE/VIAL	N50497 004
+		EQ 30GM BASE/VIAL	N50497 005
			APR 04, 1984

TICLOPIDINE HYDROCHLORIDE

TABLET; ORAL

	TICLID		
+	SYNTEX	250MG	N19979 002
			OCT 31, 1991
ə		125MG	N19979 001
			MAR 24, 1993
		/250MG/	/N19979/002/
			/OCT/31,/1991/

TIMOLOL MALEATE

TABLET; ORAL

	TIMOLOL MALEATE		
AB	NOVOPHARM	5MG	N72648 001
			JUN 16, 1993
AB		10MG	N72649 001
			JUN 16, 1993
AB		20MG	N72650 001
			JUN 16, 1993

TOLMETIN SODIUM

CAPSULE; ORAL

	TOLMETIN SODIUM		
AB	MYLAN	EQ 400MG BASE	N73393 001
			MAY 27, 1993

TABLET; ORAL

	TOLMETIN SODIUM		
>ADD> AB	GENEVA	EQ 600MG BASE	N74002 001
			SEP 27, 1993

TORSEMIDE

INJECTABLE; INJECTION

	DEMADEX		
+	BOEHRINGER MANNHEIM	10MG/ML	N20137 002
			AUG 23, 1993

TORSEMIDE

TABLET; ORAL

	DEMADEX		
+	BOEHRINGER MANNHEIM	100MG	N20136 004
			AUG 23, 1993
		5MG	N20136 001
			AUG 23, 1993
		10MG	N20136 002
			AUG 23, 1993
		20MG	N20136 003
			AUG 23, 1993

TRANYLCYPROMINE SULFATE

TABLET; ORAL

	PARNATE		
+	SKF	EQ 10MG BASE	N12342 003
			AUG 16, 1985

TRAZODONE HYDROCHLORIDE

TABLET; ORAL

	DESYREL		
AB	APOTHECON	50MG	N18207 001
AB +		100MG	N18207 002
AB		150MG	N18207 003
			MAR 25, 1985
		300MG	N18207 004
			NOV 07, 1988
/AB/	/BRISTOL/MYERS/	/50MG/	/N18207/001/
/AB/	/+/	/100MG/	/N18207/002/
/AB/		/150MG/	/N18207/003/
			/MAR/25,/1985/
		/300MG/	/N18207/004/
			/NOV/07,/1988/

	TRAZODONE HCL		
AB	MUTUAL PHARM	50MG	N73136 001
			MAR 24, 1993
AB		100MG	N73137 001
			MAR 24, 1993

TRETINOIN

	/SWAB;/TOPICAL/		
	/RETIN-A/		
	/+//JOHNSON/RW/	/0.05%/	/N16921/002/
	ə JOHNSON RW	0.05%	N16921 002

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION

	AZMACORT		
+	RHONE POULENC RORER	0.1MG/INH	N18117 001 APR 23, 1982
/+/		/0.25MG/INH/	/N18117/001/ /APR/23,/1983/

CREAM; TOPICAL

TRIAMCINOLONE ACETONIDE

	@ PENNEX PHARMS	0.025%	N88094 001 SEP 01, 1983
	@	0.1%	N88095 001 SEP 01, 1983
	@	0.5%	N88096 001 SEP 01, 1983
	/@/PHARM/BASICS/	/0.025%/	/N88094/001/ /SEP/01,/1983/
	/@/	/0.1%/	/N88095/001/ /SEP/01,/1983/
	/@/	/0.5%/	/N88096/001/ /SEP/01,/1983/
/AT/	/PHARMADERM/	/0.025%/	/N87990/001/ /JUL/07,/1983/
/AT/		/0.1%/	/N87991/001/ /JUL/07,/1983/
/AT/		/0.5%/	/N87992/001/ /JUL/07,/1983/
	@ PHARMADERM	0.025%	N87990 001 JUL 07, 1983
	@	0.1%	N87991 001 JUL 07, 1983
	@	0.5%	N87992 001 JUL 07, 1983

LOTION; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	PENNEX PHARMS	0.025%	N88450 001 APR 01, 1985
AT		0.1%	N88451 001 APR 03, 1985
/AT/	/PHARM/BASICS/	/0.025%/	/N88450/001/ /APR/01,/1985/
/AT/		/0.1%/	/N88451/001/ /APR/03,/1985/

TRIAMCINOLONE ACETONIDE

OINTMENT; TOPICAL

TRIAMCINOLONE ACETONIDE

AT	BARRE	0.5%	N89913 001 DEC 23, 1988
/AT/	/MASKA/	/0.5%/	/N89913/001/ /DEC/23,/1988/
	@ PENNEX PHARMS	0.025%	N88090 001 SEP 01, 1983
	@	0.1%	N88091 001 SEP 01, 1983
	@	0.5%	N88092 001 SEP 01, 1983
	/@/PHARM/BASICS/	/0.025%/	/N88090/001/ /SEP/01,/1983/
	/@/	/0.1%/	/N88091/001/ /SEP/01,/1983/
	/@/	/0.5%/	/N88092/001/ /SEP/01,/1983/
/AT/	/PHARMADERM/	/0.025%/	/N88692/001/ /AUG/02,/1984/
/AT/		/0.1%/	/N88690/001/ /AUG/02,/1984/
	@ PHARMADERM	0.025%	N88692 001 AUG 02, 1984
	@	0.1%	N88690 001 AUG 02, 1984

TRIFLUOPERAZINE HYDROCHLORIDE

CONCENTRATE; ORAL

/TEVA/

/AA/	/GENEVA/	/EQ 10MG BASE/ML/	/N85787/001/ /APR/15,/1982/
	TRIFLUOPERAZINE HCL		
AA	GENEVA	EQ 10MG BASE/ML	N85787 001 APR 15, 1982
	TRIFLUOPERAZINE HCL		
	@ PENNEX PHARMS	EQ 10MG BASE/ML	N88143 001 JUL 26, 1983
/AA/	/PHARM/BASICS/	/EQ 10MG BASE/ML/	/N88143/001/ /JUL/26,/1983/

TABLET; ORAL

/TEVA/

/AB/	/GENEVA/	/EQ 1MG BASE/	/N85785/001/
/AB/		/EQ 2MG BASE/	/N85786/001/
/AB/		/EQ 5MG BASE/	/N85789/001/
/AB/		/EQ 10MG BASE/	/N85788/001/

TRIFLUOPERAZINE HYDROCHLORIDE

TABLET; ORAL
TRIFLUOPERAZINE HCL

AB	GENEVA	EQ 1MG BASE	N85785 001
AB		EQ 2MG BASE	N85786 001
AB		EQ 5MG BASE	N85789 001
AB		EQ 10MG BASE	N85788 001

TRIFLUPROMAZINE

/SUSPENSION;ORAL/
/VESPRIN/
/SQUIBB/ /EQ/50MG/HCL/5ML/ /N11491/004/
ə APOTHECON EQ 50MG HCL/5ML N11491 004

TRIFLUPROMAZINE HYDROCHLORIDE

INJECTABLE; INJECTION
VESPRIN

AP	+ APOTHECON	10MG/ML	N11325 004
AP	+	20MG/ML	N11325 001
/AP/	/SQUIBB/	/10MG/ML/	/N11325/004/
/AP/		/20MG/ML/	/N11325/001/

/TABLET;ORAL/
/VESPRIN/
/+//SQUIBB/ /50MG/ /N11123/003/
/10MG/ /N11123/001/
/25MG/ /N11123/002/
ə SQUIBB 10MG N11123 001
ə 25MG N11123 002
ə 50MG N11123 003

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET; ORAL
TRIHEXYPHENIDYL HCL

AA	NYLOS TRADING	5MG	N85622 001
/AA/	/TABLICAPS/	/5MG/	/N85622/001/

TRIMEPRAZINE TARTRATE

SYRUP; ORAL
TRIMEPRAZINE TARTRATE
ə PENNEX PHARMS EQ 2.5MG BASE/5ML N88285 001
APR 11, 1985

TRIMEPRAZINE TARTRATE

SYRUP; ORAL
TRIMEPRAZINE TARTRATE
/ə/PHARM/BASICS/ /EQ/2.5MG/BASE/5ML/ /N88285/001/
/APR/11,/1985/

TRIOXSALEN

TABLET; ORAL
TRISORALEN
/ELDER/ /5MG/ /N12697/001/
ICN 5MG N12697 001

TRIPELENNAMINE HYDROCHLORIDE

TABLET; ORAL
TRIPELENNAMINE HCL

/AA/	/HEATHER/	/50MG/	/N83989/001/
	ə HEATHER	50MG	N83989 001
AA	NYLOS TRADING	50MG	N85412 001
/AA/	/TABLICAPS/	/50MG/	/N85412/001/

TUBOCURARINE CHLORIDE

INJECTABLE; INJECTION
TUBOCURARINE CHLORIDE

/AP/	/QUAD/	/3MG/ML/	/N89442/001/
			/AUG/12,/1988/
	ə QUAD	3MG/ML	N89442 001
			AUG 12, 1988

VALPROIC ACID

CAPSULE; ORAL
VALPROIC ACID

AB	PHARMACAPS	250MG	N73484 001
			JUN 29, 1993

SYRUP; ORAL
MYPROIC ACID

AA	PENNEX PHARMS	250MG/5ML	N70868 001
			JUL 01, 1986
/AA/	/PHARM/BASICS/	/250MG/5ML/	/N70868/001/
			/JUL/01,/1986/

VANCOMYCIN HYDROCHLORIDE

INJECTABLE; INJECTION
VANCOCIN HCL IN PLASTIC CONTAINER
+ LILLY — EQ 500MG BASE/100ML — N50671 001 APR 29, 1993

VERAPAMIL HYDROCHLORIDE

INJECTABLE; INJECTION
ISOPTIN
>DLT > /AP/ /KNOLL/ — 2.5MG/ML — N18485/001
>ADD > AP + KNOLL — 2.5MG/ML — N18485 001
VERAPAMIL HCL
AP MARSAM — 2.5MG/ML — N72233 001 FEB 26, 1993
>ADD > AP — 2.5MG/ML — N73485 001 SEP 27, 1993
>ADD >

TABLET; ORAL
VERAPAMIL HCL
AB WATSON LABS — 40MG — N72923 001 JUN 29, 1993
AB — 40MG — N72924 001 JUN 29, 1993

VINBLASTINE SULFATE

INJECTABLE; INJECTION
VINBLASTINE SULFATE
FUJISAWA — 1MG/ML — N89515 001 APR 29, 1987
/LYPHOMED/ — /1MG/ML/ — /N089515/001/APR/29/1987/

VITAMIN A PALMITATE

CAPSULE; ORAL
AFAXIN
@ STERLING — EQ 50,000 UNITS BASE — N83187 001
VITAMIN A
/AA/ /WARTON/ — /EQ 50,000 UNITS BASE/ — /N83665/001/
@ WHARTON — EQ 50,000 UNITS BASE — N83665 001
/AA/ /ZENITH/ — /EQ 50,000 UNITS BASE/ — /N83035/001/
/AA/ — /EQ 50,000 UNITS BASE/ — /N83190/001/
@ ZENITH — EQ 50,000 UNITS BASE — N83035 001
@ — EQ 50,000 UNITS BASE — N83190 001

VITAMIN A PALMITATE

INJECTABLE; INJECTION
AQUASOL A
/AP/ /ASTRA/ — /EQ 50,000 UNITS BASE/ML — /N06823/001/
ASTRA — EQ 50,000 UNITS BASE/ML — N06823 001
/VITAMIN A PALMITATE/
/AP/ /BEL/MAR/ — /EQ 50,000 UNITS BASE/ML — /N80819/001/
@ BEL MAR — EQ 50,000 UNITS BASE/ML — N80819 001

WARFARIN SODIUM

TABLET; ORAL
COUMADIN

/BX/ /DUPONT/	/2MG/		/N09218/013/
/BX/	/2.5MG/		/N09218/018/
/BX/+/	/5MG/		/N09218/007/
/BX/+/	/10MG/		/N09218/005/
+ DUPONT	2MG		N09218 013
	5MG		N09218 007
+	10MG		N09218 005
	2.5MG		N09218 018
	4MG		N09218 023 AUG 24, 1993
/WARFARIN/			
/BX/ /ABBOTT/	/2MG/		/N17020/001/
/BX/	/2.5MG/		/N17020/002/
/BX/	/5MG/		/N17020/003/
/BX/	/7.5MG/		/N17020/004/
/BX/	/10MG/		/N17020/005/
@ ABBOTT	2MG		N17020 001
@	2.5MG		N17020 002
@	5MG		N17020 003
@	7.5MG		N17020 004
@	10MG		N17020 005

XENON, XE-133

GAS; INHALATION
XENON XE 133

/AA/ /DUPONT/	/30MCI/VIAL/		/N17284/004/
/AA/	/40MCI/VIAL/		/N17284/005/
/AA/	/50MCI/VIAL/		/N17284/006/
/AA/	/60MCI/VIAL/		/N17284/007/
/AA/	/100MCI/VIAL/		/N17284/003/
AA MEDI PHYSICS	10MCI/VIAL		N17687 002
AA	20MCI/VIAL		N17687 003

XYLOSE

POWDER; ORAL

/AA/	/XYLO-PFAN/	/25GM/BOT/	/N17605/001/
AA	SAVAGE	25GM/BOT	N17605 001

ZINC SULFATE

/INJECTABLE;/INJECTION/

/ZINC/SULFATE/		
/LYPHOMED/	/EQ/1MG/ZINC/ML/	/N19229/002/ /MAY/05,/1987/
@ LYPHOMED	EQ 1MG ZINC/ML	N19229 002 MAY 05, 1987

ACETAMINOPHEN

SUPPOSITORY; RECTAL
NEOPAP
/ALCON/ /120MG/ /N16401/001/
POLYMEDICA 120MG N16401 001

ALUMINUM HYDROXIDE; MAGNESIUM TRISILICATE

TABLET, CHEWABLE; ORAL
/ALUMINUM/HYDROXIDE/AND/MAGNESIUM/TRISILICATE/
/PENNEX/ /80MG;20MG/ /N89449/001/
/NOV/27;/1987/
@ PENNEX 80MG;20MG N89449 001
NOV 27, 1987

BACITRACIN; POLYMYXIN B SULFATE

>_DLT_> /AEROSOL;/TOPICAL/
>_DLT_> /ANTIBIOTIC/
>_DLT_> /COMBE/ /500/UNITS/GM;/
>_DLT_> /5,000/UNITS/GM/ /N50598/001/
>_DLT_> /SEP/22;/1986/
>_ADD_> @ COMBE 500 UNITS/GM;
>_ADD_> 5,000 UNITS/GM N50598 001
>_ADD_> SEP 22, 1986

CHLORHEXIDINE GLUCONATE

SOLUTION; TOPICAL
HIBISTAT
/STUART/ /0.5%/ /N18300/001/
+ ZENECA 0.5% N18300 001

TINCTURE; TOPICAL
HIBITANE
/@/STUART/ /0.5%/ /N18049/001/
@ ZENECA 0.5% N18049 001

CHLORPHENIRAMINE MALEATE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL
ISOCLOR
CIBA 8MG;120MG N18747 001
MAR 06, 1986
/FISONS/ /8MG;120MG/ /N18747/001/
/MAR/06;/1986/

CLOTRIMAZOLE

CREAM; TOPICAL
CLOTRIMAZOLE
TARO 1% N72640 002
AUG 31, 1993

CREAM; VAGINAL
CLOTRIMAZOLE
NMC 1% N74165 001
JUL 16, 1993

CREAM, SUPPOSITORY; TOPICAL, VAGINAL
GYNE-LOTRIMIN COMBINATION PACK
+ SCHERING PLOUGH 1%;100MG N20289 002
APR 26, 1993

DIPHENHYDRAMINE HYDROCHLORIDE

SYRUP; ORAL
DIPHEN
PENNEX PHARMS 12.5MG/5ML N70118 001
OCT 01, 1985
/PHARM/BASICS/ /12.5MG/5ML/ /N70118/001/
/OCT/01;/1985/
DIPHENHYDRAMINE HCL
BARRE 12.5MG/5ML N70497 001
APR 25, 1989
/NASKA/ /12.5MG/5ML/ /N70497/001/
/APR/25;/1989/

IBUPROFEN

TABLET; ORAL
IBUPROFEN
/LUCHEN/ /200MG/ /N72901/001/
/DEC/19;/1991/
/200MG/ /N72903/001/
/DEC/19;/1991/
IBUPROFEN
NORTON HN 200MG N71144 001
JAN 20, 1987
200MG N72901 001
DEC 19, 1991
200MG N72903 001
DEC 19, 1991
/IBUPROFEN/
/GHN/ /200MG/ /N71214/001/
/DEC/01;/1986/

IBUPROFEN

TABLET; ORAL

IBUPROFEN		
/ZENITH/	/200MG/	/N71154/001/ /OCT/27/1987/
@ ZENITH	200MG	N71154 001 OCT 27, 1987
IBUPROHM		
OHM	200MG	N71214 001 DEC 01, 1986
/NEUVIL/		
/LUCHEM/	/200MG/	/N71144/001/ /JAN/20/1987/

INSULIN SUSP PROTAMINE ZINC BEEF/PORK

> DLT >	/INJECTABLE;/INJECTION/		
> DLT >	/PROTAMINE;/ZINC/&/ILETIN/I/(BEEF-PORK)/		
> DLT >	/LILLY/	/40/UNITS/ML/	/N17932/001/
> DLT >		/100/UNITS/ML/	/N17932/002/
> ADD >	@ LILLY	40 UNITS/ML	N17932 001
> ADD >	@	100 UNITS/ML	N17932 002

LOPERAMIDE HYDROCHLORIDE

SOLUTION; ORAL

LOPERAMIDE HCL		
WATSON LABS	1MG/5ML	N73062 001 MAY 28, 1993

TABLET; ORAL

LOPERAMIDE HCL		
NOVOPHARM	2MG	N73254 001 JUL 30, 1993

MICONAZOLE NITRATE

CREAM, SUPPOSITORY; TOPICAL, VAGINAL

MONISTAT 7 COMBINATION PACK		
+ ADVANCED CARE	2%;100MG	N20288 002 APR 26, 1993

PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

/CAPSULE;/ORAL/

/ACTIFED/		
/BURROUGHS/WELLCOME/	/60MG;2.5MG/	/N19208/001/ /JAN/15/1985/

/SYRUP;/ORAL/

/ACTIFED/		
/BURROUGHS/WELLCOME/	/30MG/5ML;1.25MG/5ML/	/N11935/003/ /NOV/26/1982/
/TRIOFED/		
/BARRE/	/30MG/5ML;1.25MG/5ML/	/N88115/001/ /MAR/04/1983/
/TRIPOSED/		
/HALSEY/	/30MG/5ML;1.25MG/5ML/	/N88213/002/ /MAR/30/1984/

/TABLET;/ORAL/

/ACTIFED/		
/BURROUGHS/WELLCOME/	/60MG;2.5MG/	/N11936/002/ /NOV/26/1982/
/TRI-SUPD/		
/MD/PHARM/	/60MG;2.5MG/	/N85024/002/ /JAN/10/1984/
/TRIPODRINE/		
/DANBURY/PHARMA/	/60MG;2.5MG/	/N88112/001/ /JAN/20/1983/
/TRIPOSED/		
/HALSEY/	/60MG;2.5MG/	/N88192/002/ /MAY/01/1984/
/TRIPROLIDINE/HCL/AND/PSEUDOEPHEDRINE/HCL/		
/CHELSEA/	/60MG;2.5MG/	/N88118/002/ /JAN/26/1984/

INDIUM^{111} CHLORIDE

SOLUTION; INJECTION
INDICLOR
AMERSHAM N/A N19862
DEC 29, 1992

LIST OF ORPHAN PRODUCT DESIGNATIONS & APPROVALS
[January thru September 1993]

E ric/Chemical Trade Name	***INDICATION DESIGNATED***	***SPONSOR & ADDRESS*** *DD=Date Designated* *MA=Marketing Approval*
ESULFATED HEPARIN EROPIN	TREATMENT OF CYSTIC FIBROSIS.	KENNEDY & HOIDAL, MDs. 7702 PARHAM ROAD RICHMOND VA 23294 DD 09/17/93 MA / /
THOXSALEN UVADEX	FOR USE IN CONJUNCTION WITH THE UVAR PHOTOPHERESIS TO TREAT DIFFUSE SYSTEMIC SCLEROSIS.	THERAKOS, INCORPORATED 201 BRANDYWINE PARKWAY WEST CHESTER PA 19380 DD 06/22/93 MA / /
OSALICYLATE SODIUM	TREATMENT OF CROHN'S DISEASE.	SYNCOM PHARMACEUTICALS, INC. 155 PASSAIC AVENUE FAIRFIELD NJ 07004 DD 04/06/93 MA / /
OSIDINE GABBROMICINA	TREATMENT OF TUBERCULOSIS.	KANYOK, THOMAS P. PHARM.D. UNIVERSITY OF RHODE ISLAND PROVIDENCE RI 02908-4735 DD 05/14/93 MA / /
IODARONE AMIO-AQUEOUS	TREATMENT OF INCESSANT VENTRICULAR TACHYCARDIA.	ACADEMIC PHARMACEUTICALS, INC. 25720 SAUNDERS ROAD NORTH LAKE FOREST IL 60045 DD 08/17/93 MA / /
-THYMOCYTE SERUM NASHVILLE RABBIT THYMOCYTE SERUM	TREATMENT OF ALLOGRAFT REJECTION, INCLUDING SOLID ORGAN (KIDNEY, LIVER, HEART, LUNG, AND PANCREAS) AND BONE MARROW TRANSPLANTATION.	APPLIED MEDICAL RESEARCH 1600 HAYES STREET NASHVILLE TN 37203 DD 06/02/93 MA / /
ORPHINE HCL INJECTION	TREATMENT OF THE ON-OFF FLUCTUATIONS ASSOCIATED WITH LATE-STAGE PARKINSON'S DISEASE.	BRITANNIA PHARMACEUTICALS LTD FORUM HOUSE, BRIGHTON ROAD REDHILL, SURREY UK DD 04/22/93 MA / /
AQUONE MEPRON	TREATMENT AND SUPPRESSION OF TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
AQUONE MEPRON	PRIMARY PROPHYLAXIS OF HIV-INFECTED PERSONS AT HIGH RISK FOR DEVELOPING TOXOPLASMA GONDII ENCEPHALITIS.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 03/16/93 MA / /
MYCIN SULFATE BLENOXANE	TREATMENT OF MALIGNANT PLEURAL EFFUSION.	BRISTOL-MYERS SQUIBB PO BOX 4000 PRINCETON NJ 08543-4000 DD 09/17/93 MA / /
INE WHEY PROTEIN CONCENTRATE IMMUNO-C	TREATMENT OF CRYPTOSPORIDIOSIS CAUSED BY THE PRESENCE OF CRYPTOSPORIDIUM PARVUM IN THE GASTROINTESTINAL TRACT OF PATIENTS WHO ARE IMMUNODEFICIENT/IMMUNOCOMPROMISED OR IMMUNOCOMPETENT.	BIOMUNE SYSTEMS, INCORPORATED 40 EAST SOUTH TEMPLE SUITE 310 SALT LAKE CITY UT 84111 DD 09/30/93 MA / /
ORIBINE LEUSTATIN INJECTION	TREATMENT OF NON-HODGKIN'S LYMPHOMA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202 SOUTH, P.O. BOX 300 RARITAN NJ 08869-0602 DD 04/19/93 MA / /
FOSCERIL PALMITATE, CETYL OHOL, TYLOXAPOL EXOSURF	TREATMENT OF ADULT RESPIRATORY DISTRESS SYNDROME.	BURROUGHS WELLCOME COMPANY 3030 CORNWALLIS ROAD RESEARCH TRIANGLE PK NC 27709 DD 01/11/93 MA / /
IC FIBROSIS TRANSMEMBRANE UCTANCE REGULATOR GENE	TREATMENT OF CYSTIC FIBROSIS.	GENETIC THERAPY, INC. 19 FIRSTFIELD ROAD GAITHERSBURG MD 20878 DD 01/08/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
DEPOFOAM ENCAPSULATED CYTARABINE TN=	TREATMENT OF NEOPLASTIC MENINGITIS.	KIM, SINIL M.D. UCSD CANCER CENTER/0812 SAN DIEGO CA 92103 DD 06/02/93 MA / /
DISODIUM CLODRONATE TN=	TREATMENT OF HYPERCALCEMIA OF MALIGNANCY.	DISCOVERY EXPERIMENTAL & DEVELOPMENT,INC 29949 S.R. 54 WEST WESLEY CHAPEL FL 33543 DD 06/16/93 MA / /
FACTOR XIII, RECOMBINANT TN=	TREATMENT OF CONGENITAL FACTOR XIII DEFICIENCY.	ZYMOGENETICS, INC. 4225 ROOSEVELT WAY SEATTLE WA 98105 DD 04/22/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE RENAL ALLOGRAFT REJECTION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
HUMANIZED ANTI-TAC TN=	PREVENTION OF ACUTE GRAFT-VS-HOST DISEASE FOLLOWING BONE MARROW TRANSPLANTATION.	HOFFMANN-LA ROCHE, INC. 340 KINGSLAND STREET NUTLEY NJ 07110 DD 03/05/93 MA / /
IMMUNE GLOBULIN INTRAVENOUS (HUMAN) TN= GAMIMUNE N	INFECTION PROPHYLAXIS IN PEDIATRIC PATIENTS AFFECTED WITH THE HUMAN IMMUNODEFICIENCY VIRUS.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94710 DD 02/18/93 MA / /
INTERFERON BETA (RECOMBINANT HUMAN) TN=	TREATMENT OF PRIMARY BRAIN TUMORS.	BIOGEN, INC. 14 CAMBRIDGE CENTER CAMBRIDGE MA 02142 DD 01/13/93 MA / /
INTERLEUKIN-3, HUMAN, RECOMBINANT TN=	FOR SEQUENTIAL ADMINISTRATION WITH SARGRAMOSTIM TO ACCELERATE NEUTROPHIL AND PLATELET RECOVERY IN PATIENTS UNDERGOING AUTOLOGOUS BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF HODGKIN'S DISEASE OR NON-HODGKIN'S LYMPHOMA.	SANDOZ PHARMACEUTICALS CORP 59 ROUTE 10 EAST HANOVER NJ 07936-1080 DD 09/30/93 MA / /
LIPOSOMAL DAUNORUBICIN TN= DAUNOXOME	TREATMENT OF PATIENTS WITH ADVANCED HIV-ASSOCIATED KAPOSI'S SARCOMA.	VESTAR, INC. 650 CLIFFSIDE DRIVE SAN DIMAS CA 91773 DD 05/14/93 MA / /
METHOTREXATE TN= RHEUMATREX	TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS.	LEDERLE LABORATORIES 401 N. MIDDLETOWN ROAD PEARL RIVER NY 10965-1299 DD 08/23/93 MA / /
MODAFINIL TN=	TREATMENT OF EXCESSIVE DAYTIME SLEEPINESS IN NARCOLEPSY.	CEPHALON, INC. 145 BRANDYWINE PARKWAY WEST CHESTER PA 19380-4245 DD 03/15/93 MA / /
MONOCLONAL ANTIBODY FOR IMMUNIZATION AGAINST LUPUS NEPHRITIS TN=	TREATMENT OF LUPUS NEPHRITIS.	MEDCLONE, INC. 2435 MILITARY AVENUE LOS ANGELES CA 90064 DD 01/07/93 MA / /
MONOLAURIN TN= GLYLORIN	TREATMENT OF CONGENITAL PRIMARY ICHTHYOSIS.	CELLEGY PHARMACEUTICALS, INC 371 BEL MARIN KEYS, SUITE 21 NOVATO CA 94949 DD 04/29/93 MA / /

CUMULATIVE LIST OF DESIGNATIONS & APPROVALS

Ric/Chemical Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
YCIN-C	TREATMENT OF REFRACTORY GLAUCOMA AS AN ADJUNCT TO AB EXTERNO GLAUCOMA SURGERY.	IOP INCORPORATED 3100 AIRWAY AVENUE COSTA MESA CA 92626 DD 08/20/93 MA / /
C OXIDE	TREATMENT OF PERSISTENT PULMONARY HYPERTENSION IN THE NEWBORN.	ANAQUEST, INCORPORATED 110 ALLEN ROAD LIBERTY CORNER NJ 07938 DD 06/22/93 MA / /
QUINE PHOSPHATE	FOR USE IN COMBINATION WITH CLINDAMYCIN HYDROCHLORIDE IN THE TREATMENT OF PNEUMOCYSTIS CARINII PNEUMONIA ASSOCIATED WITH ACQUIRED IMMUNODEFICIENCY SYNDROME.	STERLING WINTHROP INC. 90 PARK AVENUE NEW YORK NY 10016 DD 07/23/93 MA / /
EIN C CONCENTRATE ROTEIN C CONCENTRATE N) VAPOR HEATED, IMMUNO	FOR USE IN THE PREVENTION AND TREATMENT OF PURPURA FULMINANS IN MENINGOCOCCEMIA.	IMMUNO CLINICAL RESEARCH CORP. 750 LEXINGTON AVENUE, 19TH FLOOR NEW YORK NY 10022 DD 04/22/93 MA / /
RELIN	PREVENTION OF INFANT RESPIRATORY DISTRESS SYNDROME ASSOCIATED WITH PREMATURITY.	UCB PHARMACEUTICALS, INC. 5505-A ROBIN HOOD ROAD NORFOLK VA 23513 DD 08/24/93 MA / /
NARY SURFACTANT REPLACMENT, NE UROSURF	FOR THE TREATMENT AND PREVENTION OF RESPIRATORY DISTRESS SYNDROME IN PREMATURE INFANTS.	CHIESI PHARMACEUTICALS, INC. 150 DANBURY ROAD RIDGEFIELD CT 06877 DD 08/02/93 MA / /
ETINAMIDE	TREATMENT OF MYELODYSPLASTIC SYNDROMES.	SPARTA PHARMACEUTICALS, INCORPORATED PO BOX 13288 RESEARCH TRIANGLE PK NC 27709 DD 05/06/93 MA / /
OLE	TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS.	RHONE-POULENC RORER PHARM. 500 ARCOLA ROAD, PO BOX 1200 COLLEGEVILLE PA 19426-0107 DD 03/16/93 MA / /
INIMEX LINOMIDE	TO PROLONG TIME TO RELAPSE IN LEUKEMIA PATIENTS WHO HAVE UNDERGONE AUTOLOGOUS BONE MARROW TRANSPLANTATION.	KABI PHARMACIA, INC. 800 CENTENNIAL AVENUE PISCATAWAY NJ 08855-1327 DD 07/01/93 MA / /
LCIFEROL OSTEO-D	TREATMENT OF FAMILIAL HYPOPHOSPHATEMIC RICKETS.	LEMMON COMPANY 650 CATHILL ROAD SELLERSVILLE PA 18960 DD 07/26/93 MA / /
TROPIN BIOTROPIN	TREATMENT OF CACHEXIA ASSOCIATED WITH AIDS.	BIO-TECHNOLOGY GENERAL CORPORATION 1250 BROADWAY, 20th FLOOR NEW YORK NY 10001 DD 02/12/93 MA / /
ALFATE	TREATMENT OF ORAL MUCOSITIS AND STOMATITIS FOLLOWING RADIATION THERAPY FOR HEAD AND NECK CANCER.	FUISZ TECHNOLOGIES, LTD. 3810 CONCORDE PARKWAY, SUITE 100 CHANTILLY VA 22021 DD 07/15/93 MA / /
IDOMIDE	TREATMENT OF THE CLINICAL MANIFESTATIONS OF MYCOBACTERIAL INFECTION CAUSED BY MYCOBACTERIUM TUBERCULOSIS AND NON-TUBERCULOUS MYCOBACTERIA.	CELGENE CORPORATION 7 POWDER HORN DRIVE WARREN NJ 07059 DD 01/12/93 MA / /

NAME Generic/Chemical TN=Trade Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval
TOREMIFENE TN= ESTRINEX	TREATMENT OF DESMOID TUMORS.	ADRIA LABORATORIES P.O. BOX 16529 COLUMBUS OH 43216-6529 DD 08/17/93 MA / /
TRETINOIN TN= TRETINOIN LF, IV	TREATMENT OF ACUTE AND CHRONIC LEUKEMIA.	ARGUS PHARMACEUTICALS, INC. 3400 RESEARCH FOREST DRIVE THE WOODLANDS TX 77381 DD 01/14/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN 1 TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
TUMOR NECROSIS FACTOR-BINDING PROTEIN II TN=	TREATMENT OF SYMPTOMATIC PATIENTS WITH THE ACQUIRED IMMUNODEFICIENCY SYNDROME INCLUDING ALL PATIENTS WITH CD4 T-CELL COUNTS LESS THAN 200 CELLS PER MM3.	SERONO LABORATORIES, INC. 100 LONGWATER CIRCLE NORWELL MA 02061 DD 01/06/93 MA / /
VASOACTIVE INTESTINAL POLYPEPTIDE TN=	TREATMENT OF ACUTE ESOPHAGEAL FOOD IMPACTION.	RESEARCH TRIANGLE PHARMACEUTICALS 200 WESTPARK CORPORATE CENTER DURHAM NC 27713 DD 06/23/93 MA / /

Orphan Drug Approvals

ANTIHEMOPHILIC FACTOR (RECOMBINANT) TN= KOGENATE	PROPHYLAXIS AND TREATMENT OF BLEEDING IN INDIVIDUALS WITH HEMOPHILIA A OR FOR PROPHYLAXIS WHEN SURGERY IS REQUIRED IN INDIVIDUALS WITH HEMOPHILIA A.	MILES, INC. 4TH & PARKER STREETS BERKELEY CA 94701 DD 09/25/89 MA 02/25/93
CLADRIBINE TN= LEUSTATIN INJECTION	TREATMENT OF HAIRY CELL LEUKEMIA.	R.W.JOHNSON RESEARCH INSTITUTE ROUTE 202, PO BOX 300 RARITAN NJ 08869-0602 DD 11/15/90 MA 02/26/93
FELBAMATE TN= FELBATOL	TREATMENT OF LENNOX-GASTAUT SYNDROME.	WALLACE LABORATORIES 301B COLLEGE ROAD EAST PRINCETON NJ 08540 DD 01/24/89 MA 07/29/93
INTERFERON BETA, RECOMBINANT HUMAN TN=BETASERON	TREATMENT OF MULTIPLE SCLEROSIS.	CHIRON CORPORATION 4560 HORTON STREET EMERYVILLE CA 94608 DD 11/17/88 MA 07/23/93
LEUPROLIDE ACETATE TN= LUPRON INJECTION	TREATMENT OF CENTRAL PRECOCIOUS PUBERTY.	TAP PHARMACEUTICALS, INC. 2355 WAUKEGAN ROAD DEERFIELD IL 60015 DD 07/25/88 MA 04/16/93
LEVOMETHADYL ACETATE HYDROCHLORIDE TN=ORLAAM	TREATMENT OF HEROIN ADDICTS SUITABLE FOR MAINTENANCE ON OPIATE AGONISTS.	BIODEVELOPMENT CORPORATION 1300 NORTH 17TH STREET, SUITE 300 ARLINGTON VA 22209-2306 DD 01/24/84 MA 07/09/93
LODOXAMIDE TROMETHAMINE TN= ALOMIDE OPHTHALMIC SOLUTION	TREATMENT OF VERNAL KERATOCONJUNCTIVITIS.	ALCON LABORATORIES, INC. 6201 SOUTH FREEWAY FORT WORTH TX 76134 DD 10/16/91 MA 09/23/93

Chemical / Code Name	INDICATION DESIGNATED	SPONSOR & ADDRESS DD=Date Designated MA=Marketing Approval

Orphan Drug Approvals

OL ACETATE ACE	TREATMENT OF PATIENTS WITH ANOREXIA, CACHEXIA, OR SIGNIFICANT WEIGHT LOSS (=/>10% OF BASELINE BODY WEIGHT) AND CONFIRMED DIAGNOSIS OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS).	BRISTOL-MYERS SQUIBB 2400 WEST LLOYD EXPRESSWAY EVANSVILLE IN 47721-0001 DD 04/13/88 MA 09/10/93

DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY ONLY
IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO SEPTEMBER 1993 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR *IN VIVO* BIOEQUIVALENCE STUDIES AND *IN VITRO* DISSOLUTION TESTING. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE (HFD-650, MPN-2 ROOM 279) 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
BUMETANIDE (TABLET)	APR 23, 1993	
BUSIPRONE HYDROCHLORIDE (TABLET)	AUG 13, 1993	
CEFACLOR (CAPSULE AND SUSPENSION)	APR 23, 1993	
CAPTOPRIL (TABLET)	MAY 13, 1993	
CHOLESTRYRAMINE (POWDER)	JUL 15, 1993	
GLIPIZIDE (TABLET)	APR 23, 1993	
GLYBURIDE (TABLET)	APR 23, 1993	
GUANABENZ ACETATE (TABLET)	APR 23, 1993	
INDAPAMIDE (TABLET)	APR 23, 1993	
KETOPROFEN (CAPSULE)	APR 23, 1993	
ORAL EXTENDED (CONTROLLED RELEASE)	SEP 09, 1993	
PINDOLOL (TABLET)	APR 23, 1993	
RANITIDINE HYDROCHLORIDE (TABLET)	APR 23, 1993	
TRIAZOLAM (TABLET)	DEC 24, 1992	

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
AMINOSALICYLIC ACID GRANULES, ENTERIC-COATED; ORAL	4GM/PACKET	92 P-0356/ CP1	JACOBUS	NEW DOSAGE FORM NEW STRENGTH	APPROVED MAR 03, 1993
ACYCLOVIR SODIUM INJECTABLE; INJECTION	EQ 50MG BASE/ML (10ML/VIAL) (20ML/VIAL)	92 P-0468/ CP1	BULL	NEW DOSAGE FORM	APPROVED SEP 01, 1993
CARBOPLATIN INJECTABLE; INJECTION	10MG/ML (5ML/VIAL) (15ML/VIAL) (45ML/VIAL)	92 P-0467/ CP1	BULL	NEW DOSAGE FORM	APPROVED MAY 20, 1993
CHLORPROMAZINE HYDROCHLORIDE SOLUTION; ORAL	25MG/5ML	92 P-0284/ CP1	UDL	NEW STRENGTH	APPROVED JAN 07, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (40ML/VIAL)	92 P-0365/ CP1	LYPHOMED	NEW STRENGTH	APPROVED FEB 11, 1993
DOBUTAMINE HYDROCHLORIDE INJECTABLE; INJECTION	EQ 12.5MG BASE/ML (100ML/CONTAINER)	92 P-0045/ CP1	MARSAM	NEW STRENGTH	APPROVED SEP 01, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (12.5MG/VIAL)	92 P-0355/ CP1	LEDERLE	NEW STRENGTH	APPROVED JAN 07, 1993
ETOPOSIDE INJECTABLE; INJECTION	20MG/ML (50ML/CONTAINER)	91 P-0460/ CP1	ABBOTT	NEW STRENGTH	APPROVED FEB 11, 1993
LACTULOSE CRYSTAL; ORAL	10GM/PACKET	92 P-0370/ CP1	BENNETT AND COMPANY	NEW DOSAGE FORM	APPROVED JAN 07, 1993
METHYLPHENIDATE HYDROCHLORIDE; TABLET, EXTENDED RELEASE; ORAL	10MG	92 P-0400/ CP1	MD PHARM	NEW STRENGTH	APPROVED MAR 22, 1993
PREDNISOLONE SYRUP; ORAL	10MG/5ML	92 P-0439/ CP1	WE PHARMS	NEW STRENGTH	APPROVED MAY 20, 1993
PROPRANOLOL HYDROCHLORIDE TABLET, EFFERVESCENT; ORAL	10MG 20MG 60MG 80MG 90MG	93 P-0049/ CP1	FLEMINGTON PHARM	NEW DOSAGE FORM NEW STRENGTH	APPROVED SEP 01, 1993
TRIMETHOPRIM SOLUTION; ORAL	25MG/5ML	92 P-0500/ CP1	ASCENT PHARMS	NEW DOSAGE FORM	APPROVED MAY 20, 1993

EXCLUSIVITY TERMS

UE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. PLEASE REFER BACK TO THE PPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 13TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS ABBREVIATIONS, NEW DOSING SCHEDULE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE UPPLEMENT.

REFERENCES
NEW DOSING SCHEDULE

-20 SINGLE 32MG DOSE

REFERENCES
NEW INDICATION

-87 RENAL IMAGING AGENT FOR USE IN CHILDREN
-88 MANAGEMENT OF ENDOMETRIOSIS
-89 EPIDURAL USE IN LABOR AND DELIVERY AS AN ANALGESIC ADJUNCT TO BUPIVACAINE
-90 INTENSIVE CARE UNIT SEDATION
-91 MONOTHERAPY USE FOR HYPERTENSION
-92 ADJUNCTIVE THERAPY IN THE MANAGEMENT OF HEART FAILURE
-93 PREVENTION OF EXERCISE-INDUCED BRONCHOSPASM IN CHILDREN AGES 4-11 YEARS
-94 USE WITH MRI IN ADULTS TO PROVIDE CONTRAST ENHANCEMENT AND FACILITATE VISUALIZATION OF LESIONS IN THE BODY [EXCLUDING THE HEART]
-95 TREATMENT OF LEFT VENTRICULAR DYSFUNCTION FOLLOWING MYOCARDIAL INFARCTION
-96 TREATMENT OF SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA

REFERENCES
PATENT USE CODE

74 METHOD OF PROVIDING HYPNOTIC EFFECT
75 RELIEF OF OCULAR ITCHING DUE TO SEASONAL ALLERGIC CONJUNCTIVITIS
76 USE TO IMAGE A SUBJECT WITH A MAGNETIC RESONANCE IMAGING SYSTEM
77 TREATMENT OF SYMPTOMS OF SEASONAL ALLERGIC RHINITIS
78 ULCERATIVE COLITIS
79 SYMPTOMATIC TREATMENT OF PATIENTS WITH NOCTURNAL HEARTBURN DUE TO GERD
80 METHOD OF TREATING OCULAR BACTERIAL INFECTIONS
81 RELIEF OF SYMPTOMS ASSOCIATED WITH SEASONAL ALLERGIC RHINITIS
82 TREATMENT FOR DEMENTIA IN PATIENTS WITH ALZHEIMER'S DISEASE
83 TREATMENT OF SEIZURES

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
						I-93	JUL 20, 1996
	18473 001	ALBUTEROL; VENTOLIN				I-93	JUL 20, 1996
	19489 001	ALBUTEROL SULFATE; VENTOLIN ROTACAPS	4851229	JUN 14, 2005			
	19604 001	ALBUTEROL SULFATE; VOLMAX	4777049	OCT 11, 2005			
			4751071	JUN 14, 2005			
	19604 002	ALBUTEROL SULFATE; VOLMAX	4851229	JUN 14, 2005			
			4777049	OCT 11, 2005			
			4751071	JUN 14, 2005		NS	DEC 23, 1995
			5061494	OCT 29, 2008			
>ADD>	18276 004	ALPRAZOLAM; XANAX	4517199	MAY 14, 2002	U-15	NS	JUL 30, 1996
>ADD>	20258 001	APRACLONIDINE HYDROCHLORIDE; IOPIDINE	4219559	AUG 26, 1999		NCE	DEC 29, 1993
	19402 001	ASTEMIZOLE; HISMANAL	4522807	JUN 11, 2002		NC	DEC 07, 1995
	20045 001	AVOBENZONE; SHADE UVAGUARD	4387089	JUN 07, 2002			
			4252984	AUG 30, 1999			
	19807 001	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4252984	AUG 30, 1999			
	19807 002	BETAXOLOL HYDROCHLORIDE; KERLEDEX	4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
	20186 001	BISOPROLOL FUMARATE; ZIAC				NC	FEB 26, 1996
			4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
	20186 002	BISOPROLOL FUMARATE; ZIAC				NC	FEB 26, 1996
			4258062	MAR 24, 1998	U-63	NCE	JUL 31, 1997
	20186 003	BISOPROLOL FUMARATE; ZIAC				NC	FEB 26, 1996
			4105776	AUG 08, 1995		I-95	SEP 23, 1996
>ADD>	18343 001	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
>ADD>	18343 002	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
>ADD>	18343 003	CAPTOPRIL; CAPOTEN	4105776	AUG 08, 1995		I-95	SEP 23, 1996
>ADD>	18343 005	CAPTOPRIL; CAPOTEN	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20210 001	CISAPRIDE MONOHYDRATE; PROPULSID	4962115	OCT 09, 2007	U-79	NCE	JUL 29, 1998
	20210 002	CISAPRIDE MONOHYDRATE; PROPULSID				NCE	FEB 26, 1998
	20229 001	CLADRIBINE; LEUSTATIN				ODE	FEB 26, 2000
			RE32393	SEP 18, 1996		NDF	JUN 18, 1996
>ADD>	19287 001	DIAZEPAM; DIZAC	5212326	JAN 29, 2008			
	18723 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 002	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	18723 003	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19680 001	DIVALPROEX SODIUM; DEPAKOTE	5212326	JAN 29, 2008			
	19794 001	DIVALPROEX SODIUM; DEPAKOTE CP	5212326	JAN 29, 2008			
	19794 002	DIVALPROEX SODIUM; DEPAKOTE CP					

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18651 001	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 002	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	18651 003	DRONABINOL; MARINOL				ODE	DEC 22, 1999
	19616 004	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	19616 005	ENOXACIN; PENETREX	4359578	NOV 16, 2001		NCE	DEC 31, 1996
	20164 001	ENOXAPARIN SODIUM; LOVENOX				NCE	MAR 29, 1998
>ADD>	20189 001	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
>ADD>			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
>ADD>	20189 002	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
>ADD>			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
>ADD>	20189 003	FELBAMATE; FELBATOL	5082861	JAN 21, 2009	U-83	ODE	JUL 29, 2000
>ADD>			4978680	DEC 18, 2007	U-83	NCE	JUL 29, 1998
	20073 001	FLUMAZENIL; MAZICON	4316839	MAR 03, 2003		NCE	DEC 20, 1996
>ADD>	18936 001	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003			
>ADD>	18936 006	FLUOXETINE HYDROCHLORIDE; PROZAC	4626549	DEC 02, 2003			
			4314081	FEB 02, 2001			
			4194009	APR 19, 1994			
			4018895	APR 19, 1994	U-12		
	20068 001	FOSCARNET SODIUM; FOSCAVIR	4215113	JUN 06, 2000	U-64	NCE	SEP 27, 1996
	20123 001	GADODIAMIDE; OMNISCAN	4687659	AUG 18, 2004	U-76	NCE	JAN 08, 1998
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4957939	MAR 03, 2004		I-94	AUG 17, 1996
	17783 003	GLIPIZIDE; GLUCOTROL				NCE	MAY 08, 1994
>ADD>	20051 003	GLYBURIDE; GLYNASE	4735805	APR 05, 2005		NP	MAR 04, 1995
>ADD>			4916163	APR 10, 2007		NCE	MAY 01, 1994
>ADD>	20051 004	GLYBURIDE; GLYNASE	4735805	APR 05, 2005		NP	MAR 04, 1995
>ADD>			4916163	APR 10, 2007		NCE	MAY 01, 1994
	19726 001	GOSERELIN ACETATE; ZOLADEX				I-88	FEB 02, 1996
	19032 001	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19032 002	GUANFACINE HYDROCHLORIDE; TENEX				I-91	MAY 11, 1996
	19891 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	19892 001	HYDROMORPHONE HYDROCHLORIDE; DILAUDID				NCE	JAN 11, 1994
						NDF	DEC 07, 1995
	18538 002	INDAPAMIDE; LOZOL				NS	APR 29, 1996
						NCE	JUL 06, 1993
	19710 005	IOVERSOL; OPTIRAY 350				I-48	JUL 27, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
20215 001	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
20215 002	ISOSORBIDE MONONITRATE; MONOKET				NCE	DEC 30, 1996
					NS	JUN 30, 1996
20225 001	ISOSORBIDE MONONITRATE; IMDUR				NCE	DEC 30, 1996
					NDF	AUG 12, 1996
20225 002	ISOSORBIDE MONONITRATE; IMDUR				NCE	DEC 30, 1996
					NDF	AUG 12, 1996
19084 001	KETOCONAZOLE; NIZORAL	4335125	JUN 15, 1999		I-30	JAN 27, 1996
19700 001	KETOROLAC TROMETHAMINE; ACULAR	5110493	MAY 05, 2009	U-75	NCE	NOV 30, 1994
		4454151	JUN 12, 2001	U-75	NDF	NOV 09, 1995
		4089969	MAY 16, 1997	U-75		
20263 001	LEUPROLIDE ACETATE; LUPRON	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 002	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 003	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000
20263 004	LEUPROLIDE ACETATE; LUPRON DEPOT-PED	4917893	MAR 24, 2004			
		4849228	JUL 18, 2006		NP	APR 16, 1996
		4728721	MAR 01, 2005			
		4677191	JUN 30, 2004			
		4652441	MAR 24, 2004			
		4005063	JAN 25, 1996		ODE	APR 16, 2000

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18948 001	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
						ODE	DEC 16, 1999
	18948 002	LEVOCARNITINE; CARNITOR				I-86	DEC 16, 1995
						ODE	DEC 16, 1999
	20315 001	LEVOMETHADYL ACETATE HYDROCHLORIDE; ORLAAM				NCE	JUL 09, 1998
						ODE	JUL 09, 2000
	19558 001	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 002	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 003	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19558 004	LISINOPRIL; PRINIVIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 001	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 002	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 003	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 004	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
	19777 005	LISINOPRIL; ZESTRIL	4374829	DEC 30, 2001		I-92	JUN 09, 1996
>ADD>	20191 001	LODOXAMIDE TROMETHAMINE; ALOMIDE				NCE	SEP 23, 1998
	20013 001	LOMEFLOXACIN HYDROCHLORIDE; MAXAQUIN	4528287	MAY 05, 2005	U-36	NCE	FEB 21, 1997
	19658 001	LORATADINE; CLARITIN	4282233	AUG 04, 1998	U-77	NCE	APR 12, 1998
>ADD>	20049 001	MESALAMINE; PENTASA	4980173	DEC 25, 2007	U-78		
			4496553	JAN 29, 2002	U-78	NP	MAY 10, 1996
	20098 001	MIVACURIUM CHLORIDE; MIVACRON	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	20098 002	MIVACURIUM CHLORIDE; MIVACRON IN DEXTROSE 5%	4761418	JAN 22, 2006		NCE	JAN 22, 1997
	19583 001	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	19583 002	NABUMETONE; RELAFEN	4420639	DEC 13, 2002		NCE	DEC 24, 1996
	20109 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1999		NCE	FEB 13, 1995
	19356 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 2000		NCE	MAR 01, 1993
	20150 001	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 002	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20150 003	NICOTINE; NICOTROL	4915950	APR 10, 2007		NP	APR 22, 1995
	20066 001	NICOTINE POLACRILEX; NICORETTE DS				NCE	JAN 13, 1994
	20198 001	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 002	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
	20198 003	NIFEDIPINE; ADALAT CC	4892741	JAN 09, 2007			
>ADD>	19921 001	OFLOXACIN; OCUFLOX	4551456	NOV 05, 2002	U-80	NDF	JUL 30, 1996
			4382892	MAY 10, 2000			
	20007 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	JAN 03, 2005		D-20	FEB 02, 1996
						I-9	AUG 13, 1996

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20103 001	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
	20103 002	ONDANSETRON HYDROCHLORIDE; ZOFRAN	4695578	SEP 22, 2004		NCE	JAN 04, 1996
	20036 001	PAMIDRONATE DISODIUM; AREDIA	3962432	JUL 16, 1996	U-53		
	20036 003	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
	20036 004	PAMIDRONATE DISODIUM; AREDIA	4711880	DEC 08, 2004			
			3962432	JUL 16, 1996	U-53	NCE	OCT 31, 1996
	20091 001	PERFLUBRON; IMAGENT				NCE	AUG 13, 1998
	20014 001	PIRBUTEROL ACETATE; MAXAIR	4664107	MAY 12, 2004			
	19795 001	PODOFILOX; CONDYLOX				NCE	DEC 13, 1995
	19898 004	PRAVASTATIN SODIUM; PRAVACHOL	4346227	AUG 24, 1999		NCE	OCT 31, 1996
	19568 001	PREDNICARBATE; DERMATOP	4242334	DEC 30, 1999	U-50	NE	SEP 23, 1994
	19627 001	PROPOFOL; DIPRIVAN				I-90	MAR 08, 1996
>ADD>	19664 001	PSEUDOEPHEDRINE HYDROCHLORIDE; SELDANE-D	4996061	FEB 26, 2008			
>ADD>			4929605	MAY 29, 2007	U-81		
>ADD>			4254129	MAR 03, 1998	U-81		
	50689 001	RIFABUTIN; MYCOBUTIN				ODE	DEC 23, 1999
>ADD>	19650 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
>ADD>	19649 001	RIMANTADINE HYDROCHLORIDE; FLUMADINE				NCE	SEP 17, 1998
	19839 001	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 002	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 003	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19839 004	SERTRALINE HYDROCHLORIDE; ZOLOFT	4536518	DEC 31, 2005		NCE	DEC 30, 1996
	19766 001	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 002	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 003	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	19766 004	SIMVASTATIN; ZOCOR	4444784	DEC 24, 2005	U-59	NCE	DEC 23, 1997
	20134 001	STRONTIUM CHLORIDE, SR-89; METASTRON				NCE	JUN 18, 1998
	19050 001	SUFENTANIL CITRATE; SUFENTA				NR	MAR 19, 1996
						I-89	MAR 19, 1996
	20080 001	SUMATRIPTAN SUCCINATE; IMITREX	4816470	MAR 28, 2006	U-72		
>ADD>	20070 001	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
>ADD>	20070 002	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
>ADD>	20070 003	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
>ADD>	20070 004	TACRINE HYDROCHLORIDE; COGNEX	4816456	MAR 28, 2006	U-82	NCE	SEP 09, 1998
	19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3				I-87	NOV 27, 1995

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	20043 003	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
	20043 004	TEMAFLOXACIN HYDROCHLORIDE; OMNIFLOX	4730000	JAN 30, 2006	U-36	NCE	JAN 30, 1997
>ADD>	18163 003	TEMAZEPAM; RESTORIL	5211954	MAY 18, 2010			
			5030632	JUL 09, 2008	U-70	NS	OCT 25, 1994
>ADD>	20223 001	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
>ADD>			4112097	SEP 05, 1995			
>ADD>			4026894	MAY 31, 1994		I-96	SEP 29, 1996
>ADD>	20223 002	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
>ADD>			4112097	SEP 05, 1995			
>ADD>			4026894	MAY 31, 1994		I-96	SEP 29, 1996
>ADD>	20223 003	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
>ADD>			4112097	SEP 05, 1995			
>ADD>			4026894	MAY 31, 1994		I-96	SEP 29, 1996
>ADD>	20223 004	TERAZOSIN HYDROCHLORIDE; HYTRIN	4251532	FEB 17, 2000			
>ADD>			4112097	SEP 05, 1995			
>ADD>			4026894	MAY 31, 1994		I-96	SEP 29, 1996
>ADD>	18949 001	TERFENADINE; SELDANE	4254129	MAR 03, 1998	U-81		
	19979 001	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
			4051141	SEP 27, 1996		NCE	OCT 31, 1996
	19979 002	TICLOPIDINE HYDROCHLORIDE; TICLID	4591592	NOV 01, 2005			
			4051141	SEP 27, 1996		NCE	OCT 31, 1996
>ADD>	20136 001	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>			4018929	APR 19, 1994		NCE	AUG 23, 1998
>ADD>			RE30633	APR 19, 1994			
>ADD>	20136 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>			4018929	APR 19, 1994		NCE	AUG 23, 1998
>ADD>			RE30633	APR 19, 1994			
>ADD>	20136 003	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>			4018929	APR 19, 1994		NCE	AUG 23, 1998
>ADD>			RE30633	APR 19, 1994			
>ADD>	20136 004	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>			4018929	APR 19, 1994		NCE	AUG 23, 1998
>ADD>			RE30633	APR 19, 1994			
>ADD>	20137 002	TORSEMIDE; DEMADEX	4822807	APR 18, 2006			
>ADD>			4018929	APR 19, 1994		NCE	AUG 23, 1998
>ADD>			RE30633	APR 19, 1994			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
18207 004	TRAZODONE HYDROCHLORIDE; DESYREL	4258027	MAR 24, 1998			
		4215104	JUL 29, 1997			
18776 003	VECURONIUM BROMIDE; NORCURON	4297351	OCT 27, 1998			
		4237126	DEC 02, 1997		NCE	APR 30, 1994
19908 001	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997
19908 002	ZOLPIDEM TARTRATE; AMBIEN	4382938	MAY 10, 2000	U-74	NCE	DEC 16, 1997

DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST
PATENT AND EXCLUSIVITY DATA

APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
19862 001	INDIUM 111 CHLORIDE; INDICLOR				NCE	DEC 29, 1997

*U.S. Government Printing Office: 1993 — 301-037/80003

New 14th Edition

APPROVED DRUG PRODUCTS

WITH
THERAPEUTIC EQUIVALENCE EVALUATIONS

14TH EDITION

Superintendent of Documents Subscription Order Form

Order Processing Code
* 7229

Charge your order. It's easy! MasterCard VISA

☐ **Yes,** please send me the following indicated subscriptions:

__ subscriptions of **APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS**, ADP, and the monthly Cumulative Supplements, for $55.00 per year.

The total cost of my order is $_____. Prices include regular domestic postage and handling and are subject to change. International customers please add 25%.

For privacy protection, check the box below:

☐ Do not make my name available to other mailers.

Please choose method of payment:

☐ Check payable to Superintendent of Documents
☐ GPO Deposit Account ☐☐☐☐☐☐☐ – ☐☐
☐ VISA or MasterCard
☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐☐

(Company or personal name)

(Additional address/attention line)

(Street address)

(City, State, ZIP Code)

(_____)
(Daytime phone including area code)

(Purchase Order No.)

(Credit card expiration date)

Thank you for your order!

(Authorizing Signature) (04/93)

Mail To: Superintendent of Documents, Government Printing Office, P.O. Box 371954 Pittsburgh, PA 15250-7954
To **FAX** your charge order, call (202) 512-2233.
To charge your subscription call (202) 783-3238.